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Summary 
 
Introduction 
Infectious diseases are still a main cause of mortality and morbidity in developing 
countries, especially in children under the age of 5 years. For many of these 
diseases no vaccines are available. An ideal vaccine should be easy to administer, 
well tolerated, protect against multiple pathogens, easy to manufacture, available at 
low cost (ideally < 1 $ per dose), and able to induce long-term protection. 
NVGH’s mission is to develop effective and affordable vaccines for neglected 
diseases of impoverished communities. Towards this goal, NVGH is developing 
platform technologies that can be applied to the development of vaccines for several 
pathogens. One major platform is based on outer membrane particles, called 
Generalized Modules for Membrane Antigens (GMMA). This platform is used in three 
major programs of NVGH: Shigella, a major cause of dysentery with more than 
125 million cases and 100,000 deaths per year, invasive non-Typhoidal Salmonella 
(iNTS), with estimated more than 100,000 deaths per year, and Neisseria menigitidis, 
responsible for epidemic outbreaks causing more than 50,000 deaths per year and 
permanent sequelae. 
The GMMA platform takes advantage of the ability of Gram-negative bacteria to 
naturally shed small particles from the outer membrane into the environment. The 
naturally shed particles, called native outer membrane vesicles (NOMV), consist of 
outer membrane lipids, outer membrane proteins, and soluble periplasmic 
components. They present surface antigen in their natural environment and 
orientation and thus have been proposed for use as vaccines. However, the yield is 
usually too low for a practical production. NVGH has developed a high yield 
production process suitable for industrial production using genetic modification of 
bacteria to induce high level shedding of outer membrane particles. To differentiate 
these particles that are released from the genetically modified bacteria from NOMV 
and other types of particles produces by bacteria, they were named GMMA. 
GMMA are highly immunogenic. In part, this is related to strong self-adjuvanticity. 
Since GMMA are derived from the outer membrane of Gram-negative bacteria, they 
naturally contain high levels of Pathogen-Associated Molecular Patterns (PAMPs). 
PAMPs are present only in bacteria and are sensed by Pattern Recognition 
Receptors (PRRs), including Toll-like receptors (TLRs), expressed on a wide range of 
mammalian cells. The receptors of particular importance for recognition of Gram-
negative bacteria are TLR4 and TLR2. TLR4 is the receptor involved in the 
recognition of lipopolysaccharide (LPS). TLR2 is involved in the recognition of a wide 
range of molecules, including lipoproteins which, together with LPS, are major 
constituents for the outer membrane of Gram-negative bacteria. 
The single most abundant and highly potent immune-stimulatory component in 
GMMA is the LPS. Depending on the dose of GMMA to be used in a vaccine, strong 
activation of the innate immunity may lead to unacceptable reactions in human 
subjects, e.g. a febrile response, or in extreme cases, septic shock, especially if 
parenterally administered. Thus, the reactogenicity of GMMA, especially the LPS 
endotoxicity, might need to be modified. 
LPS consists of three main regions, i.e. the glycolipid lipid A, a core oligosaccharide, 
and an outer polysaccharide chain (O antigen). The lipid A is the reactogenic part 
interacting with TLR4. The most reactogenic form of lipid A is a hexa-acylated 
glucosamine disaccharide phosphorylated at the 1 and 4’ positions. This structure is 
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common to E. coli and Shigella. During the lipid A synthesis first a tetra-acylated core 
structure composed of the phosphorylated glucosamine disaccharide acylated at 2, 
3, 2’ and 3’ position with R-3-hydroxymyristate is generated. Subsequently, the late 
acyltransferases HtrB (also called LpxL) and MsbB (also called LpxM) transfer a 
lauroyl fatty acid (HtrB) and a myristoyl fatty acid (MsbB) to the hydroxymyristate in 
the 2’ and 3’ positions, respectively. 
The total number and the length of acyl chains are critical factors for full lipid A 
activation of human TLR4. Changes to the structure of the lipid A, either by removal 
of critical components or by replacement e.g. of one of the acyl chains by a different 
acyl residue, effects the binding and recognition by TLR4 and results in a lower 
endotoxicity in vitro. Thus, changes in the acylation status of lipid A presents an 
attractive way for reducing the TLR4-mediated endotoxicity of GMMA. The effects of 
genetic lipid A modification needs to be evaluated in the context of the relative 
contribution of TLR2 and TLR4 pathways to the activation of human cells to define 
the impact on the overall reduction of GMMA reactogenicity. 
 
Aims of the project 
The broad aim of the project was to identify ways of reducing the reactogenicity of 
GMMA. This broad aim was divided into three specific goals: 
1. Proof of feasibility of reduction of GMMA endotoxicity by lipid A modification 
using Shigella. 
2. Assessment of relative contribution of TLR4 and TLR2 pathways to stimulation 
of human cells by GMMA with different lipid A modifications 
3. Demonstration of general applicability of the identified methods for the GMMA 
platform. 
The work for goals 1 and 2 has been part of the NVGH program to develop a Shigella 
GMMA vaccine. The work for goal 3 has been involved in the development of GMMA-
based non-Typhoidal Salmonella and Neisseria meningitidis vaccines for Africa. 
 
1. Proof of feasibility of reduction of GMMA endotoxicity by genetic lipid A 
modification 
 
Optimization of GMMA quantification 
Establishing a consistent and reproducible method for the quantification of GMMA is 
important in order to use them as vaccine and for comparing them in functional 
assays. GMMA are conveniently quantified based on protein amount. The gold 
standard for protein quantification is quantitative amino acid (AA) hydrolysis. It is a 
primary method as it is not affected by protein composition and does not need a 
calibration curve with a standard protein. However, analysis based on AA content is 
slow and for this purpose secondary colorimetric assays using a standard protein are 
usually preferred. 
I compared different routinely used color-based protein assays for quantifying GMMA 
samples: Bradford assay, Lowry assay, and Non-Interfering protein assay (NI), a 
method that involves a protein precipitation step. I examined several factors to 
determine the most useful secondary assay for measuring the protein concentration 
of GMMA: the ease of performing the assay, the reproducibility of the assay, the 
linearity of the assay, and the comparability of the results for GMMA from multiple 
different bacteria. By these criteria, the Lowry assay was superior. It was by far the 
simplest assay to perform, gave substantially lower inter- and intra-assay variation 
than the other assays, and most importantly showed the most consistent results for 
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different types of GMMA. The Lowry assay consistently overestimated the GMMA 
protein concentration by about 35% as the color yield of BSA differed from the color 
yield of GMMA. In contrast, the Bradford assay underestimated the GMMA protein 
concentration by 50 % to 80%, and the NI assay varied from giving a very similar 
result as the AA quantification to 40% underestimation based on the type of GMMA. 
The results of the Bradford and NI assays varied even for GMMA from isogenic 
strains differing by a single mutation making them less useful for comparing different 
GMMA than the Lowry assay. These results also highlighted the need for caution 
when comparing results obtained with NOMV by various laboratories if different 
protein assays were used.  
 
Genetic lipid A modification in S. sonnei and S. flexneri and MALDI-TOF 
analysis 
The htrB or msbB genes encoding for the late acyl transferases were inactivated in 
GMMA-producing S. sonnei and S. flexneri strains. All of the lipid A mutants were 
able to reach high optical densities in the medium optimized for industrial production 
and produced GMMA with similar yields. Electron microscopy confirmed that lipid A 
modification did not alter the size or organization of GMMA. In addition, SDS-PAGE 
showed that the overall protein composition remained similar. Four protein bands 
were found to be up-regulated in GMMA from S. flexneri ∆htrB. As these were 
identified by peptide mass fingerprinting to be predicted cytoplasmic proteins, no 
effect on the reactogenicity studies was expected.  
To analyze the lipid A composition resulting from the different genetic modifications, 
the lipid A was purified from GMMA and analyzed by MALDI-TOF. The main peaks in 
the mass spectra of lipid A from S. sonnei and S. flexneri GMMA with wild-type lipid A 
had an m/z corresponding to the theoretical mass of the hexa-acylated lipid A of 
1798 Da. The results of deleting the msbB gene from both S. sonnei and S. flexneri 
as well as by deleting the htrB gene from S. sonnei were as expected: conversion of 
a hexa-acylated lipid A to a penta-acylated lipid A through loss of a myristic acid (a 
C14 fatty acid chain, 210 m/z shift in ∆msbB) or lauric acid (a C12 fatty acid chain, 182 
m/z shift, ∆htrB). In contrast, the spectra obtained from S. flexneri ∆htrB GMMA, 
showed a peak at 1851 m/z as dominant species, corresponding to a hexa-acylated 
lipid A but with different composition compared to the wild-type lipid A. The m/z is in 
accordance with the exchange of a C12 chain at the HtrB site for a C16:1 fatty acid 
chain (m/z shift of 54 to WT, m/z shift of 236 to S. sonnei ∆htrB). The presence of a 
palmitoleoyl chain in lipid A from S. flexneri ∆htrB GMMA was confirmed by Collision 
Induced Decay MS/MS analysis. The palmitoleoylated hexa-acylated form was also 
the main form in lipid A preparations from of GMMA from htrB mutants of other 
S. flexneri strains, e.g. serotypes 3a and 6, suggesting a strong selection for 
palmitoleoylation after htrB knock out in S. flexneri. To confirm that the lipid A 
modifications observed in the htrB mutants were linked to the htrB deletion, the 
mutants were complemented with a low copy plasmid encoding htrB. As expected, 
the respective MALDI-TOF spectra showed a lipid A with an m/z of wild-type hexa-
acylated lipid A. No hepta-acylated lipid A was observed, suggesting that the 
palmitoleoyl chain peak was attached to the HtrB site or is dependent on the HtrB 
site being vacant.  
It is unclear why the palmitoleoylation was not found in S. sonnei ∆htrB. In addition to 
our findings with S. flexneri ∆htrB, an E. coli htrB mutant has previously been 
described to produce palmitoleoylated lipid A, but as a minor species. 
Palmitoleoylation at the HtrB site is known to occur as cold response in E. coli 
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catalyzed by LpxP. After growth of S. sonnei ∆htrB at 12°C to induce the cold 
response, small amounts of palmitoleoylated lipid A were detected by MALDI-TOF, 
demonstrating that LpxP is functional. By quantitative real time PCR we observed a 
7-fold higher expression of the lpxP gene at 30°C in S. flexneri ∆htrB compared to 
S. sonnei ∆htrB, most likely accounting for the difference in the palmitoleoylation. 
  
TLR4 stimulation by GMMA after lipid A modification  
In order to assess the ability of the different lipid A mutants to activate TLR4 a 
reporter cell line expressing luciferase under control of human TLR4 was used.   
GMMA from S. flexneri ∆msbB and S. sonnei ∆msbB showed an approximately 600-
fold decrease in their ability to stimulated TLR4 compared to the parent GMMA with 
wild-type lipid A. A substantial further decrease of stimulatory activity was observed 
with GMMA from S. sonnei ∆htrB. Luciferase induction was only detectable at a high 
concentration, requiring a 60,000-fold higher amount of GMMA than the parent 
GMMA with wild-type lipid A and a 100-fold higher amount than ∆msbB GMMA to 
induce the same level of induction.  
In contrast, GMMA from S. flexneri ∆htrB with palmitoleoylated hexa-acylated lipid A 
retained higher TLR4 stimulation than ∆msbB GMMA requiring 10-fold less GMMA to 
result in similar induction of luciferase. Accordingly they showed a relatively small 
(50-fold) decrease of stimulatory activity compared to GMMA with wild-type lipid A. 
This suggested that the palmitoleoylated hexa-acylated lipid A retained TLR4 
stimulatory activity but that the substitution of the lauroyl chain by the palmitoleoyl 
chain decreased TLR4 stimulation compared to wild-type lipid A. 
 
2. Assessment of relative contribution of TLR4 and TLR2 pathways to 
stimulation of human cells by GMMA with different lipid A modifications 
 
In order to evaluate the endotoxin activity of GMMA in a more natural context, GMMA 
purified form different mutants were used to stimulate human Peripheral Blood 
Mononuclear Cells (PBMC) in a Monocyte Activation Test (MAT). 
GMMA purified from Shigella strains carrying lipid A modification (both htrB and 
msbB) showed a reduction in their activity to stimulate cytokine production 
(Interleukin 6 [IL-6], IL-8, IL-1β, Tumor Necrosis Factor α) in comparison to GMMA 
from strains without LPS modifications, with a similar trend as observed in TLR4-
specific assay. GMMA purified from ∆msbB strains required an approximately 300-
fold higher amount, GMMA from S. flexneri ∆htrB an approximately 50-fold higher 
amount compared to GMMA with wild-type lipid A to induce similar IL-6 release. In 
contrast, GMMA from S. sonnei ∆htrB showed a 800-fold decreased ability to 
stimulate IL-6 release from PBMC and thus a lower decrease in activity than 
expected from the 60,000-fold reduction of TLR4 stimulation, indicating that 
additional TLR pathways contribute to the stimulation of PBMC, most likely the TLR2 
pathway. 
In order to determine the relative contribution of the TLR4 and TLR2 pathway to the 
stimulation of human PBMC by GMMA, PBMC were incubated with anti-TLR4 or anti-
TLR2 antibodies to selectively block TLR4 or TLR2 activity prior to stimulation by 
GMMA. No remaining TLR4 activity of GMMA from S. sonnei ∆htrB with penta-
acylated lipid A was detected. GMMA with penta-acylated lipid A from ∆msbB strains 
retained some ability to activate human TLR4, but the induction of IL-6 via the lipid A 
dependent TLR4 in these GMMA was smaller than the induction via TLR2. This 
showed that the residual reactogenicity in GMMA with penta-acylated lipid A was 
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mainly mediated through TLR2. In contrast, a substantial decrease of activation by 
GMMA from S. flexneri ∆htrB was achieved using anti-TLR4 antibody but not with 
anti-TLR2 antibody demonstrated that palmitoleoylated hexa-acylated lipid A retained 
strong TLR4 activation. 
To confirm that the differences in the relative contribution of TLR4 and TLR2 to 
activation observed in the blocking experiments were solely dependent on the 
differential TLR4 activation by the different GMMA the ability of the GMMA to 
activated TLR2 was tested using a human TLR2 reporter cell line. All four ∆msbB or 
∆htrB GMMA showed similar TLR2 activation.  
 
Conclusion: Feasibility of reduction of reactogenicity by lipid A modification 
Proof of concept of reduction of reactogenicity of GMMA by genetic lipid A 
modification has been obtained. 
GMMA with penta-acylated lipid A showed a marked reduction in the induction of 
inflammatory cytokines from human PMBC. Deleting htrB gene from S. sonnei 
resulted in a 800-fold reduction of cytokine stimulatory activity and the remaining 
activity was TLR2-mediated. GMMA from msbB deletion strains showed a 300-fold 
reduction. They retained detectible TLR4 activity, however, the major activated 
pathway was TLR2, similar as for S. sonnei ∆htrB GMMA.  
In contrast, compensatory palmitoleoylation in the S. flexneri ∆htrB GMMA resulted in 
retained TLR4 activation by the hexa-acylated lipid A and thus higher reactogenicity 
suggesting that modifications yielding penta-acylated lipid A will be preferred. 
 
3. Demonstration of general applicability of the identified methods for the 
GMMA platform  
 
Salmonella 
Salmonella enterica is a species within the Enterobacteriaceae closely related to 
Shigella and shares the same hexa-acylated lipid A. Thus, as in Shigella, lipid A 
modification by deletion of htrB and msbB of GMMA-producing strains of Salmonella 
enterica serovars Typhimurium (S. Tm) and Enteritidis (S. En) was investigated. 
However, the situation in Salmonella is more complex as the lipid A is, at least in 
part, hepta-acylated through the PagP-catalyzed addition of a palmitoyl chain (a C16 
fatty acid chain) to hydroxymyristate in position 2. The relative amounts of hexa- and 
hepta-acylated lipid A vary in different strains from more than 95% hexa-acylated to 
more than 30% hepta-acylated. In line with the presence of a mixture of hexa- and 
hepta-acylated lipid A in GMMA before lipid A modifications, the removal of a single 
acyl chain by deletion of msbB or htrB resulted a mixture of penta- and hexa-acylated 
lipid A lacking the myristoyl or a lauroyl chain, respectively. Interestingly, after htrB 
deletion in S. En, we observed the same  compensatory palmitoleoylation as 
observed in S. flexneri ∆htrB resulting in a mixture of hexa- and hepta-acylated lipid 
A with the replacement of the lauroyl chain by the palmitoleoyl chain (m/z shift =54).  
S. Tm ∆msbB GMMA contained more than 95% penta-acylated lipid A and showed 
similar level of IL-6 stimulation from human PBMC as Shigella GMMA with penta-
acylated lipid A. All other tested STm and SEn GMMA with lipid A modifications 
contained a higher percentage of hexa-acylated lipid A. In accordance to the results 
obtained with S. flexneri ∆htrB GMMA with hexa-acylated palmitoleoylated lipid A, S. 
Tm and S. En GMMA with hexa-acylated lipid A retained higher TLR4 activity and are 
less likely to result in a useful vaccines. 
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In conclusion, S. Tm GMMA with penta-acylated lipid A showed a similarly reduced 
reactogenicity profile as Shigella GMMA with penta-acylated lipid A. However, to 
obtain Salmonella GMMA with predominantly penta-acylated lipid A and without 
hexa-acylated lipid A, additional mutations to htrB or msbB might be needed.  
 
Neisseria 
The reduction of GMMA endotoxicity by genetic lipid A modification was also 
assessed in Neisseria meningitidis, a species less genetically related to Shigella. 
Lipid A from Neisseria is hexa-acylated with a different fatty acid composition and 
distribution compared to Shigella lipid A. In addition, the phosphate in 4’ position 
carries a phosphoethanolamine. Despite the differences, similar amounts of 
Neisseria and Shigella GMMA with wild-type lipid A induce similar levels of IL-6 
release from human PBMCs. To obtain penta-acylated lipid A we deleted the gene 
lpxL1, as was previously reported, encoding an acyl transferase that adds a lauroyl 
chain to the hydroxymyristoyl in 2’ position. Penta-acylation of the resulting lipid A 
was confirmed by MALDI-TOF showing an m/z shift of 182 Dalton to WT lipid A, 
consistent with the absence of the lauroyl chain.  
The resulting GMMA from the Neisseria ∆lpxL1 mutant showed a marked reduction 
of TLR4 activation and stimulation of IL-6 from human PBMC, at similar levels to 
S. sonnei ∆htrB GMMA. This result emphasized that despite differences in lipid A 
composition, penta-acylated lipid A retains little TLR4 activation and results in 
substantial reduction of the reactogenicity of GMMA.  
 
Conclusions 
The broad aim of the thesis was to examine ways of reducing the reactogenicity of 
GMMA to make them suitable for use as human vaccine. It resulted in surprisingly 
complex outcome. 
I demonstrated the feasibility to reduce GMMA reactogenicity by lipid A modification. I 
found a clear relation between the composition of the lipid A species and 
reactogenicity. Our analysis of GMMA from isogenic lines and from different species 
highlighted the importance of determining the composition of the lipid A after the 
genetic modification as the same genetic modification gave different outcomes even 
in closely related Shigella species.  
I demonstrated in Shigella, Salmonella, and Neisseria that GMMA with penta-
acylated lipid A have a marked reduction of cytokine stimulation ability. Using 
Shigella GMMA we showed that the residual reactogenicity is predominantly TLR2 
mediated. In contrast, GMMA with hexa-acylated lipid A, either through 
palmitoleoylation after htrB knock-out, and/or due to additional palmitoylation in 
Salmonella, retain TLR4 stimulatory activity and are less likely to be useful as 
vaccine.  
Based on the results presented in this thesis, genetic modification of the lipid A 
biosynthesis pathway resulting in penta-acylated lipid A is a promising strategy for 
reducing the reactogenicity of GMMA. If further decrease of reactogenicity was 
required, modifications of TLR2 activating components would be necessary. However, 
the level of reduction required for an acceptable vaccine will depend on the dose 
necessary to give a strong immune response and that can only be determined by 
clinical trials. Clinical trials underway now using the S. sonnei ∆htrB GMMA should 
give an important indication of the tolerability of these constructs. 
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Riassunto 
 
Introduzione 
Le malattie infettive sono ancora oggi una delle cause principali di mortalità e 
morbidità nei paesi in via di sviluppo, specialmente nei bambini di età inferiore ai 5 
anni e per molte di queste malattie non sono disponibili vaccini. Un vaccino ideale 
dovrebbe essere facile da amministrare, ben tollerato, conferire protezione contro 
molteplici patogeni, facile da fabbricare, disponibile a basso costo (idealmente < 1 $ 
per dose) ed essere in grado di indurre una protezione a lungo termine. 
La missione di NVGH è quella di sviluppare vaccini efficaci e accessibili per le 
malattie trascurate che affliggono i paesi poveri. Per perseguire questo obiettivo, 
NVGH sta sviluppando piattaforme tecnologiche che possono essere applicate allo 
sviluppo di vaccini per diversi agenti patogeni. Una importante piattaforma si basa su 
particelle membrana esterna, nominate Moduli Generalizzati per Antigeni di 
Membrana (Generalized Modules for membrane Antigens, GMMA). Questa 
piattaforma è utilizzata nei tre maggiori programmi di NVGH: Shigella, una delle 
principali cause di dissenteria, che causa più di 125 milioni di casi e 100,000 morti 
all'anno, Salmonella non-Tifoidea invasiva (iNTS), con circa più di 100,000 morti 
all'anno, e Neisseria menigitidis, responsabile di epidemie che causano più di 50,000 
morti all'anno e sequele permanenti. 
La piattaforma GMMA sfrutta la capacità dei batteri Gram-negativi di espellere 
naturalmente piccole particelle dalla membrana esterna e rilasciarle nell’ambiente. 
Queste particelle naturalmente rilasciate, chiamate anche vescicole di membrana 
esterna native (Native Outer Membrane Vesicles, NOMV), sono costituite da lipidi e 
proteine della membrana esterna e componenti periplasmatiche solubili. Esse 
presentano antigeni di superficie nel loro orientamento e conformazione naturale, 
quindi sono stati proposti per l'uso come vaccini. Tuttavia, la resa è di solito troppo 
bassa per un utilizzo pratico. NVGH ha sviluppato un processo di produzione ad alta 
resa adatto per la produzione industriale, mediante modificazione genetica dei batteri 
al fine di indurre un elevato livello di rilascio. Per differenziare le particelle rilasciate 
dai batteri geneticamente modificati dalle NOMV e da altri tipi di particelle prodotte 
dai batteri, sono stati chiamate GMMA . 
GMMA sono altamente immunogeniche ed in parte questo è legato alla forte 
capacità auto-adiuvante. Poiché GMMA derivano dalla membrana esterna dei batteri 
Gram-negativi, queste contengono alti livelli di molecole chiamate Pathogen 
Associated Molecular Patterns (PAMPs). I PAMPs sono molecole presenti solo nei 
batteri e sono riconosciute da Pattern Recognition receptors (PRR), tra i quali i Toll-
like receptors (TLR), che sono espressi su una vasta gamma di cellule di mammifero. 
I recettori di particolare importanza per il riconoscimento dei batteri Gram-negativi 
sono il TLR4 ed il TLR2. Il TLR4 è il recettore coinvolto nel riconoscimento del 
lipopolisaccaride (LPS), mentre il TLR2 è coinvolto nel riconoscimento di una vasta 
gamma di molecole, tra cui lipoproteine che, insieme all’LPS, rappresentano i 
costituenti essenziali della membrana esterna dei batteri Gram-negativi. 
Il singolo componente immuno-stimolante più abbondante e più potente presente 
nelle GMMA è rappresentato dall’LPS. A seconda della dose di GMMA che debba 
essere utilizzata in un vaccino, una massiccia attivazione dell'immunità innata può 
provocare reazioni inaccettabili in soggetti umani, ad esempio una risposta febbrile o, 
in casi estremi, shock settico, soprattutto se somministrato per via parenterale. Per 
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questo motivo, la reattogenicità delle GMMA, ed in particolare l’endotossicità 
dell’LPS, potrebbe dover essere modificata. 
L’LPS è costituito da tre regioni principali: il glicolipide “lipide A”, un “core” 
oligosaccaridico, ed una catena polisaccaridica esterna (l’antigene O). Il lipide A è la 
parte reattogenica della molecola che interagisce con il TLR4. La forma più 
reattogenica di lipide A è rappresentata da un disaccaride di glucosamina esa-acilato 
e fosforilato nelle posizioni 1 e 4’. Questa struttura è la forma comune presente in E. 
coli e Shigella. Durante la biosintesi del lipide A viene prima generata una struttura di 
base tetra-acilata, composta da un disaccaride di glucosamina fosforilato ed acilato 
nelle posizioni 2, 3, 2‘ e 3’ con R-3-idrossimiristoile. Successivamente le acilasi 
tardive HtrB (chiamata anche LpxL) ed MsbB (chiamata anche LpxM) trasferiscono 
l’acido grasso lauroile (HtrB) e l’acido grasso miristoile (MsbB) sugli idrossimiristati 
nelle posizioni 2' e 3' rispettivamente. 
Il numero totale e la lunghezza delle catene aciliche sono fattori critici per la piena 
attivazione del lipide A TLR4 umano. Modifiche nella struttura del lipide A, sia per 
quanto riguarda la rimozione che per quanto riguada la sostituzione, ad esempio, di 
una delle catene aciliche con un diverso residuo acilico, hanno effetti sul legame e 
sul riconoscimento da parte del TLR4, che si traduce in una minore endotossicità in 
vitro. Per cui i cambiamenti nello stato acilazione del lipide A rappresentano un modo 
interessante per ridurre l’endotossicità TLR4-mediata delle GMMA. Al fine di valutare 
l'effetto di tali modificazioni genetiche sulla reattogenicità complessiva delle GMMA e 
di individuare ulteriori strategie per ridurre la reattogenicità di quest’ultime, è 
importante determinare il contributo relativo dei pathways TLR2 e TLR4 
nell'attivazione delle cellule umane da parte di GMMA. 
 
Obiettivi del progetto 
L'obiettivo generale del progetto è quello di individuare i metodi per ridurre la 
reattogenicità delle GMMA. Questo obiettivo principale è stato diviso in tre obiettivi 
specifici: 
1. La prova di fattibilità della riduzione della reattogenicità delle GMMA mediante 
modifica genetica del lipide A utilizzando Shigella. 
2. La valutazione del contributo relativo dei pathways TLR4 e TLR2 nella 
stimolazione delle cellule umane mediante GMMA con differenti modificazioni 
del lipide A. 
3. La dimostrazione di applicabilità generale dei metodi individuati per la 
piattaforma GMMA. 
Il lavoro per obiettivi 1 e 2 è parte del programma NVGH per sviluppare un vaccino 
per Shigella utlizzando le GMMA. L'obiettivo 3 è coinvolto nello sviluppo vaccini 
basati su GMMA contro Salmonellae invasive non-Tifoidee e Neisseria meningitidis 
per un loro utilizzo in principalmente in Africa. 
 
1. Prova di fattibilità della riduzione dell’endotossicità delle GMMA mediante 
modificazione genetica del lipide A 
 
Ottimizzazione dei motodi di quantificazione delle GMMA 
Stabilire un metodo coerente e riproducibile per la quantificazione dei campioni 
GMMA è importante al fine di utilizzarli come vaccino e per confrontarle in saggi 
funzionali. Le GMMA sono convenientemente quantificate sulla base del loro 
contenuto proteico. Lo standard per la quantificazione delle proteine è l’idrolisi di 
aminoacidi (AA) quantitativa. Si tratta di un metodo primario, in quanto non è 
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influenzato dalla composizione proteica del campione di partenza, e non necessita di 
una curva di calibrazione con una proteina standard. Tuttavia, l'analisi basata sul 
contenuto AA è lenta e per questo scopo saggi colorimetrici secondari che 
utilizzando una proteina standard sono normalmente preferiti. Ho, quindi, confrontato 
differenti dosaggi colorimetrici di proteine utilizzati abitualmente, nella quantificazione 
di campioni di GMMA: il saggio Bradford, il saggio Lowry, e il saggio Non-Interfeering 
(NI), un metodo che prevede una fase di precipitazione delle proteine. Ho esaminato 
diversi fattori per determinare il saggio secondario più utile per misurare la 
concentrazione delle proteine nelle GMMA: la facilità di esecuzione del test, la 
riproducibilità del dosaggio, la linearità del dosaggio e la comparabilità dei risultati 
per GMMA provenienti da batteri diversi. Valutando questi criteri, il test Lowry si è 
dimostrato migliore. È di gran lunga il saggio più semplice da eseguire, presenta 
inferiore variazione inter- e intra-saggio rispetto agli altri metodi, e soprattutto ha 
mostrato i risultati più coerenti per i diversi tipi di GMMA. Il saggio di Lowry 
costantemente sovrastima la concentrazione proteica nelle GMMA di circa il 35% 
utilizzando la BSA come standard. Al contrario, il saggio Bradford sottostimava la 
concentrazione proteica delle GMMA dal 50% al 80%, mentre il saggio NI variava dal 
dare un risultato molto simile a quello della quantificazione AA, alla sottostima del 
40% in base al tipo di GMMA testato. Il fatto che i risultati di questo saggio varino, 
quindi, anche per GMMA provenienti da ceppi isogenetici che differiscono per una 
singola mutazione, lo rende meno utile per confrontare diverse GMMA, soprattutto in 
saggi funzionali. 
I risultati hanno anche evidenziato la necessità di cautela quando si confrontano i 
risultati ottenuti con NOMV da vari laboratori se sono stati usati diversi dosaggi di 
proteine . 
 
Modifica genetica del lipide A in S. sonnei e S. flexneri ed analisi MALDI -TOF 
I geni htrB o msbB, codificanti per aciltransferasi tardive, sono stati inattivati in ceppi 
di S. sonnei e S.flexneri produttori di GMMA. Tutti i ceppi mutanti nel lipide A erano in 
grado di raggiungere elevate densità ottiche nel terreno ottimizzato per la produzione 
industriale ed hanno prodotto GMMA con rese analoghe. Mediante microscopia 
elettronica è stato confermato che modifiche nel lipide A non hanno alterato la 
dimensione o l'organizzazione delle GMMA. Inoltre, mediante SDS - PAGE è stato 
osservato che la composizione proteica compessiva rimaneva simile. Solo quattro 
bande proteiche sono state osservate come sovraregolate in GMMA da S. flexneri 
∆htrB; queste sono state identificate mediante Peptide Mass Fingerprinting e sono 
state predette come proteine citoplasmatiche, per cui nessun alcun effetto sugli studi 
di reattogenicità è stato predetto. 
Per analizzare la composizione del lipide A risultante dalle diverse modificazioni 
genetiche, quest ultimo è stato purificato da GMMA ed analizzato tramite 
spettrometria MALDI- TOF. I principali picchi osservati negli spettri di massa di lipide 
A da GMMA provenienti da S. sonnei e S.flexneri con lipide A wild-type hanno un 
rapporto massa/carica (m/z) corrispondente alla massa teorica del lipide A esa-
acilato di 1798 Da. I risultati della delezione del gene msbB, sia da S. sonnei che da 
S.flexneri, nonché quelli dell’eliminazione del gene htrB da S. sonnei sono stati quelli 
previsti: la conversione di un lipide A esa-acilato ad uno penta-acilato dovuto alla 
mancanza di un acido miristico (una catena di acido grasso C14, shift m/z di 210 nel 
caso di ∆msbB) o di un acido laurico (una catena di acido grasso C12, shift m/z di 182 
nel caso di ∆msbB). Al contrario, lo spettro ottenuto da GMMA di S. flexneri ∆htrB, 
ha mostrato un picco a 1851 m/z come specie dominante, corrispondente ad un 
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lipide A esa-acilato ma con composizione differente rispetto al lipide A wild-type 
(WT). Il m/z è conforme allo scambio di una catena C12 nel sito HtrB con una catena 
C16:1 di acido grasso (spostamento m/z di 54 rispetto a WT, 236 m/z rispeto a GMMA 
da S. sonnei ∆htrB). La presenza di una catena di palmitoleoile nel lipide A 
proveniente da GMMA di S. flexneri ∆htrB è stata confermata dall'analisi mediante 
spettrometria massa/massa avvalendosi del Collision Induced Decay. La forma esa-
acilata palmitoleoilata è anche la principale forma di lipidi A presente in GMMA da 
mutanti htrB con diverso background genetico e da altri ceppi di S. flexneri, ad 
esempio sierotipi 3a e 6, suggerendo una forte selezione per la palmitoleoilazione 
dopo delezione di htrB in S. flexneri. Per confermare che le modifiche osservate nei 
mutanti nei lipidi A ∆htrB fossero direttamente legate alla delezione di htrB, le 
mutazioni sono state complementate utilizzando un plasmide a basso numero di 
copie codificante il gene htrB. Come previsto, i rispettivi spettri MALDI-TOF hanno 
mostrato un lipide A esa-acilato con m/z di tipo WT; inoltre non è stato osservato 
lipide A epta-acilato A, suggerendo che la catena palmitoilica venga attaccata al sito 
HtrB o sia dipendente dal fatto che il sito HtrB sia libero. 
Non è chiaro il motivo per cui la palmitoleoilazione non sia stata osservata in S. 
sonnei ∆htrB. In aggiunta ai nostri risultati, un mutante di E. coli ∆htrB è stato 
precedentemente descritto come capace di produrre lipide A palmitoleoilato, ma 
come specie minore. La palmitoleoilazione nel sito htrB è riportata come risposta da 
freddo in E. coli catalizzata da LpxP. Dopo una crescita di S. sonnei ∆htrB a 12 °C 
per indurre la risposta da freddo, piccole quantità di lipide A palmitoleoilato sono 
state rilevate mediante MALDI-TOF, dimostrando che il gene lpxP è funzionale. 
Molto probabilmente la differenza nella palmitoleoilazione nei due mutanti è 
riconducibile ad un livello di espressione 7 volte più elevato del gene lpxP a 30 °C in 
S. flexneri ∆htrB rispetto a S. sonnei ∆htrB come osservato mediante PCR 
quantitativa in tempo reale. 
 
Stimolazione del TLR4 da parte di GMMA dopo modifica genetica del lipide A 
Per valutare la capacità dei diversi mutanti di lipide A di attivare TLR4 è stata 
utilizzata una linea cellulare che esprime un gene reporter di luciferasi sotto il 
controllo del TLR4 umano.  
GMMA purificate da mutanti ∆msbB hanno mostrato una diminuzione di circa 600 
volte nella loro capacità di stimolare il TLR4 rispetto a GMMA contenenti lipide A 
wild-type. Un’ulteriore sostanziale diminuzione di attività stimolante è stata osservata 
con GMMA da S. sonnei ∆htrB. L’induzione della luciferasi è stata rilevabile solo ad 
una concentrazione elevata di GMMA, richiedendo una quantità 60,000 volte più 
elevata rispetto a quella necessaria nel caso di GMMA contenenti lipide A WT e 100 
volte superiore rispetto a GMMA ∆msbB nell’indurre lo stesso livello di attivazione. 
Al contrario, GMMA da S. flexneri ∆htrB, contenenti lipide A esa-acilato 
palmitoleoilato, hanno manetenuto una superiore capacità di stimolare il TLR4 
umano rispetto alle GMMA ∆msbB, richiedendo una quantità di GMMA 10 volte 
inferiore per provocare una simile induzione di luciferasi. Di conseguenza queste 
GMMA hanno mostrato una relativamente piccola (50 volte) diminuzione di attività 
stimolante rispetto al GMMA contenenti lipide A WT. Questo suggerisce che lil lipide 
A esa-acilato palmitoleoilato mantiene attività stimolante del TLR4, ma che la 
sostituzione della catena di lauroile con quella di palmitoleoile provoca una diminuizie 
della stimolazione del TLR4 rispetto al lipide A WT.  
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2. Valutazione del contributo relativo dei pathways TLR4 e TLR2 nella 
stimolazione delle cellule umane mediante GMMA contenenti differenti 
modificazioni dei lipide A  
 
Al fine di valutare l'attività di endotossica delle GMMA in un contesto più naturale, 
GMMA purificate dai diversi mutanti sono state usate per stimolare cellule umane 
mononucleate da sangue periferico (PBMC) in un test di attivazione dei monociti 
(MAT). . 
GMMA purificate da ceppi di Shigella contenenti lipide A modificato (sia ∆htrB che 
∆msbB) hanno mostrato una diminuzione della capacità di stimolare la produzione di 
citochine (interleuchina 6 [IL- 6], IL-8, IL-1β, Tumor Necrosis Factor-α) rispetto a 
GMMA purificate da ceppi senza modifiche nell’LPS, con una tendenza simile a 
quella osservata nel test TLR4-specifico. GMMA purificate da ceppi ∆msbB 
necessitano di una quantità circa 300 volte superiore rispetto alle GMMA con lipide A 
WT per indurre un simile rilascio di IL-6, mentre GMMA da S. flexneri ∆htrB di circa 
50 volte maggiore. Al contrario, GMMA da S. sonnei ∆htrB hanno mostrato un 
capacità 800 volte inferiore nella capacità di stimolare il rilascio di IL-6 da PBMC, per 
cui una diminuzione minore in attività rispetto a quanto previsto dalla riduzione di 
60,000 volte osservata nella stimolazione di TLR4 (rispetto a GMMA contenenti lipide 
A WT), ad indicare che ulteriori PRR contribuiscono alla stimolazione dei PBMC, 
molto probabilmente la via TLR2. 
Al fine di determinare il contributo relativo dei pathways TLR4 e TLR2 nella 
stimolazione mediante GMMA di PBMC umani, quest’ultimi sono state incubati con 
anticorpi anti-TLR4 o anti-TLR2 per bloccare selettivamente l’attività di TLR4 o TLR2 
prima della stimolazione con GMMA. Non è stata rilevata alcuna attività residua di 
TLR4 in GMMA da S. sonnei ∆htrB con lipide A penta-acilato A. GMMA con lipide A 
penta-acilato da ceppi ∆msbB, invece, hanno mantenuto una certa capacità di 
attivare il TLR4 umano, ma l'induzione di IL- 6 TLR4-dipendente in queste GMMA era 
più piccola rispetto all'induzione TLR2-dipendente. Questo ha dimostrato che la 
reattogenicità residua nella GMMA contenenti lipide A penta-acilato è mediata 
principalmente da TLR2. Al contrario, una sostanziale diminuzione nell’attivazione di 
GMMA da S. flexneri ∆htrB è stata ottenuta utilizzando anticorpi anti-TLR4 ma non 
con anticorpi anti-TLR2, dimostrando che il lipide A esa-acilato palmitoleoilato 
mantiene una forte attività stimolante nei confronti del TLR4. 
Per confermare che le differenze nel contributo relativo di TLR4 e TLR2 
all'attivazione osservato negli esperimenti di blocco erano dipendenti esclusivamente 
dalla differenziale attivazione di TLR4 da parte delle differenti GMMA, la capacità 
delle GMMA di attivare il TLR2 è stata testata utilizzando una linea cellulare che 
esprime solo il TLR2 umano  Tutti e quattro le GMMA ∆msbB o ∆htrB hanno 
mostrato in questo saggio simile attivazione del TLR2. 
 
Conclusione: fattibilità della riduzione di reattogenicità mediante modifica del lipide A 
La prova concenttuale della riduzione della reattogenicità delle GMMA mediante 
modificazione genetica del lipide A è stata ottenuta. 
GMMA con lipide A penta-acilato hanno mostrato una marcata riduzione nella 
capacità di induzione di citochine infiammatorie da PMBC umani. La delezione del 
gene htrB da S. sonnei ha comportato una riduzione di 800 volte dell’attività 
stimolante di citochine e l'attività residua è TLR2-mediata. GMMA da mutanti con 
delezione di msbB hanno mostrato, invece, una riduzione di 300 volte, mantenendo 
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un’attività TLR4-mediata misurabile; tuttavia, la principale via attivata era quella 
TLR2-mediata, similmente a quanto osservato per GMMA da S. sonnei ∆htrB. 
Al contrario, una compensazione mediante palmitoleoilazione in GMMA da S. flexneri 
∆htrB ha comportato il mantenimento dell'attivazione TLR4-mediata da parte del 
lipide A esa-acilato, e quindi una superiore reattogenicità, suggerendo che 
modificazioni che risultino in lipidi A penta-acilati siano da preferirsi. 
 
3. Dimostrazione di applicabilità generale dei metodi individuati per la 
piattaforma GMMA 
 
Salmonella 
Salmonella enterica è una specie di Enterobacteriaceae strettamente correlata a 
Shigella, con la quale condivide lo stesso lipide A esa-acilato. Per cui, come per 
Shigella, è stato indagatao l’effetto di una modifica del lipide A, mediante delezione di 
htrB e msbB, in ceppi GMMA-produttori di Salmonella enterica sierotipi Typhimurium 
(S. Tm) e Enteritidis (S. En). 
Tuttavia, la situazione in Salmonella è più complessa rispetto a Shigella, in quanto il 
lipide A è, almeno in parte, epta-acilato a causa del'aggiunta, catalizzata da PagP, di 
una catena di palmitoleoile (una catena di acido grasso C16) a livello 
dell’idrossimiristato in posizione 2. Le quantità relative di lipide A esa- ed epta-acilato 
variano in ceppi diversi, da più del 95% esa-acilato ad oltre il 30 % epta-acilato. In 
accordo con la presenza di una miscela di lipide A esa- ed epta-acilato nel lipide A 
prima delle modifiche genetiche del lipide A, l'eliminazione di una singola catena 
acilica dovuta alla delezione di msbB o htrB hanno comportato l’ottenimento di una 
miscela di lipide A penta- ed esa-acilato mancante di una catena miristoilica o 
lauroilica rispettivamente. È interessante notare come, dopo delezione di htrB in 
SEn, sia stata osservata la stessa compensazione mediante palmitoleoilazione 
osservata in S. flexneri ∆htrB, risultante in una miscela di lipide A esa- ed epta-
acilato con la sostituzione della catena di lauroile con quella di palmitoleoile 
(spostamento m/z = 54). 
GMMA da S. Tm ∆msbB, contenenti oltre il 95% di lipide A penta-acilato, hanno 
mostrato un analogo livello di rilascio di IL-6 da PBMC rispetto a GMMA di Shigella 
contenenti lipide A penta-acilato. Tutte le altre GMMA da STm e SEn con 
modificazioni del lipide A che sono state testate, contenevano una percentuale più 
elevata di lipide A esa-acilato e, in linea con i risultati ottenuti con GMMA da S. 
flexneri ∆htrB contenneti lipide A esa-acilato palmitoleoilato, GMMA di S. Tm e S. En 
con lipide A esa-acilato hanno mantenuto attività stimolante TLR4 superiore rispetto 
a quelle con lipide A penta-acilato, risultando in una minore  probabilità di tradursi in 
un vaccini utili. 
In conclusione, GMMA da S. Tm con lipide A penta-acilato A hanno mostrato un 
profilo di reattogenicità ridotto in maniera simile a quanto osservato in GMMA di 
Shigella contenenti lipide A penta-acilato. Tuttavia, per ottenere GMMA di Salmonella 
con lipide A prevalentemente penta-acilato e senza lipide A esa-acilato, ulteriori 
mutazioni potrebbero essere necessarie oltre ad htrB o msbB. 
 
Neisseria 
La riduzione di endotossicità delle GMMA mediante modificazione genetica del lipide 
A è stata valutata anche in Neisseria meningitidis, una specie meno geneticamente 
correlate a Shigella.  
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Il lipide A di N. meningitidis è esa-acilato, ma con una composizione e distribuzione 
degli acidi grassi differente rispetto al lipide A di Shigella. Inoltre, sul fosfato in 
posizione 4' è presente una fosfoetanolamina. Nonostante le differenze, simili 
quantità di GMMA da Neisseria e Shigella contenenti lipide A WT, hanno indotto 
simili livelli di rilascio di IL-6 da PBMC umani. Per ottenere un lipide A penta-acilato è 
stato deleto il gene lpxL1 che, come precedentemente riportato, codifica per una 
aciltransferasi che aggiunge una catena di lauroile all’idrossimiristoile in posizione 2'. 
La penta-acilazione del lipide A risultante è stata confermata tramite MALDI-TOF con  
uno spostamento m/z di 182 Dalton rispetto al lipide A WT, coerente con l'assenza 
della catena lauroilica. 
Le GMMA provenienti dal mutante Neisseria ∆lpxL1 hanno mostrato una marcata 
riduzione dell'attivazione di TLR4 e di stimolazione di IL-6 da PBMC umani, a livelli 
simili a quelli osservati in S. sonnei ∆htrB GMMA. Questo risultato ha sottolineato 
che, nonostante le differenze di composizione, il lipide A penta-acilato conserva poca 
capicità di attivazione del TLR4, e questo  si traduce in una sostanziale riduzione 
della reattogenicità delle GMMA. 
 
Conclusioni 
L'obiettivo generale della tesi è stato quello di esaminare i metodi per ridurre la 
reattogenicità di GMMA in modo da renderle idonee ad essere utilizzate come 
vaccino ad uso umano. Il risultato è stato sorprendentemente complesso. 
Ho dimostrato la possibilità di ridurre la reattogenicità delle GMMA mediante 
modificazione del lipide A. Ho trovato, inoltre, una chiara relazione tra la 
composizione delle varie specie di lipide A e la reattogenicità. La nostra analisi di 
GMMA purificate da linee isogeniche e da specie diverse ha evidenziato l'importanza 
di determinare la composizione del lipide A dopo la modificazione genetica, dato che 
la stessa modificazione genetica ha dato risultati diversi anche in specie di Shigella 
strettamente correlate. 
Ho dimostrato in Shigella, Salmonella e Neisseria che GMMA con lipide A penta-
acilato presentano una marcata riduzione della capacità di stimolazione di citochine 
e, utilizzando GMMA di Shigella, che la reattogenicità residua in è prevalentemente 
TLR2-mediata. Al contrario, GMMA con lipide A esa-acilato, sia attraverso 
palmitoleoilazione dopo delezione di htrB, che a causa di una ulteriore 
palmitoilazione in Salmonella, mantengono una residua attività stimolante sul TLR4, 
rendendo meno probabile il loro utilizzo come vaccino. 
Sulla base dei risultati presentati in questa tesi, quella della modificazione genetica 
del lipide A risultante in un lipide A penta-acilato rappresenta una strategia 
promettente per ridurre la reattogenicità delle GMMA. Se si renderà necessaria 
un’ulteriore riduzione della reattogenicità, modifiche nelle molecole responsabile 
dell’attivazione del TLR2 sarebbero necessarie. Tuttavia, il livello di riduzione 
richiesto per un vaccino accettabile dipende dalla dose necessaria per dare una forte 
risposta immunitaria, e questa può essere determinata solo da studi clinici. Studi 
clinici in corso utilizzando la GMMA di S. sonnei ∆htrB dovrebbero dare 
un'indicazione importante della tollerabilità di questi costrutti. 
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Introduction 
 
Neglected disease and need of vaccines 
 
Globally diarrheal disease, especially during the first 5 years of life, results in about 
760,000 deaths annually, mostly in sub-Saharan Africa and south Asia (1). In those 
areas the poverty of people, the low sanitary and hygienic conditions, the difficult 
access to hospitalization, malnutrition and concomitant diseases that 
immunocompromise people, strongly facilitates the spread of enteric pathogens (2).  
Enteric diseases are also a significant cause of morbidity among people from 
industrialized countries, mostly as traveler’s diarrhea and during military operations. 
In addition, there are long-term consequences of early childhood diarrheal disease 
on growth and physical and cognitive development (3). 
Gram-negative bacteria are the major causes of neonatal sepsis in developing 
countries, causing a wide range of diarrheal, respiratory and invasive diseases (4); 
between them the most frequent Gram-negative isolates are E. coli, Salmonella spp. 
and Shigella spp., as well as other non-invasive pathogens, like Vibrio cholerae and 
enterotoxigenic E. coli (ETEC) (5). The wide diversity of bacterial and viral infections 
that may cause diarrhea complicates accurate surveillance and diagnosis, especially 
in developing countries with little or no access to modern laboratory procedures. In 
fact, it must be considered not only that several different pathogens may cause 
diarrheal diseases, but also the antigenic and strain diversity among these 
pathogens, raising severe obstacles for proper etiological diagnostic and the 
development of effective vaccines (3). In fact, besides the progressive improvement 
of basic hygienic and sanitary conditions, access to clean water and better nutrition 
obtained in the last years (4), that resulted in the decrease the deaths caused by 
enteric infections, immunization still represent the most cost effective and efficient 
way to control and possibly defeat infectious disease. Unfortunately, vaccines are not 
yet available to prevent many major bacterial infections especially affecting 
developing countries, for example, Shigella and non-Thypoidal Salmonella infections.  
An ideal vaccine should be easy to administer, i.e. not requiring high professional 
skills for being administered, well tolerated, formulated for protecting against multiple 
pathogens (both for reducing cost and also for reducing the number of injections per 
child)), easy to manufacture, has low cost (ideally lower than 1 $ per dose), and able 
to induce long-term protection. 
The mission of NVGH is to develop effective and affordable vaccines for neglected 
diseases of impoverished communities. Thus, NVGH is developing platform 
technologies that can be applied to the development of vaccines for several 
pathogens. One major platform is based on outer membrane particles called 
Generalized Modules for Membrane Antigens (GMMA). This platform is used in three 
major programs of NVGH, Shigella, non-Typhoidal Salmonella and Neisseria 
meningitidis. 
 
Shigella 
 
Shigella are a non-motile, facultative anaerobic, Gram-negative bacteria that belong 
to the family Enterobacteriaceae. Shigella are the causative agents of shigellosis, a 
global human health problem, especially in developing countries and in children 
younger than 5 years (6), with more than 125 million cases (7) and 100,000 deaths  
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(8) per year. This estimate indicates a significant decrease in deaths in the last 10 
years (9) assumed to be due to non-specific intervention as improved nutrition, 
vitamin A supplementation and measles vaccination (7). However, the incidence rate 
remained high. Shigellosis is also a frequent cause of traveler’s diarrhea (10). 
Humans and non-human primates are the only hosts for Shigella, in which they can 
cause diarrheal disease. The bacteria multiply within colonic epithelial cells, causing 
mucosal ulceration, inflammation, and bleeding. Transmission usually occurs by 
fecal-oral contact and thus is promoted by substandard hygienic conditions. As few 
as 10-100 microorganisms may be sufficient to start infection, indicating that Shigella 
is highly contagious (11). The disease caused by Shigella can range from mild 
diarrhea to a severe form of dysentery with frequent mucoid bloody stools, abdominal 
cramps and tenesmus. The severity of disease depends on the infecting species and 
also on the condition of the patient, especially the nutritional status and immune 
status (12). 
Starting from the first Shigella strain isolated in 1896, now called Shigella dysenteriae 
type 1, today the genus Shigella includes 50 different serotypes characterized by the 
carbohydrate composition of the O antigen (OAg) of the LPS. These serotypes are 
grouped into 4 serogroups that historically were classified as species, based on 
biochemical and serological differences: Shigella dysenteriae (group A, 15 
serotypes), Shigella flexneri (group B, 15 serotypes), Shigella boydii (group C, 20 
serotypes) and Shigella sonnei (group D, 1 serotype). In addition, more than a dozen 
putative new serotype or subtype strains are being considered for possible official 
classification (13). S. flexneri and S. sonnei are endemic and cause most of the 
infections. S. dysenteriae type I is epidemic and Shigella boydii is currently not 
regarded of global importance (10).  
Shigella is genetically closely related to Escherichia coli. The sequence divergence 
between S. flexneri and E. coli K12 is only 1.5%, and biochemically, Shigella is very 
similar to enteroinvasive Escherichia coli (12).  
Due to the global emergence of drug resistance, the choice of antimicrobial agents 
for treatment of shigellosis is limited. In addition, the costs of treatment could be 
inhibitory, considering that this disease is endemic in the poorest area of the world. 
Thus, there is remerging interest in developing a vaccination against Shigella. 
Currently, no vaccine is available. Natural immunity to Shigella is protective but 
serotype-specific. Thus, the large number of serotypes (10) and constant changes of 
the serotypes present in a given region has been a challenge for vaccine 
development (10). 
 
Shigella vaccine 
 
As mentioned above, shigellosis is mainly a disease of the poorest people in the 
world and results in a high number of deaths. Thus, vaccination offers the greatest 
hope as an effective and sustainable strategy against that disease.  
Considering that immunity in Shigella is serotype-specific and that multiple serotypes 
are present at same time, (10) a broadly protective vaccine will be needed to target 
multiple serotypes. This could be achieved using a multivalent O antigen vaccine or a 
protein-based vaccine targeting proteins that are conserved in the different Shigella 
strains.  
For developing a broadly protectiveShigella vaccine based on serotypes, the Global 
Enteric Multicenter Study (GEMS) suggest that a quadravalent vaccine, containing 
strains or antigens from S. sonnei and S. flexneri 2a, 3a and 6, would directly cover 
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approximately 65% of current circulating strains.  With cross protection based on 
shared S. flexneri group antigens, such a quadravalent vaccine could cover more 
than 85% of currently circulating Shigella strains. Many argue for including S. 
dysenteriae 1 coverage in a serotype-based vaccine in the expectation that 
pandemic Shigella dysentery will return and a vaccine could constitute an important 
public health tool (13). 
Different types of vaccines candidates against Shigella have been developed and 
tested so far, but all presented some problems. The main approaches have been 
based on live attenuated Shigella vaccine candidates and O antigen conjugates 
which both raise serotype-specific responses. Live attenuated strains or killed whole-
cell vaccines have the advantage of presenting almost all the antigenic repertoire of 
the bacteria to the host immune system and are easy to manufacture, but it is very 
difficult to obtain strains that are sufficiently attenuated to avoid reactogenicity and 
maintaining good immunogenicity (14,15). O antigen conjugates, i.e. vaccines in 
which polysaccharide antigens are covalently linked to carrier proteins, like 
recombinant Pseudomonas exoprotein A (rEPA), have been shown to induce 
protection against homologous strains (16) but are not able to generate cross-
protection against other strains of Shigella (17,18).An interesting bioconjugate 
vaccine technology developed at GlycoVaxyn, in Switzerland, utilizes recombinant 
DNA technology to catalyze the in vivo synthesis of conjugate vaccines by using the 
glycosylation machinery from Campylobacter cloned in an E. coli production strain for 
generating a protein carrier glycosylated with a specific Shigella OAg, then purified 
as a conjugate vaccine (19); a S. dysenteriae 1 OAg–rEPA bioconjugate vaccine 
produced in this system was found safe and immunogenic after two doses. Other 
strategies involved the use of proteosomes (20) and a nuclear protein-ribosomal 
vaccine (21), but these also raised O antigen-specific responses. 
To achieve cross protection the ideal approach could be the use of a protein based 
vaccine containing proteins conserved in the different strains and thus could give 
broad spectrum protection. Protein vaccine candidates against shigellosis were 
developed by purifying outer membrane proteins (22) or Ipa proteins (23,24), but they 
were not protective against all of the tested strains, e.g the Invaplex vaccine, 
formulated from a bacterial extract composed of Ipa proteins, which are highly 
conserved among all Shigella serotypes and have an essential role in Shigella 
pathogenesis, and LPS. In animals, serotype-specific protection has been 
demonstrated and has also been shown to be safe and immunogenic after intranasal 
delivery in healthy volunteers (25). Despite all these efforts, only one Shigella 
vaccine candidate, the S. sonnei OAg-conjugate has so far been tested in Phase III 
clinical trials and has been shown to elicit approximately 70% protection in adults 
with one immunization and in children older than 3 years of age with two 
immunizations (16,26). 
 
Salmonella 
 
The genus Salmonella causes a large global burden of morbidity and mortality and it 
is composed of two distinct species: Salmonella bongori and Salmonella enterica, 
which has been divided into six subspecies. The subspecies have been classified 
into more than 50 serogroups based on the OAg, and are divided into 2,400 serovars 
based on the flagellar antigen (27). 
Salmonella infections in humans can be divided into typhoid fever, caused by 
Salmonella enterica serovar Typhi (S. Typhi) and Paratyphi (S. Paratyphi), and a 
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range of diarrheal diseases, caused by a large number of non-typhoidal Salmonella 
serovars (NTS) (27).  
Typhoid fever is a global problem, that causes every year more than 27 million cases 
worldwide resulting in an estimated 217,000 deaths (28). This disease is most 
common among children, especially in areas of Asia and Africa that lack clean water 
and adequate sanitation, and is also an important travel-associated disease (29). S. 
Typhi is an exclusively human pathogen, and typhoid fever is characterized by high 
fever, severe headache, nausea, abdominal pains, and loss of appetite, constipation 
or sometimes diarrhea that can last for several weeks. The most frequent 
complications, that can results in death in 1-4% of the cases, are intestinal 
perforation and peritonitis or severe toxic encephalopathy (30). Paratyphoid fever, 
which is caused by any of three serotypes of S. Paratyphi A, B and C, is similar in its 
symptoms to typhoid fever, but tends to be milder, with a lower fatality rate (28). 
NTS serovars, such as S. enterica serovar Typhimurium and Enteriditis, also cause a 
significant disease burden, with an estimated 100,000 deaths/year (31). The host 
range of non-Typhoidal Salmonella serovars is broad. In industrialized countries, 
NTS infection is commonly due to food contaminations. NTS disease cause usually 
self-limiting diarrhea associated with nausea, vomiting and abdominal pain in healthy 
individuals and bacteremia occurring in less than 5% of patients with mortality rate 
lower than 1%. In contrast, in sub-Saharan Africa, NTS serovars cause high rates of 
bacteremia in the immune-compromised patients and in children younger than 5 
years, and where often associated with HIV infection (32,33). In addition to sepsis, 
invasive NTS (iNTS) can seed to the meninges, especially in children. Also 
antimicrobial resistance is widely spread and increases the problems in treatment of 
disease (30). 
 
Salmonella in Africa 
 
Salmonella Typhi represent the most common form of invasive Salmonella disease in 
South-East Asia, but it is non common in sub-Saharan Africa. In sub-Saharan Africa, 
instead, invasive NTS are among the most common isolates from febrile 
presentations in adults and children, and Salmonella Typhimurium and Salmonella 
Enteritidis represent the most common serovars. 
In sub-Saharan Africa, high-risk hosts for iNTS were represented by young children 
and HIV-infected individuals, with case fatality rates around 20–25%. In contrast HIV 
infection does not appear to predispose to infection with Salmonella Typhi in parts of 
Africa where typhoid fever has been reported (34). iNTS infections in sub-Saharan 
Africa were often associated also with malaria, severe anemia and malnutrition, as 
these are also risk factors for iNTS (35). iNTS disease, nevertheless, is not only the 
responsible of deaths in presence of coinfentions, it remains a problem in locations 
where malaria is almost absent (36), or where HIV prevalence is low (37), and 
continues to be a problem in children not infected with HIV. 
Due to the absence of a clear clinical presentation (fever is the most common clinical 
feature and gastrointestinal symptoms occur in less than half of the patients) and 
high incidence of confections, iNTS can be the cause of deaths without being 
diagnosed, and a lot of deaths due to iNTS will be recorded as due to HIV, malaria 
and malnutrition (35). Infact, a diagnosis is only possible where blood culture is 
available, and that is, unfortunately, not so common in sub-Saharan Africa.  Thus, it 
is difficult to quantify with precision the overall incidence of iNTS disease in sub-
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Saharan Africa. Data obtained in 11 study sites across sub-Saharan Africa give rates 
of around 500/100,000 children/year (38). 
The disease is highly seasonal (39) with peaks of infection during the rainy season in 
both adults and children coincide with increased incidences of malaria and 
malnutrition. Invasive NTS disease has also been present in epidemics that last 
several years and are caused by sequential single serotypes among adults and 
children. These epidemics have been linked to the emergence of resistance to 
commonly used antimicrobial drugs (39). In general increasing antibiotic resistance 
strongly complicated the treatment of salmonellosis. iNTS disease in Africa, unlike 
NTS disease in industrialized nations, does not have an animal reservoir(35).  
 
Salmonella vaccine 
 
Several vaccines are available for S. Typhi and Paratyphi, instead the situation is 
less developed for NTS. For which concerns S. Typhi, the live attenuated oral 
vaccine Ty21a, obtained by chemical mutagenesis from wild type is immunogenic 
and protective above the age of 5 years (40), like the Vi capsular polysaccharide and 
several other live attenuated strains (41), but requires multiple doses s (42). Because 
of the limitations of the currently available vaccines, considerable interest remains in 
developing new vaccines that are immunogenic and well tolerated in infants and offer 
greater protection to older children and adults. The most promising candidates are a 
new generation of live-attenuated vaccine strains and especially Vi-conjugate 
vaccines (the immunogenicity of polysaccharide antigens in infants is greatly 
enhanced when they are conjugated to a carrier protein and antigens became T-cell 
dependent antigens) (43). Several Vi-conjugate vaccines are in late stages of 
development, like the Vi-rEPA (44), using the recombinant Pseudomonas aeruginosa 
exotoxin A as the protein carrier, and the Vi-CRM197, a conjugate vaccine developed 
by NVGH for infant immunization; immunogenicity and safety were assessed in two 
phase 2 trials conducted in endemic countries (Pakistan, India and Philippines) in 
adults and children younger than 2 years. The vaccination was conducted in 
concomitance with vaccines of the Expanded Programme on Immunization (EPI), 
according to WHO schedule, showing a promise for potential inclusion of Vi-CRM197 
in EPI schedules of countries endemic for typhoid (45). 
There are currently no vaccines directed against S. Paratyphi. Several candidate 
vaccines against S. Paratyphi are under investigation. Also for that disease live 
attenuated strain were developed and the NVGH O:2 polysaccharide conjugated to 
Vi-CRM197 with the ultimate aim of manufacturing a bivalent enteric fever vaccine 
(43). 
The diversity of nontyphoidal Salmonella serovars makes the development of a 
vaccine a big challenge; however S. Enteritidis and S. Typhimurium are the most 
common serovars in sub-Saharan Africa and account for nearly all iNTS reported 
(46). The development of vaccines against iNTS for Africa is in progress with O 
polysaccharide-flagellin conjugate vaccine (47) and live attenuated (48). 
 
Neisseria meningitidis 
 
Neisseria meningitidis is a Gram-negative encapsulated, aerobic diplococcus, which 
colonizes the nasopharynx of humans and has no other known environmental niche 
(49). It is one of the major causes of bacterial meningitis and sepsis, and is the only 
form of bacterial meningitis responsible for epidemic levels of meningitis infection 
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worldwide (50). Bacterial meningitis is a serious threat to global health, accounting 
for an estimated 170,000 death/year (50). Up to 25% of survivors develop permanent 
sequelae, such as epilepsy, mental retardation, or sensorineural deafness (50). The 
disease still remains one of the most feared infections due to its rapid progression 
and the tendency to cause outbreaks and epidemics. Clinical syndromes caused by 
N. meningitidis include meningitis, with or without meningococcemia, relatively mild 
bacteremia, fulminant meningococcemia, meningoencephalitis, pneumonia, and 
septic arthritis, as well as other presentations. Even when the disease is diagnosed 
early and adequate therapy is instituted, 5–10% of patients die (50). Together with 
Haemophilus influenzae and Streptococcus pneumoniae, Neisseria meningitidis is 
one of the major causes of bacterial meningitis and sepsis, causing at least 500,000 
cases and more than 50,000 deaths every year (50).  
The bacteria are commonly carried asymptomatically in the upper respiratory tract of 
between 8–20% of healthy individuals (51) and more frequently in adolescents and 
other populations with close contact. Only occasionally N. meningitidis invades the 
bloodstream and meninges to cause disease. The disease incidence varies in human 
populations from rare to over 1,000 per 100,000 people/year in localized outbreaks, 
epidemy and pandemy (52). 
A polysaccharide capsule, which covers the outer membrane of the bacteria, is a 
major virulence factor for N. meningitidis and although capsular-deficient strains are 
commonly isolated, these are non-infectious (53). Capsule mediates resistance to 
phagocytosis, complement mediated lysis and protects against environmental insults. 
Neisseria meningitidis has been divided in 13 serogroups based on different capsular 
polysaccharide structure, but only 6 serogroups are associated with significant 
pathogenic potential: A, B, C, W-135, Y and X (54). Neisseria meningitidis has been 
further classified into serotypes and serosubtypes, basing on antigenic differences of 
the major outer membrane proteins PorB and PorA. N. meningitidis presents a 
different distribution in different areas of the world (50). N. meningitidis B is a major 
cause of sporadic or endemic meningitis in developed countries, accounting for up to 
80% in certain European countries, with most of the remaining cases being caused 
by serogroup C strains (55) (and Y in North America), instead the type of strains 
presents in Africa is quite different (56).  
 
Neisseria in Africa 
 
Neisseria meningitidis is a major cause of epidemics in sub-Saharan Africa (56). 
These were mainly caused by strains belonging to capsular group A, that is 
responsible of epidemics. Outbreaks occur during the dry season and diminish with 
the onset of the rainy season (57). It’s also has been observed an increasing 
contribution of serogroups W and X strains with epidemic potential in the last two 
decades (58,59).  
A polysaccharide conjugate vaccine (MenAfriVac) has been developed for preventive 
mass immunization in the meningitis belt against serogroup A. Where the vaccine 
has been implemented, the number of reported cases caused by serogroup A strains 
has decreased dramatically, but group W and X strains remain a persistent problem. 
This observation underlines the need for an affordable vaccine that can provide 
broad protection against all three main serogroups causing meningitis in Africa and 
potentially against new disease-causing serogroups that may emerge in the region in 
the future (Koeberling at al., 2014 submitted). 
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Neisseria vaccine 
 
The rapid onset of invasive meningococcal disease, the high incidence in childhood, 
the severity of the sequellae and the high mortality rate clearly indicate the 
importance of vaccine development against N. meningitidis. An ideal meningococcal 
vaccine should be able to protect against all disease-causing meningococci, 
developing protective immunity at the mucosal surface and in the circulation (50). 
Several polysaccharide vaccines, which have been available for over 30 years, exist 
against serogroups A, C, Y, W-135 in various combinations. A major advance in the 
prevention of meningococcal disease has been the development and introduction of 
meningococcal polysaccharide-protein conjugate vaccines (60). These vaccines are 
immunogenic, particularly for children under 2 years of age whereas polysaccharide 
vaccines are not. All these vaccines have been proven to be safe and effective with 
infrequent and mild side effects. The development of vaccines for serogroup B 
Neisseria meningitidis remains a challenge (61), due to the fact that the serogroup B 
capsule has an identical structure to polysialic structures expressed in fetal neural 
tissue, and does not induce a protective IgG response, rendering needed the 
development of a different class of antigens to obtaining an efficient  vaccine. 
The most promising candidate protein vaccine antigen against meningococcus to 
date is factor H binding protein (fHbp). The fHbp gene is present in most invasive 
meningococcal isolates independent of serogroup. fHbp has been divided into three 
antigenic variants (v. 1, 2 or 3) (62). Within each variant, the peptides differ by a few 
amino acids and are identified by a unique peptide ID. The outer membrane protein, 
PorA, is highly immunogenic but antibodies to PorA tend to provide subtype-specific 
protection, especially in young children (63). 
Bexsero, a vaccine developed by Novartis Vaccines and Diagnostics, has been 
recently approved and is the first vaccine against N. meningitidis B strain. It is a multi-
component meningococcal B vaccine (also called 4CMenB) containing three surface-
exposed recombinant proteins (fHbp, NadA and NHBA) and New Zealand strain 
detergent extracted outer membrane vesicles (NZ OMV) with PorA 1.4 antigenicity.  
A four-dose schedule for infants (three primary doses and one booster dose) and a 
two-dose schedule for adolescents provided an estimated coverage  between 66 – 
91% against meningococcal serogroup B strains worldwide (64). 
Research is continuously developing and several promising and innovative vaccines 
against meningitidis are based on Native Outer Membrane Vesicles (NOMV) (65).  
 
Native Outer Membrane Vesicles (NOMV) NVGH vaccine platform: Generalized 
Modules for Membrane Antigens (GMMA) 
 
One of the platform technologies developed by NVGH to develop effective and 
affordable vaccines is based on Generalized Modules for Membrane Antigens. This 
platform technology takes advantage of the ability of Gram-negative bacteria to 
naturally shed small particles from the outer membrane into the environment (native 
outer membrane vesicles, NOMV). NVGH has developed a high yield production 
process using genetic modification of bacteria to induce high level shedding of these 
outer membrane particles. To differentiate these particles that are released from the 
genetically modified bacteria from NOMV and other types of particles produced by 
bacteria, they were named GMMA. 
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Native Outer Membrane Vesicles (NOMV) 
 
Composition and biological role  
 
Gram-negative bacteria naturally release blebs from the outer membrane usually 
called Outer Membrane Vesicles (OMV) (66) or more specifically native Outer 
Membrane Vesicles (NOMV). These are small spherical structures, 30-250 nm in 
diameter, which protrude from the outer membrane and then are released into the 
environment (Fig. 1) (67). The term OMV has also been used for vesicles derived by 
detergent-extraction of homogenized bacteria which have a very different 
composition (68) and have been used as vaccines (69). Thus, to avoid confusion the 
term NOMV is used for particles naturally shed from the surface. 
The two-layered outer membrane of Gram-negative organisms is an asymmetric 
membrane composed of an outer layer containing surface proteins and 
lipopolisaccaride (LPS). The inner leaflet consists of phospholipids and lipoproteins 
that link the outer membrane to a thin layer of peptidoglycan. Between the outer 
membrane and peptidoglycan lies a gelatinous material called periplasm, which also 
separates the peptidoglycan and the cytoplasmic membrane (70). NOMV, in general, 
maintain the structure, composition, and orientation of the outer membrane, including 
the presence of LPS, glycerophospholipids, outer membrane proteins and also 
contain soluble periplasmic proteins entrapped in the lumen (71,72).  
Gram-negative bacteria, both pathogenic and non-pathogenic, secrete NOMV during 
constitutive growth, including E. coli, N. meningitidis, V. cholerae, Pseudomonas 
aeruginosa, Brucella melitensis, and Helicobacter pylori especially during the end of 
log phase growth and at sites of cell division (73). Proposed models for vesicle 
formation conclude that an intact peptidoglycan layer is not contained within NOMV 
and that vesicle production probably originates at sites where the outer membrane-
peptidoglycan linkages are disrupted. 
 
 
 
Fig. 1 Native Outer Membrane Vesicles (NOMV) generation. Modified from (67) 
 
In the literature this particles have usually been called Outer Membrane Vesicles 
(OMV).  
NOMV are very similar to but not identical to that in the outer membranes. For the 
most part, NOMV are devoid of inner membrane and cytosolic constituents. Some 
proteins and lipids are consistently detected in NOMV while others are always 
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excluded. Proteomic analyses of the protein content of NOMV from several different 
organisms have shown that vesicles enclose a wide variety of envelope components 
(70).  
NOMV have been discussed to have different biological roles, e.g. as delivery 
vehicles for active components to host cells, as nucleators in the formation of 
bacterial communities (biofilms) and as contributors to bacterial survival and 
virulence (72). 
The composition of NOMV from pathogens should reflect the state of the bacterial 
outer membrane, and were also dependent on the site of culturing of the bacteria. 
Active toxins are associated with several pathogen-derived NOMV and some of the 
toxins appear to be enriched in NOMV. In some cases, NOMV-associated toxins are 
more active than the toxins alone, and some toxins are associated with the exterior 
surface of NOMV (74). 
 
Potential of NOMV as vaccine 
 
As NOMV represent the envelope of Gram-negative bacteria and, thus, most of the 
components that might be recognized by the immune system (75), they have been 
proposed for use as vaccines. Also, NOMV combine both adjuvant and carrier 
activity, increasing the low immunogenic properties of some protein antigens (70). It 
was also demonstrated that proteins from a foreign source can be  localized in the 
outer membrane and periplasm of the parent cell and successively internalized into 
OMVs (74).  
NOMV have been shown to induce protection in mice against multiple pathogens, 
including Salmonella enterica serovar Typhimurium (76), Helicobacter pylori (77), 
Vibrio cholera (78,79) and Shigella bodyii (80) or to elicit antibodies with in vitro 
bactericidal activity in mice, e.g. for Neisseria meningitidis (81,82). In addition, NOMV 
have been tested as veterinary vaccine candidate, e.g. against Edwardisiella tarda 
implicated in the death of see water fish (83).  
The yield of NOMV is usually too low for a practical production. The application of 
NOMV as vaccines requires high production and efficient purification. Various 
methods have been employed to induce and increase blebbing of the outer 
membrane of Gram-negative microbes. These techniques include inhibiting protein 
synthesis, autolytic cell wall degradation by lysine starvation, increasing growth 
temperature (even to 55oC), and the addition of sub-lethal doses of antibiotics 
(70,72). However, all of these conditions alter the composition of OMVs  so that they 
are no longer “native” and have not resulted in true high yield production. 
 
High yield GMMA production process for use as vaccines 
 
NVGH has developed a high yield NVGH has developed a high yield production 
process suitable for industrial production using genetic modification of bacteria to 
induce high level shedding of outer membrane particles.  
As mentioned above, NOMV preferentially form where the link between the inner and 
outer membrane is weakened. In the case of Shigella and Salmonella, this linkage 
can be genetically disregulated by deletion of tolR, a gene of the Tol-Pal pathway 
(66,84). The Tol-Pal system is present in most of Gram-negative bacteria and is 
required to maintain outer membrane integrity. Thus, a mutation in any of tol-pal 
genes, and especially on tolR, confers a defect in other membrane integrity, resulting 
in a major release of GMMA (84). In the case of N. meningitidis, which do not have a 
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homologue of tolR, deletion of gna33, encoding a membrane bound lipoprotein with 
murein hydrolase activity, has been shown to impair the integrity of the cell envelope 
and increase the release of GMMA (68).  
No growth defects or obvious loss of membrane integrity have been detected in 
production strain lacking tolR (66,84). However, deletion of gna33 (in Neisseria) 
resulted in slightly slower growth than the wild-type. 
Another challenge for GMMA production at industrial scale was the identification of 
an efficient purification method. A widely used methods at research scale is the 
separation of GMMA from the bacterial cells by low speed centrifugation, in which the 
outer membrane particles remain in the culture supernatant, followed by collection of 
the particles by using ultrafiltration (85). Also alternative methods have been tested, 
e.g. purification over a sucrose density gradient or gel filtration chromatography, 
resulting in vesicles of high purity and being relatively homogeneous. Those systems 
were based on differential diffusion and pore size exclusion, but the use of 
ammonium sulfate in the precipitation of OMVs before density gradient centrifugation 
can lead to artifacts (72).  
NVGH has developed a new method to collect GMMA from bacterial suspensions, by 
using two consecutive Tangential Flow Filtration steps: the first one with 0.22 µm to 
separate the biomass from the GMMA, and the second one with a smaller cut-off for 
puryfing and concentrating GMMA (66), thus resulting in an high yield process.  
 
Reactogenicity 
 
Innate immune stimulation, Pathogen Associated Molecular Patterns and Toll-
like receptors 
 
Usually, when occurs infections or tissue damages, the activation of innate immunity 
takes place within minutes and lasts for several days with the purpose of recognizing 
and clearing most of the microbes or damaged tissue. The adaptative immune 
response, instead, follows the innate ones and peaks within the following weeks, 
resulting in an immunological memory that can last for the life of the individual. 
Induction of adaptive immune responses and especialy the immunological the 
memory is the response desired from vaccination. 
sion of pathogenic infectious agents are generally initiated via host recognition of 
conserved molecular structures, known as Pathogen-Associated Molecular Patterns 
(PAMPs). PAMPs include molecules generally present in bacteria, including 
lipoproteins and the LPS of Gram-negative bacteria, but also components, necessary 
for the survival of specific pathogens in the host, e.g. flagella (86). These PAMPs are 
sensed by receptors, called Pattern Recognition Receptors (PRRs), which are 
predominantly expressed on innate immune cells such as dendritic cells, 
macrophages and neutrophils. The interactions of PAMPs with PRRs rapidly induces 
host immune responses via the activation of complex signaling pathways that 
culminate in the induction of inflammatory responses mediated by various cytokines 
and chemokines, which subsequently facilitate the eradication of the pathogen (87). 
There are several classes of PRRs, such as Toll-Like Receptors (TLRs), RIG-I-Like 
Receptors (RLRs), NOD-Like Receptors (NLRs) and DNA receptors (cytosolic 
sensors for DNA), that sense various classes of pathogen’s molecules including 
proteins, lipids, carbohydrates and nucleic acids (88). 
TLRs are the most widely studied PRRs, and were first discovered in Drosophila as 
proteins involved embryonic development. Since then, many homologous proteins 
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have been discovered in different organisms and, today, in humans, 10 TLR family 
members have been identified and 12 in mice (TLR1 to 9 are conserved in both 
humans and mice). TLR 1, 2, 4, 5 and 6 are primarily expressed on the cell surface 
and recognize PAMPs derived from bacteria, fungi and protozoa (Fig.2), whereas 
TLR 3, 7, 8 and 9 are exclusively expressed within endocytic compartments and 
primarily recognize nucleic acid PAMPs derived from various viruses and bacteria 
(87).  
 
Fig. 2 Interaction between various PAMPs and TLRs exposed on cell surface. Picture from (87) 
 
TLRs are type I membrane glycoproteins that consist of an extracellular Leucine Rich 
Repeats (LRRs), required for PAMP recognition, and a cytoplasmic TIR domain (that 
consist in 150 aminoacids and show homology with Interleukin-1 receptor), required 
for downstream signaling. TLR signaling is primarily meditated via the recruitment of 
different TIR domain containing adaptor molecules such as MyD88, TRIF, TIRAP, 
and TRAM to the TIR domains of the different TLRs. Recruitment of these adaptor 
molecules activates various transcription factors such as NF-κB, IRF3/7, and MAP 
kinases to induce the production of pro-inflammatory cytokines (for example IL-6) 
and type I interferons (86). Each TLR recognizes only specific PAMPs. 
 
Needs of reduction of endotoxicity for using GMMA in vaccination 
 
As GMMA are derived from the outer membrane of Gram-negative bacteria, they 
naturally contain high levels of PAMPs, for example lipopolysaccharide (LPS), and 
could trigger a strong stimulation of the innate immune response that could 
potentially result in unacceptable reactions in human subjects, e.g. a febrile response, 
or in extreme cases, septic shock (89), especially if parenterally administered. Thus, 
the reactogenicity of GMMA, especially the LPS endotoxicity, might need to be 
modified. However, limited activation of the innate immune response will aid the 
immune response to the vaccine and thus, a balance of triggering immune 
stimulation and reactogenicity is desired in a vaccine (90). Considering the 
composition of GMMA, the main TLRs activated in the host are likely TLR4 and TLR2 
(91). TLR4 is the receptor involved in the recognition of LPS with MD-2, CD14 and 
LBP (87,92). TLR2 is involved in the recognition of a wide range of PAMPs that 
include lipoproteins (di- or tri-acetylated) (87).  
LPS very likely is the major reactogenic component that is present in outer 
membrane of Gram-negative bacteria and thus in GMMA. Its structure is amenable to 
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genetic modification to reduce the activation of the TLR4 pathway. Thus, to asses the 
feasibility of reduction of GMMA reactogenicity, at NVGH, reduction of LPS 
endotoxicity was addressed first.  
Shigella and Salmonella has previously been reported to stimulate TLR2 responses; 
e.g. porins, lipoproteins, and major outer membrane proteins from Shigella flexneri 
and Shigella dysenteriae have been found to stimulate TLR2 (93-97).  
 
LPS 
 
LPS consists of three main regions: the glycolipid lipid A, a core oligosaccharide, and  
the outer polysaccharide chain (O antigen) consisting of 20-40 repeating units of 
usually 2-8 sugar molecules (Fig. 3). The OAg, if present (for example is not present 
in N. meningitidis), is the most variable part of LPS and shows even a high degree of 
variability between different strains of the same species (98). The variation of OAg 
lies in the sugar composition, the arrangement of the sugars, and the linkages 
between the sugars within the O unit as well as the linkages between O units (99). 
OAg is an important component in the resistance to serum-mediated killing, 
phagocytosis, and to killing by cationic peptides. OAg is highly immunogenic, thus 
widely used as main antigen in various vacines. 
 
 
Fig. 3 LPS structure. Picture from (100) 
 
The lipid A, that anchors the LPS to outer membrane of bacteria, is the reactogenic 
part of LPS and thus the part that can be modified to detoxify the LPS. Lipid A “core 
structure” is composed by a β-1’,6-linked disaccharide of glucosamine 
phosphorylated at the 1 and 4’ positions and acylated at 2, 3, 2’ and 3’ position with 
R-3-hydroxymyristate (structure usually called lipid IV A), that is a conserved 
structure in most of Gram-negative bacteria (101,102). Subsequently, the late 
acyltransferases HtrB (also called LpxL) and MsbB (also called LpxM) transfer a 
lauroyl fatty acid to the 3’ position (HtrB, (103)) and a myristoyl fatty acid at position 2’ 
(MsbB, (104)). This structure is common to E. coli and Shigella (101,102) (Fig. 4A). 
Exceptions to this this hexa-acylated lipid A structure are present, for example, in the 
case of Salmonella enterica, with the addition of a seventh fatty acid chain to hexa-
acylated lipid A by a 2-O-palmitoylation catalized by PagP (105), expressed under 
certain conditions modulates the bacterial pathogenesis (106) (fig. 4A). Further 
modifications at the E. coli wild type lipid A structure were induced upon cold-shock 
with the addition of a palmitoleoyl chain in place of lauroyl chain catalyzed by LpxP 
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(107,108) (Fig. 4A). Other differences in lipid A structure are observed in different 
species, especially regarding types of fatty acid chains attached on lipid A and 
addition of phospatidiletanolamine and/or arabinose to 1 and 4’ phosphate groups 
(101). It is the case, for example, of the Neisseria meningitidis lipid A, constituted of a 
β-1’,6-linked disaccharide of glucosamine phosphorylated at the 1 and 4’ positions 
and acylated at 2, 2’ with R-3-hydroxymyristate and at 3, and 3’ position with a R-3-
hydroxylauroylate with the presence of secondary lauroyl chains in position 2’ and 2’ 
to the hydroximyristate chains. Furthermore the phosphate in 1 position is piro-
phosporilated by a phospoetanolamine (Fig. 4B). 
 
 
 
Fig. 4 A) Shigella and Salmonella type lipid A. B) N. meningitidis type lipid A. Lipid A structures 
usually found and some of enzymes involved in last steps of lipid A biosynthesis. 
 
Strategy for reduction of reactogenicity used 
 
Changes to the structure of the lipid A effect the binding and recognition by TLR4. 
The total number and the length of acyl chains, plus the presence of the two 
phosphates in positions 1 and 4’ are critical factors for full lipid A activation of human 
TLR4/MD-2. The most endotoxic form of lipid A consists of a hexa-acylated 
glucosamine disaccharide phosphorylated at the 1 and 4’ position with acyl chains 
from 12 to 14 carbons in length and an asymmetric (4/2) distribution (109-111).   
Alteration to this structures, both in terms of lacking or presence of a different, even if 
chemically related, constituent of the previous structures, results in a lower 
endotoxicity in vitro (109,110).   
Modifications in lipid A structure in terms of numbers/types of fatty acid chains 
present and in terms of changes in type/presence of substituent in the phosphates 
regions, represents systems used quite extensively by different species of bacteria in 
response to changes in environmental conditions and are modulated in 
pathogenesis, helping on the evasion the recognition by TLR4 (109,110,112,113); 
e.g. a palmitoleoyl fatty acid is incorporated at the 3’ position instead of the lauryl 
chain, catalyzed by LpxP in E. coli under cold shock conditions (107,108). Especially 
pathogenic bacteria use modifications of the lipid A structure as a strategy to evade 
host recognition (101,114). E.g. induced by the temperature increase from 25°C in 
the environment to 37°C in the host, Yersinia pestis produces a tetra-acylated lipid A, 
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that is poorly recognized by the host’s TLR4 (115). Similar strategies have been used 
naturally by Helicobacter  pylori, Legionella pneumophila and Francisella (101), that 
naturally possess lipid A moiety that are poorly recognized by human TLR4 helping 
them to evade host immune response (114). In the case of Salmonella enterica has 
been observed the addition of a seventh fatty acid chain to hexa-acylated lipid A by a 
2-O-palmitoylation catalized by PagP in certain environmental conditions (e.g. like 
different magnesium concentration). The palmitoleoylation has been used also by a 
wide range of bacteria and is correlated to modulating bacterial pathogenesis (106). 
Other differences in lipid A, besides the changes of type and/or number of fatty acid 
chains, have been observed in different  bugs, especially regarding addition of 
phospatidyletanolamine and/or arabinose to 1 and 4’ phosphate groups (101). 
Similar strategies as observed in pathogenic bacteria have been used with the 
objective of decreasing LPS reactogenicity. A primary focus has been the 
modification of the acylation of the lipid A  by inactivation of the genes encoding the 
late acyltransferases HtrB (103) and MsbB (104), resulting in predominantly penta-
acylated LPS. As humans are very sensitive to LPS usually the level of reduction of 
endotoxicity achieved by the modifications has been assessed in in vitro assays 
measuring cytokine release from human peripheral blood monocytes (PBMC), mainly 
looking at TNF-α and IL-6. It’s hard a correlation between results of reactogenicity 
observed in mice and in humans due to the fact that penta-acylated lipid A acts as 
antagonist for human TLR4 but as agonist for mouse TLR4 (116), and pure 
pirogenicity test in rabbits were too expensive and ethically not good for being 
performed as routine use. Thus, is important to study cytokine response directly in 
human cells or using cell lines that mimics the human TLR4 recognition system. A 
strong decrease of lipid A endotoxicity has been observed for both htrB and msbB 
inactivation using human cell lines. E.g. inactivation of htrB results in 40-fold 
decrease of TNF-α production in Haemophilus (117), whereas inactivation of msbB 
resulted in 10,000-fold decrease of TNF-α production in E. coli (118,119).  
This approach of generating a lipid A molecule with decreased acylation has been 
used for the reduction of endotoxicity of live attenuated vaccine strains, e.g. Shigella 
flexneri 2a (120), and has also been tested with NOMV from Salmonella enterica 
(121), Neisseria meningitidis by lpxL1 or lpxL2 knock-outs (65,81,122-125), and in  
and Vibrio cholera (79) with promising results both in terms of reactogenicity than 
immunogenicity in mice. Experience with outer membrane particles generated with 
modified LPS in humans has been obtained in a Phase I clinical trial with NOMV from 
∆lpxL1 (126) and ∆lpxL2 (127) Neisserria meningitidis mutants. The NOMV with 
penta-acylated lipid A showed 100-fold reduced by in vitro TNF-α, 200-fold reduced 
by pyrogenicity, good adjuvanticity (65) and was well tolerated and immunogenic in a 
Phase I clinical trial (126). Those clinical studies confirm the good correlation 
between in vitro results (65) about reduction of endotoxicity and safety in humans 
(126,127). 
We have described the high yield production process for GMMA from Shigella based 
on tolR knock out and demonstrated the feasibility of using this process with a 
modification of the lipopolysaccharide structure (128). After lipid A modifications 
usually the ability to grow of bacteria in rich media (129) and at 37°C is reduced 
(128,130), with also other modifications like suppressor mutations (129,131) have 
been observed and a general increased sensitivity to antibiotics (108) and the 
induction of sigma E regulon (129,132). 
Other modifications of lipid A, besides the deletion of genes that encodes the late 
acyltrasferases LpxL and LpxM, were analyzed with the objective of decreasing 
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reactogenicity; some of them included the dephosphorylation of lipid A by knocking-in 
the dephosphorylases encoded by lpxE from Francisella tularensis in Salmonella 
enterica (133), or by overexpressing the deacylases enchoded by lpxR, causing the 
cleavage of two fatty acid chains (134,135), or PagL, that acts as 3-O-deacylases 
(134). Unfortunately both those results didn’t gave unsatisfactory results or in terms 
of decreasing reactogenicity or not complete de-acylation and so presence of lipid A 
molecules not deacylated in the mixture 
 
Aims of the project 
 
The broad aim of the project is to identify ways of reducing the reactogenicity of 
GMMA. This broad aim was divided into three specific goals: 
 
1. Proof of feasibility of reduction of GMMA endotoxicity by lipid A modification 
using Shigella. 
 
2. Assessment of relative contribution of TLR4 and TLR2 pathways to stimulation 
of human cells by GMMA with different lipid A modifications 
 
3. Demonstration of general applicability of the identified methods for the GMMA 
platform. 
 
The work for goals 1 and 2 is part of the NVGH program to develop a Shigella GMMA 
vaccine. The goal 3 is involved in the development of GMMA-based non-Typhoidal 
Salmonella and Neisseria meningitidis vaccines for Africa. 
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Material and methods 
 
Strains and generation of mutations 
 
Shigella strains 
 
Shigella sonnei 53G (136) and Shigella flexneri 2a 2457T (137) were chosen as 
parent strains. The list of Shigella mutants strains used in this study and their 
abbreviated identifications are listed in Tab. 1. As all strains used in this study are 
GMMA-producing strains (thus lackying tolR gene, substituted by Kn resistance 
cassette as reported in (66)) the abbreviated names only refer to the additional 
mutations and characteristics. The tolR gene knock-out in both S. flexneri and S. 
sonnei strains was achieved as previously described on (128). The curing of 
virulence plasmid (-p) in S. sonnei was achieved as described in (128). For 
generation of mutants from S. flexneri 2a without virulence plasmid, a white colony 
was selected by white appearance on Congo red agar before the start of the genetic 
modification. The curing of the virulence plasmid (pINV) was confirmed by the 
absence of the origin of replication (ori) and the plasmid encoded gene ospD3 using 
PCR. The primers are listed in Tab 2. To generate the tolR deletion in S. flexneri 2a 
and plasmid-cured S. flexneri 2a –pINV the same strategy and primers as previously 
described for the generation of the S. sonnei ∆tolR mutant (138) were used. 
The null mutation of msbB1(120), htrB (103) and rfbG (essential for O antigen 
biosynthesis in S. flexneri, (139)) were obtained by replacing the gene of interest 
(gene) with an antibiotic resistance cassette using the following strategy. The 
upstream and downstream regions of gene of interest were amplified using the 
primer pairs gene-U and gene-D or rfbF and rfc (for the rfG knock out). The 
resistance cassette used to replace gene was amplified using primer pairs 
EcoRV.Ery.F/EcoRV.Ery.R or EcoRV.Cm.F/EcoRV.Cm.R. The fragments were 
inserted into pBluescript (Stratagene) so that the antibiotic resistance gene 
interposed the flanking regions of gene. The replacement construct (upstream region 
– resistance cassette – downstream region) was amplified using the primers binding 
to the 5’end of upstream flanking region and the 3’end of the downstream flanking 
region of gene (see Tab. 2) and used to transformed recombination prone tolR-
deletion strains of S. sonnei or S. flexneri as previously described (128). In S. sonnei, 
the htrB gene was replaced by the chloramphenicol resistance gene cat (140). S. 
sonnei -p ∆tolR ∆msbB was obtained as described in (128). In S. flexneri, msbB1 
and htrB were replaced by cat and rfbG was replaced by the erythromycin resistance 
gene erm (141). In the rfbG knockout, also the flanking genes rfbF and rfc (139) were 
partially deleted. The rfbG deletion was introduced before the msbB or htrB deletion. 
The msbB1 mutation was only introduced into the plasmid-cured strain as the 
plasmid carries a second copy of msbB (msbB2, (120)). For simplicity, the mutant is 
referred to an ∆msbB. 
To complement strains carrying the htrB deletion, the htrB gene was amplified from 
Shigella sonnei 53G including  239 bp upstream and 172 bp downstream using 
primers P1.htrBcompl-EcoRI and P2.htrBcompl-NcoI and inserted into low copy 
vector pACYC184 (New England BioLabs®). The resulting plasmid pACYChtrB was 
introduced into electrocompetent S. sonnei or S. flexneri ∆htrB cells.  
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Primer name Sequence 5’ → 3’ 
htrB-U1 Xba Sma CTAGTCTAGAAACCCGGGCAATTGTATGTATTGTCG 
htrB-soU2 SacI ACTCGAGCTCCCGTCATCATCCAACGC 
htrB-flexU2 SacI ACTCGAGCTCATCCGATATACGTTCGCCC 
htrB-soD1 SalI ACGCGTCGACCTCAGTAATCAGGGTTCTTTG 
htrB-soD2 SmaI CTAACCCGGGTAAATCTCCCCTGCCGGATG 
htrB-flexD1 SalI ACGCGTCGACCCTGTAATCTCAGGTCAAATG 
htrB-flexD2 SmaI CTAACCCGGGTAAATCTCCCATGCCGGATG 
msbBflex-U5 Sma CTAGTCTAGAAACCCGGGTGATAGTGTAGCGGCACA 
msbBflex-U3 Sac ACTCGAGCTCGTGAGCAAAGCCAGCTG 
msbBflex-D5 SalI ACGCGTCGACCTCGGTGTGGAAATTGG 
msbBflex-D3 Xba Sma CTAACCCGGGCAACGTACTTACTCTACCG 
rfbF-1stop Sma CTAACCCGGGCTAAGCATCTAAGACACCATTCTGTATC 
rfbF-2 SalI ACGCGTCGACAATATCCTGGAGCATACGTGT 
rfc-1 SacI ACTCGAGCTCACCAATAACGCCTGTTTTCTG 
rfc-2 XbaSma3 CTAGTCTAGAAACCCGGGCTTCTTTGTCGGCTTATTAGC 
P1.htrBcompl-EcoRI  ACCGGAATTCGTGTAACACTGGCATGGTGTA 
P2.htrBcompl-NcoI CATGCCATTGTAGCAATCCGCTGTTGGTGCG 
EcoRV.Ery.F AGCTTGATATCAGAGTGTGTTGATAGTGCAGTATC 
EcoRV.Ery.R AGCTTGATATCACCTCTTTAGCTTCTTGGAAGCT 
EcoRV.Cm.F AGCTTGATATCTGTGACGGAAGATCACTTCG 
EcoRV.Cm.R AGCTTGATATCGGGCACCAATAACTGCCTTA 
virGup -5 Sac ACTCGAGCTCTGTAGTTGATTTGACAGTTGACATCC 
virGup-3 Sma CTAACCCGGGCACTATATTATCAGTAAGTGGTTGATAAACC 
virGdown-5 Sma CTAACCCGGGCGTGTTGATGTCCTGC 
virGdown-3 Sal ACGCGTCGACAGTTCAGTTCAGGCTGTACGC 
wzz-5 Sac ACTCGAGCTCGGCAGACTCAGCGCAAG 
wzz-3 Sma CTAACCCGGGCATTGACACAACAATACGTAACCCAG 
wgbZ-5 Sma CTAACCCGGGTGCGATTTGGTAATGTACTCGG 
wgbZ-3 SalI ACGCGTCGACATTGCTCGCTTGTGATAACAGC 
nadA-5 Sma CTAACCCGGGCAAGCAACTCTATGTCGGTGGAAT 
nadA-3 Hind TATCAAGCTTGGCAAGGCCAATACACAGC 
nadB-5 Hind TATCAAGCTTAGGGTTAGAGTGTCTCGTTTTTG 
nadB-3 Sma CTAACCCGGGCCAGACCAGAACTATTCC 
Ori-1 CGGCATCAGAATAATACAAGCAGC 
Ori-2 AGGTGTACCGTGCTCTGGG 
ospD3-1 GTTTTGCCTCATTCAAGATATCACC 
ospD3-2 TGACGATGGTTTGTCAGGATTGC 
lysP.F CCGAAACTAAAACTACAGAAGCGC 
lysP.R CCTTCTTCAACATAGTTCTGACCG 
msbB.F CGCCAAAGTTCCGTGATCCCATT 
msbB.R CTCTTCGATGATCTCCAGCCCTT 
lpxP.F GGCTTTGGGTACAGCTTCCTTA 
lpxP.R CCAACCCTTCAACATCAAACC 
 
Tab. 1 List of primers used.
 
 
During cultivation in vitro, S. sonnei spontaneously loses the virulence plasmid giving 
rise to phase II OAg deficient colonies (142). In order to avoid the loss of the pSS 
and consequently of the ability to synthetize the OAg repeating units, a mutant 
selectable for the presence of the pSS was produced by replacement of the plasmid-
encoded virulence gene virG (143) in S. sonnei ∆tolR with the genes nadA and nabB 
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from E. coli (144). These genes encode intermediate steps in the nicotinic acid 
biosynthesis that are defective in wild-type Shigella sonnei. Inserting nadA and nadB 
into the virulence plasmid allows the strain to grow without exogenous nicotinic acid. 
Thus, growth in chemically defined media without nicotinic acid serves as selection 
for bacteria containing the plasmid. Similarly, a S. sonnei O antigen deficient strain 
still carrying the virulence plasmid was obtained by replacement of the plasmid-borne 
gene cluster encoding the biosynthesis of the O repeating units from gene wzz to 
wbgZ with the genes nadA and nabB from E. coli in S. sonnei ∆tolR to yield S. sonnei 
∆tolR ∆wbg.  
Strain name 
abbreviation Genotype 
OAg LPS 
mod* Ref 
Ss
-p-OAg S. sonnei –pSS ∆tolR - - (128) 
Ss
-p-OAg ∆msbB S. sonnei –pSS ∆tolR ∆msbB - + (128) 
Ss
-p-OAg ∆htrB S. sonnei –pSS ∆tolR ∆htrB - + This study 
Sf
-p-OAg S. flexneri 2a –pINV ∆tolR ∆rfbG - - This study 
Sf
-p-OAg ∆msbB S. flexneri 2a –pINV ∆tolR ∆rfbG  ∆msbB  - + This study 
Sf
-p-OAg ∆htrB S. flexneri 2a –pSS ∆tolR ∆rfbG  ∆htrB  - + This study 
Ss
-p-OAg ∆htrB 
(pACYChtrB)  S. sonnei –pSS ∆tolR ∆htrB (pACYChtrB) - - This study 
Sf
-p-OAg ∆htrB  
(pACYChtrB) 
S. flexneri 2a –pINV ∆tolR ∆rfbG ∆htrB 
(pACYChtrB)  - - This study 
Sf+p-OAg S. flexneri 2a +pINV ∆tolR ∆rfbG - - This study 
Sf+p+OAg  S. flexneri 2a +pINV ∆tolR  + - This study 
Sf
-p+OAg  S. flexneri 2a –pINV ∆tolR  + - This study 
Sf+p+OAg ∆htrB S. flexneri 2a +pINV ∆tolR ∆htrB + + This study 
Sf
-p+OAg ∆htrB S. flexneri 2a –pINV ∆tolR ∆htrB + + This study 
Sf+p+OAg ∆htrB 
(pACYChtrB) 
S. flexneri 2a +pINV ∆tolR ∆htrB 
(pACYChtrB) + + This study 
Sf
-p+OAg ∆htrB 
(pACYChtrB) 
S. flexneri 2a –pINV ∆tolR ∆htrB 
(pACYChtrB) + + This study 
Ss+p-OAg S. sonnei +pSS ∆tolR ∆wbg - - This study 
Ss+p+OAg S. sonnei +pSS ∆tolR ∆virG + - This study 
Ss+p+OAg ∆htrB S. sonnei 2a +pINV ∆tolR ∆virG ∆htrB + + This study 
Ss+p+OAg ∆htrB 
(pACYChtrB) 
S. sonnei 2a +pINV ∆tolR ∆virG ∆htrB 
(pACYChtrB) + + This study 
Sf
–p+OAg ∆msbB S. flexneri 2a -pINV ∆tolR ∆msbB + + This study 
Sf3a  S. flexneri 3a +pINV ∆tolR  + - This study 
Sf3a ∆htrB S. flexneri 3a +pINV ∆tolR ∆htrB + + This study 
Sf6 S. flexneri 6 +pINV ∆tolR  + - This study 
Sf6 ∆htrB S. flexneri 6 +pINV ∆tolR ∆htrB + + This study 
Tab. 2 List of Shigella strains used in this study and their abbreviations. + means presence and 
– means absence of the characteristic. *LPS mod, lipid A of LPS modified; -pSS, -pINV, cured of 
virulence plasmid; +pSS, +pINV, virulence plasmid present 
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The mutations were generated using the same strategy as above with the execption 
that instead of the antibiotic resitance cassette the genes nadA and nadB (144) from 
E. coli, were used to replace the gene of interest. The upstream and downstream 
regions of virG were amplified using primer pairs virGup-5/virGup-3 and virGdown-
5/virGdown-3. For the OAg knock out, internal fragments of the genes wzz and wbgZ 
were amplified by PCR using primers wzz-5_Sac, wzz-3_Sam, and wbgZ-5_Sma and 
wgbZ-3_Sal, respectively. The “nadAB” cassette was generated by amplifying nadA 
and nadB from E. coli using primers nadA-5/nadA-3 and nadB-5/nadB-3. The 
fragments were inserted into pBluescript (Stratagene) so that nadA and nadB were 
linked and interposed the flanking regions of the gene of interest. 
 
Salmonella strains 
 
Salmonella enterica serovar Typhimurium D23580 is an invasive strain isolated in 
Malawi in 2004 (145). The double mutant ∆tolR ∆wbaP of D23580, lacking the O-Ag 
repeating unit (O:4,5), was used in this study. First the rough ∆wbaP mutant of 
D23580 was constructed by homologous recombination as described by Datsenko 
and Wanner (146), replacing wbaP coding sequence with a kanamycin resistance 
(Kmr) cassette. Briefly, we used one-step PCR protocol to fuse the 50 bp wbaP 
upstream and downstream regions to the Kmr gene using the primer pair 
wbaP1/wbaP2 (Tab.2) and the plasmid pKD4 as template. The linear fragment was 
then used to transform the recombination-prone D23580 strain (carrying the helper 
plasmid pSIM18) (147) and wbaP mutants were selected by plating transformed 
bacteria on Luria-Bertani (LB) plates containing 25 µg/ml kanamycin. Afterwards, tolR 
knock-out gene was performed following the same procedure. tolR coding sequence 
was replaced with a chloramphenicol resistance (Cmr) cassette using the plasmid 
pKD3 as template and the primer pair tolRP1/tolRP2 (Tab. 3). tolR mutants were 
selected by plating transformed bacteria on LB plates containing 20 µg/mL 
chloramphenicol. 
 
Identification  Strains genotypes Lip.A 
modified 
 OAg Reference 
S.Tm
 
 S. Typhimurium 1418 ∆tolR - + This study 
S.Tm ∆htrB S. Typhimutium 1418 ∆tolR ∆htrB + + This study 
S.Tm ∆msbB S. Typhimutium 1418 ∆tolR ∆htrB + + This study 
S.En
 
 S. Enteritidis 618 ∆tolR - + This study 
S.En ∆htrB S. Enteritidis 618 ∆tolR ∆htrB + + This study 
S.En ∆msbB S. Enteritidis 618 ∆tolR ∆htrB + + This study 
Salmonella S. Typhimurium D23580 - - This study 
 
Tab. 3 List of Salmonella strains used in this study and their abbreviations. + means presence 
and – means absence of the characteristic. 
 
Salmonella enterica serovar Typhimurium 1418 and Salmonella enterica serovar 
Enteritidis 618 are invasive strains isolated from animal source. Different Salmonella 
mutants were obtained by homologous recombination as described by Datsenko and 
Wanner (146), replacing target gene coding sequence with an antibiotic resistance 
cassette. Salmonella enteritidis spp. mutants with ∆tolR and ∆htrB or ∆msbB in 
different combinations were generated (stains and abbreviations are listed in Tab. 3). 
To generate the knock-out mutants, transformants were selected on LB agar plates 
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containing 30 µg/mL kanamycin (tolR mutant), 20 µg/mL tetracyclin (msbB mutant) 
and 20 µg/mL chloramphenicol (htrB mutant). 
 
Neisseria strains 
 
Different Neisseria meningitidis W-135 mutants carrying ∆cps, ∆lpxL1, ∆gna33, or 
overespressinf factor H binding protein (OE fHbp) in different combinations were 
generated (mutants and their abbreviations are listed in Tab. 4). Deletion of lpxL1 
and gna33 (68,148) was performed by insertional inactivation as described 
previously (149). Deletion of the capsular biosynthesis was performed by 
replacement of a DNA fragment containing synX, ctrA and the intergenic promoter 
that drives transcription of the capsular biosynthesis and transport operon with a 
chloramphenicol resistance gene (149). OE fHbp was obtained by insertion of fHbp 
gene (150) under the regulation of a strong syntetic promoter. To generate the 
knock-out mutants, N. meningitidis was transformed with 0.5 to 1 ug linearized 
plasmid DNA and transformants were selected on GC agar plates containing 80 
ug/mL kanamycin (lpxL1 mutant), 5 ug/mL erythromycin (gna33 mutant) and 5 ug/mL 
chloramphenicol (capsular KO mutant). 
 
Identification  Strains genotypes Lip. A 
modified 
Reference 
Nm
 
 N. meningitidis ∆cps - This study 
Nm ∆fHbp N. meningitidis ∆cps ∆fHbp - This study 
Nm ∆fHbp OE fHbp N. meningitidis ∆cps ∆fHbp OE fHbp - This study 
Nm ∆fHbp ∆lpxL1  N. meningitidis ∆cps ∆fHbp ∆lpxL1 + This study 
Nm ∆fHbp ∆lpxL1 OE fHbp N. meningitidis ∆cps ∆fHbp ∆lpxL1OE fHbp + This study 
Neisseria N. meningitidis ∆fHbp ∆lpxL1 ∆gna33 + This study 
 
Tab. 4 List of Neisseria strains used in this study and their abbreviations. + means presence and 
– means absence of the characteristic. 
 
Growth conditions 
 
Shigella bacterial strains were routinely grown at 30°C in liquid or on solid M9 
medium supplemented with nicotinic acid (Na2HPO4 7 g/L, KH2PO4 3 g/L, NaCl 0,5 
g/L, NH4Cl 1 g/L, MgSO4 1M 2mL/L, CaCl2 1M 0,1 mL/L, glucose 0,4%, nicotinic acid 
0,01 g/L) or in chemically defined medium (SDM), with the same composition to the 
previously described SSDM (128) with the exception of the carbon source: KH2PO4 
13,3 g/L, (NH4)2HPO4 4 g/L, Citric acid 1,7 g/L, L-aspartic acid 2,5 g/L, D-Glucose 15 
g/L, CoCl2 6H2O 0.0025 g/L, MnCl2 4H2O 0.015 g/L, CuCl2 2H2O 0.0015 g/L, H3BO3 
0.003 g/L, Na2MoO4 2H2O 0.0025 g/L, Zn(CH3COO)2 2H2O 0.0025 g/L, Ferric citrate 
2 µM, MgSO4 2 mM, Thiamine 0.05 g/L, Nicotinic acid 0.01 g/L, pH 6,7 (with NH4OH). 
When required, kanamycin (30 µg/mL), chloramphenicol (20 µg/mL), erythromycin 
(100 µg/mL), or tetracycline (20 µg/mL) were added. 
Salmonella bacterial strains were grown at 30/37°C in Lauria Bertani (LB) liquid 
coltures with the addition in the pre-coltures of the required antibiotics. 
Neisseria bacterial strains were grown at 37°C in liquid coltures in meningococcus 
chemically-defined medium (MCDMI) with the addition in the pre-coltures of the 
required antibiotics. 
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Production and purification of GMMA 
 
Preparation of GMMA from Shigella strains 
 
For GMMA production overnight cultures were grown in presence of the specific 
selective antibiotics and used to inoculate the production medium to an OD of 0.03-
0.05. Production cultures were incubated at 30°C and 200 rpm overnight. Culture 
supernatants were collected by 10 min centrifugation at 5,000g followed by 0.22 µm 
filtration. GMMA were concentrated using an Amicon stirrer cell with a regenerated 
cellulose filter with a nominal molecular weight limit of 100 kDa (Amicon Ultracell) 
under nitrogen flow. The retentate was collected in 70 mL ultracentrifuge propylene 
tube (Beckman Coulter) and ultracentrifuged at 186,000 g using 45Ti rotor (Beckman 
Coulter) for 2 hours at 4°C. Pellets were resuspended in 4 mL of PBS followed by 
0.22 µm filtration. GMMA were stored at 4°C. 
 
Preparation of GMMA from Salmonella strains 
 
5 mL of LB was inoculated with single colonies of Salmonella enterica serovar 
Typhymurium ∆OAg and incubated at 30°C over-night in presence of selective 
antibiotic. The starter culture was used to inoculate 70 mL LB to OD=0.05 and the 
culture was incubated at 30°C over-night (approximately 15 hours). The culture was 
centrifuged and the supernatant was sterilized by filtration through a 0.22 µm filter. 
To collect the GMMA the sterile culture supernatant was centrifuged (186,000 g, 2 
hours, 4°C), the membrane pellet was washed once with PBS and after a second 
centrifugation step the GMMA pellet was resuspended in 1X PBS and was sterilized 
by filtration through a 0.22 µm filter. 
 
Preparation of GMMA from N. meningitidis strains 
 
7 mL of Meningitis chemically defined medium I (MCDMI) was inoculated with single 
colonies to OD = 0.15 to 0.17 and incubated at 37°C, 5% CO2 to mid log phase 
(OD=0.6). The starter culture was used to inoculate 50 mL MCDMI to OD=0.05 to 0.1 
and the culture was incubated at 37°C, 5% CO2, 185 rpm until stationary phase 
(approx. 9 hours). The culture was centrifuged and the supernatant was sterilized by 
filtration through a 0.22 µm filter. To collect the GMMA the sterile culture supernatant 
was centrifuged (186,000 g, 2 hours, 4 °C), the membrane pellet was washed once 
with PBS and after a second centrifugation step the GMMA pellet was resuspended 
in 1X PBS and was sterilized by filtration through a 0.22 µm filter. 
 
Protein quantification of GMMA 
 
Standard curve for the assays were prepared with bovine serum albumin (Pierce) in 
the range 1-10 µg/assay for Bradford assay and 4-50 µg/assay in both Lowry and 
Non-Interfeering assays.  
 
Bradford assay 
 
Bradford Protein Assay (Bio-Rad) kit is used following the producers specifications. 
Prior quantification GMMA were diluted 1:2 with 6.0 M guanidine hydrochloride pH 
7.8 (vol/vol) and boiled for 10 minutes vortexing occasionally. Different quantities of 
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samples were adjusted to a final volume of 200 µL with water. 800 µL of Bradford 
reagent concentrate (5X) diluted with water were added to each sample. 
Absorbances were measured at 595 nm after 30 minutes. 
 
Lowry assay 
 
Detergent Compatible (DC) Protein assay (Bio-Rad) is used following the producers 
specifications. Different quantities of GMMA were adjusted to a final volume of 25 µL 
with water. 125 µL of Reagent A’ (prepared adding 20 µL of reagent S to every mL of 
reagent A) were added and samples were vortexed. 1 mL of reagent B was added 
and absorbances were read at 750 nm after 15 minutes. 
 
Non-Interfering protein assay (NI assay) 
 
For the assay use the standard procedure reported in the NI manual (G-bioscience, 
USA). 
Different quantities of GMMA were adjusted to a final volume of 25 µL with water. 
500 uL of Universal Protein Precipitation Agent (UPPA) I was added, incubated for 2 
minutes and vortexed. Afterwards 500 µL of UPPA II was added and vortexed. 
Samples were centrifuged for 5 minutes at 10,000 g and supernatants were 
discarded by inverting the tube. Sample were centrifuged a second time for 5 
minutes at 10,000 g and supernatant was discarded by using a pipette. 500 µL of 
reagent 1 (prepared adding 400 µL of water to 100 µL of Copper solution) were 
added to each sample and resuspend vortexing. 1 mL of reagent 2 was added 
(prepared adding 1 part of Color reagent B every 100 part of Color reagent A) and 
Abs was read at 480 nm after 15 minutes (using water as blank). 
 
Quantitative aminoacid hydrolysis analysis 
 
Aminoacid hydrolysis analysis of GMMA was performed by AltaBioscience 
(Birmingham, UK) using an ion exchange separation of aminoacid followed by post 
column detection with ninidrine [1;50]. 
 
SDS-PAGE 
 
GMMA were denatured for 3 min at 95°C in sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) sample buffer containing 2% (wt/vol) SDS. GMMA 
were loaded onto 12% (wt/vol) polyacrylamide gels (BioRad, Hercules, U.S.A.). Gels 
were run in 3-(N-morpholino)-propanesulfonic acid (MOPS) buffer (BioRad) and were 
stained with Coomassie Blue Stain (Sigma-Aldrich) following the data sheet’s 
procedures for proteins. 
 
Negative Staining Trasmission Electron Microscopy 
 
A drop of 5 µL of GMMA suspension prediluted 100 µg/mL was placed onto 300 
mesh copper formvar/carbon-coated grids and adsorbed for 5 min. Grids were then 
washed with few drops of distilled water and blotted with a Whatman filter paper. For 
negative staining, grids were treated with 2% uranyl acetate in ddH2O for 1 min, 
blotted with Whatman filter paper and air-dried and observeded with a Tecnai 2 Spirit 
transmission electron microscope (FEI, Eindoven, the Netherlands) operating at 80 
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kV. Electron micrographs were recorded at a nominal magnification of 87,000 – 
105,000 X. 
The non-parametric Kruskal-Wallis test has been used to statistically evaluate GMMA 
dimensions (with n=30 per strain). 
For bacteria 5 µL of liquid colture were prediluted to O.D.=0,1 in PBS and were 
placed on copper formvar/carbon-coated grids and adsorbed for 5 min. Afterwards 
the drop was dried using a Whatman filter paper and 5 µL of formaldeyde (sigma 
Aldrich) 2% (in PBS) were added and incubated 5 min. The residual drop were dried 
using Whatman filter paper and observeded with a CM100 transmission electron 
microscope (Philips, Eindoven, the Netherlands) operating at 80 kV.  
 
Monocyte Activation Test (MAT) 
 
PBMC isolation and freezing 
 
Buffy coat from different donors were used to isolate PBMC by Ficoll (Amersham 
Pharmacia Biotec, cat N° 17-1440-03) density centrifugation and following protocol 
reported in (123).  
PBMC were frozen resuspending in freezing medium (heat-inactivated FBS (Fetal 
Bovine Serum), 10%DMSO) at a consentration of 5x107 cells/cryovial. Cryovials were 
prepared dispensing 1 mL aliquots of cell suspension in pre-cooled 2 mL cryovials 
marked with subject’s code and were immediately transferred into the Cell Freezing 
Box (Nalgene) and stored at –80°C for 24-48h and then transfered in Liquid Nitrogen 
tank. 
 
PBMC thawing and stimulation 
 
For thawing, each cryovial conserved in liquid nitrogen was warmed at 37°C in water 
bath gently shaking until a small, pea-sized pellet of ice remained. 1 mL of thawing 
medium (PBS without Ca2+ and Mg2+, with 2.5 mM EDTA and 20 µg/mL DNAse  
(Sigma, 20 mg/mL stock) warmed at 37°C was added directly into each cryovial; 
thus, the cell suspension was added to a 40 mL of warm thawing medium. Each 
cryovial was rinsed with 1 mL of fresh thawing medium to collect residual cells and 
samples were centrifuged at 320 g for 10 minutes at room temperature. Supernatants 
were discarded by gently inverting the tube and the pellet of cells were washed with 
40 mL of pre-warmed thawing medium and centrifugation and discarding of 
supernatants were repeated. Pellet cointaining PBMCs was diluted in adequate 
volume of medium RPMI-1640 complete (with 25 mM HEPES, glutammine, 10% 
Fetal Bovine Serum (FBS) + 1% Antibiotics Penicilline-Streptomicine (InvitroGen)).  
For the stimulation PBMC were cultured at a density of 2 x 105 cells/well with 180 µL 
of medium RPMI-1640 complemented with 25 mM HEPES, 2 mM glutamine, 10% 
FBS,  1% Pen-Strep (InvitroGen) in 96-well round bottom plates. After incubation at 
37°C for 30 min, 20 µL of 10-fold serial dilutions of in PBS (0.0001-1,000 ng/mL final 
concentration in the assay) were added. In blocking experiments, 2.5 µg/mL of TLR4 
blocking antibody (e-Bioscience) and/or 1.5 µg/mL of TLR2 blocking antibody (e-
Bioscience) in RPMI were added for 30 minutes before the addition of GMMA. Cells 
were incubated for 4 hours at 37°C and supernatants were recovered after 
centrifugation of the plates at 400 g and stored at -80°C until analysis.  
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Cytokine analysis by ELISA and 7-plex Mesoscale 
 
For IL-6 detection by ELISA Nunc MaxiSorp 96-well plates were coated overnight at 
4°C with 2 µg/mL human IL-6 capture antibody (eBioscience 14-7069) in PBS, 
subsequently washed with PBS with 0.05% Tween 20 (PBS-T), blocked for 1 h with 
PBS with 1% BSA at room temperature (RT) and washed 3-times with PBS-T. 50 µL 
of supernatants from PBMC experiments, diluted 1:4 with PBS, were incubated for 2 
h at RT. A two-fold dilution series of recombinant human IL-6 (eBioscience 39-8069) 
of 31.24 pg/mL to 4,000 pg/mL in RPMI with 10% FBS was included as standard 
curve on each plate (in duplicate). Plates were washed with PBS-T. Bound IL-6 was 
detected using 2 µg/mL of biotin-conjugated anti-human IL-6 (e-Bioscience 13-7068) 
in PBST with 0.1% BSA for 2 h at RT, followed by 3 washes with PBS-T, 20 min 
incubation at RT with streptavidin-horse radish peroxidase (R&D Systems, DY998) 
diluted 1:200 in PBS-T with  0.1% BSA, 3 washes with PBS-T, and a color reaction 
with 100 µL/well of substrate (R&D Systems, DY999) for 8 min at RT in the dark. The 
reaction was stopped by adding 50 µL/well of 12.5% sulfuric acid. The plates were 
read at 450 nm and 630 nm and the OD450nm-630nm was determined. IL-6 
concentrations in the samples were calculated in comparison to the IL-6 standard 
using a four parameter logistic curve and plotted against the amount of GMMA in the 
sample. Results below the detection limit were assigned half of the detection limit. 
The average of the IL-6 release at the lowest concentration of GMMA that did not 
trigger activation was defined as background level. For comparison of the stimulatory 
activity of GMMA, the amounts of GMMA needed to obtain a 10-fold increase of IL-6 
release over background were determined from the generated curves.
 
Mesoscale 7-spot (MSD Technology) analysis for cytokines IL-6, IL-8, IL-1β, TNF-α, 
IL-10, IL-12, and IFN-γ, was performed with 25 µL of supernatants from PBMC 
according to the manufacturer’s instructions. Concentrations of the different cytokines 
in the samples were determined in comparison to the preloaded standard in the 
plates. The average of the cytokine release at the lowest concentration of GMMA that 
did not trigger activation was defined as background level. For comparison of the 
stimulatory activity of GMMA, the amounts of GMMA needed to obtain a 10-fold 
increase of cytokines released over background were determined from the generated 
curves. 
The average cytokine release at the lowest concentration of GMMA that did not 
trigger activation was defined as background level. For comparison of the stimulatory 
activity of GMMA, the amounts of GMMA needed to obtain a 10-fold increase of IL-6 
release over background were determined from the generated curves. The non-
parametric Mann-Whitney test was used to statistically evaluate the results obtained 
with different GMMA. 
For statistical analysis of the results of the TLR blocking experiments, the ratio of IL-6 
produced by PBMC treated with anti-TLR4 or anti-TLR2 and the IL-6 produced by 
PBMC not treated with blocking antibodies, stimulated with the same concentration of 
GMMA, was calculated as to normalize between the different experiments using 
PBMC from different donors. The ratio was determined for each replicate in the 
experiments. The non-parametric Wilcoxon signed rank test was used to assess if 
the obtained ratios were significantly different form 1 (no effect by blocking). 
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NF-kB luciferase reporter assay 
 
TLR-specific activation assays were performed using Human Embryonic Kidney 293 
(HEK293) cells expressing luciferase under control of the NF-kB promoter and stably 
transfected with either TLR4, MD2, and CD14 (TLR4-HEK293) or TLR2 (TLR2-
HEK293) (151). HEK293 transfected cells were maintained in DMEM medium 
complemented with 4,5 g/L of glucose and HEPES (Invitrogen), 10% fetal bovine 
serum (FBS) 1% penicillin-streptomycin solution (Pen-Strep, Invitrogen) and specific 
antibiotics for the different cell lines: puromycin (5 µg/mL), blasticidin (10 µg/mL) and 
hygromycin (250 µg/mL) for TLR4-HEK293 cells, and puromycin and hygromycin for 
TLR2-HEK293 cells. 
For the NF-kB luciferase assay 25,000 cells/well were seeded in 90 µL of complete 
DMEM medium without antibiotics in 96-well microclear luciferase plates (PBI 
international) and incubated for 24 hours at 37°C. 10 µL of serial 5-fold dilutions of 
GMMA in PBS (0.0001-1,000 ng/mL final concentration in the assay) were added. 
After incubation for 5 h at 37°C supernatants were aspired from each well and cells 
were lysed for 20 minutes at room temperature using 20 µL/well of 1:5 diluted 
‘passive lysis buffer’ (Promega). Produced luciferase was detected using 100 µL/well 
of luciferase assay reagent (Promega) and emitted light was immediately quantified 
using a luminometer Lmax II384 (Molecular Devices). NF-κB actiation of cells 
stimulated with GMMA is expressed as fold-increase of emitted light over the average 
result of PBS-stimulated control cells. Values were plotted as average of duplicates ± 
SD (NF-kB fold induction). Data were analyzed by Excel and GraphPad Prism. For 
comparison of the stimulatory activity of GMMA, the amounts of GMMA needed to 
obtain a 3-fold (TLR4 experiments) or 10-fold (TLR2 experiments) induction of NF-κB 
were determined from the generated curves. The non-parametric Mann-Whitney test 
was used to statistically evaluate the results obtained with different GMMA. 
 
MALDI-TOF and MS/MS analysis on lipid A 
 
Lipid A was precipitated from GMMA using mild acid hydrolysis with 1 % acetic acid  
for 2 h at 100°C (152). Samples were centrifuged at 14,000 g for 15 min, the pellets 
resuspended in water, and washed twice with water. The pellets were dried overnight 
using a speedvac and resuspended in chloroform-methanol 4:1 and mixed with an 
equal volume of Super DHB solution (Sigma-Aldrich). 2 µL of the mixture were 
loaded to the target plate (MTP 384 target plate ground steel BC, Bruker Daltonics) 
and analyzed by Ultraflex MALDI-TOF (Bruker Daltonics) in reflectron ion-negative 
mode. A Peptide Calibration Standard (Bruker Daltonics), mixed with the Super DHB 
solution, was included in each analysis. For MS/MS analysis of lipid A, main peaks 
from the linear mode analysis were selected for Collision Induced Dissociation (CID) 
and resulting fragments were detected by MALDI-TOF-TOF in ion negative mode. 
For each sample, spectra represent the integration of the analysis of 20 different 
areas of the spot by 50 single laser shots. The m/z rations were determined by Flex 
Analysis software in comparison to the Peptide Standard.  
 
Peptide Mass Fingerprinting (PMF)  
 
Protein spots were excised from the gel and processed as previously described (128). 
Briefly, mass spectra were acquired on an Ultraflex MALDI TOF-TOF mass 
spectrometer (Bruker Daltonics) in reflectron, positive mode, in the mass range of 
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900 to 3,500 Da. Spectra were externally calibrated by using a combination of 
standards pre-spotted on the target (Bruker Daltonics). MS spectra were analyzed by 
PMF with flexAnalysis (flexAnalysis version 2.4, Bruker Daltonics). Monoisotopic 
peaks were annotated with flexAnalysis default parameters and manually revised. 
Protein identification was carried from the generated peak list using the Mascot 
program (Mascot server version 2.2.01, Matrix Science). Mascot was run on a 
database containing protein sequences deduced from sequenced Shigella genomes 
used in (66). 
 
KDO quantitation by semi-charbazide method 
 
Core reducing end KDO (2-keto-3-deoxyoctonate) was quantified using the 
semicarbazide/High Performance Liquid Chromatography-Size Exclusion 
Chromatography (HPLC-SEC) method as we previously reported (153). To apply the 
method to GMMA, 150 µg of GMMA were hydrolyzed in 1% acetic acid for 3 h at 
100°C and subsequently centrifuged for 15 min at 14,000 g. Supernatants were 
collected and dried in a speedvac and the pellets were resuspended in water. 
Samples and a standard of 4 µg/mL to 40 µg/mL KDO ammonium solution (Sigma 
Aldrich, K2755) were derivatized using semicarbazide and analyzed by HPLC-SEC 
using a TSKgel G3000 PW-XL column (TOSOH, 808021). The amount of core 
reducing end KDO was calculated using the calibration curve built with the peak 
areas of derivatized KDO standard at 252 nm. 
 
Quantitative real time PCR and RNA isolation 
 
RNA was purified using RNeasy Plus Mini Kit (Qiagen) from 2 mL of bacteria grown 
at 30°C to an optical density (OD) of 1 with on-column DNase purification step. Purity 
of RNA was evaluated by gel and NanoDrop profile. Retrotrascription was performed 
using Superscript II; for each reaction 2 µg of RNA, 1 µL of 10 mM sNTP mix, 1 µL of 
random primers (50 ng/µL) and DEPC-treated water to 10 µL were added and 
incubated at 65°C for 5 min. 
9 µL of reaction mix (composed by 2 µL of 10X RT buffer, 4 µL 25 mM MgCl2, 2 µL 
0,1M DTT and 1 µL of RNase OUT 40 U/µL) were added to each RNA/primers 
mixture and incubated at room temperature for 2 min. 1 µL of SuperScript II RT were 
added to each tube (Negative Control: 1 µL of DEPC-treated water) and incubated  at 
room temperature for 10 min, afterwards at 42°C for 50 min. and reaction was 
terminated incubating at 70°C for 15 min and then chilling on ice. 1 µL RNase H was 
added to each tube and incubated for 20 minutes at 37°C. The reaction was purified 
with QIAquick (Quiagen) PCR purification kit following manufacturer instructions. 
Quantitative RT-PCR for genes lysP, lpxP, and msbB was performed using 10 ng 
cDNA, SYBR green kit (Lifetechnologies), and 0.4 µM primers lysP.F/lysP.R, 
lpxP.F/lpxP.R, msbB.F/msbB.R (sequences of primers reported in Tab. 1) in 
thermocylcer MX3005P (Stratagene) with 40 cycles (95°C, 15 sec; 60°C, 60 sec). 
Fold induction was calculated as 2-∆(∆Ct), were ∆Ct is the difference between the 
number of cycle of amplification needed to reach the threshold (fluorescence 
dRn=0,018) for lpxP or msbB versus the cycle of amplification of the house-keeping 
gene lysP (154) in same strain or versus the cycle of amplification of the  late acyl 
transferase gene msbB of the constitutive lipid A biosynthesis pathway(155) in same 
strain. ∆(∆Ct) represent the difference in the ∆Ct obtained for the same gene in the 
different strains. 
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Results 
 
Comparison of different color-based 
methods to AA hydrolysis for measuring 
GMMA protein concentration 
 
Establishing a consistent and reproducible method for the quantification of GMMA 
samples is important in order to use them as vaccine and for comparing them in 
functional assays. GMMA are conveniently quantified based on protein amount, 
although other assays, e.g. sugar or lipid content, may be appropriate for specific 
vaccines.  Even in these cases, since protein assays are usually simpler to perform, 
for in process assays, e.g. during purification or formulation, measuring protein 
content is preferred.  
The quantitative amino acid (AA) hydrolysis is considered a primary method for 
protein quantification (156), as it is not affected by protein composition and does not 
need a calibration curve with a standard protein. Routine AA analysis slightly 
underestimates the actual concentration due to the loss of cysteine and tryptophan 
during the analysis, but this difference is usually  marginal and can be corrected in a 
more detailed analysis (157). However, analysis based on AA content is slow and 
therefore not suitable for in-process assays, and for this purpose secondary 
colorimetric assays using a standard protein are usually preferred and have been 
used by different groups (66,68,83). Thus, to establish the best method for 
quantifying GMMA samples, we have compared  different commercially available 
color based protein assays: Bradford assay (158), Lowry assay (159) and Non-
Interfering protein assay (NI), a method that involves a protein precipitation step that 
allows to discard interfering agents already been used for the quantification of GMMA 
samples (83); for all of them GMMA protein concentration has been evaluated by 
using their amino acid content as the primary standard compared to the color yield of 
bovine serum albumin (BSA) as a secondary standard.  
The criteria for evaluating the colorimetric assays were: the ease of performing the 
assay, the reproducibility of the assay, the linearity of the assay, and the 
comparability of results for GMMA produced from different bacterial lines (Shigella, 
Salmonella and Neisseria).  
 
Color yield and reproducibility 
 
The quantities of the different GMMA as measured using Bradford, Lowry and NI 
assays using a BSA standard curve and the reproducibility of the results are listed in 
Tab. 5. The concentrations of GMMA shown in this table were determined by 
comparison of the color yield obtained with the GMMA to the color yield of the BSA 
standard. 
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Tab.5 – Results and analysis of concentrations obtained by different assays 
 
With all of the GMMA, the Bradford assay gave a substantially higher color yield than 
the equivalent amount of BSA and, without applying a color yield factor, 
underestimated the protein content by up to 80% (Fig. 5). In addition, the difference 
between the Bradford results and the quantitative AA hydrolysis results varied for 
GMMA produced from different species and with different genetic modifications 
without a clear correlation to phenotypic background tested.  For example, in multiple 
assays, the S. flexneri +p ∆OAg consistently gave nearly twice the BSA equivalent as 
S. flexneri –p ∆OAg although they have similar amino acid compositions (Tab. 5) and 
were tested at similar concentrations. 
 
Fig. 5 – Results obtained quantifying GMMA by different assays – related to Tab.5. Values and 
standard deviations were normalized to percentages measured in comparison to AA hydrolysis. A) 
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GMMA were respectively obtained from: 1. Ss –p ∆OAg; 2. Ss +p ∆OAg, 3. Ss +p; 4. Sf +p ∆OAg; 5. 
Sf +p; 6. Sf -p ∆OAg. B) GMMA were obtained from 7. Salmonella; 8. Neisseria 
 
By contrast, GMMA assayed by Lowry gave a consistently lower color yield than BSA 
and in the absence of a color yield factor for the Shigella and Salmonella GMMA 
underestimated the protein content of the GMMA by about 35% (Fig. 5).  For both the 
Bradford and Lowry assays, Neisseria GMMA gave a lower color yield (i.e. a higher 
BSA equivalent) than the Shigella and Salmonella GMMA. The Neisseria GMMA also 
have a substantially different amino acid composition compared to the Shigella and 
Salmonella GMMA (Tab. 6). 
 
 
Tab. 6 – AA hydrolysis analysis results 
 
On average, with the NI assay, the GMMA gave approximately a 20% lower color 
yield than BSA (Fig. 5).  However there was variation between closely related GMMA 
e.g., the S. flexneri +p ∆OAg gave 40% higher BSA equivalent as S. flexneri +p. 
When using plastic cuvettes, the Lowry assay gave a lower average inter- and intra-
assay variation than the other methods (Tab. 5). With quartz cuvettes, the 
reproducibility of the Lowry assay was further improved: the intra-assay variation 
decreased to less than 4% for each sample (Tab. 7). 
 
 
 
Tab. 7 – Results and analysis of intra-assay variations obtained by Lowry assay using quartz 
cuvettes 
 
For all the assays the measurements of GMMA concentration were performed in the 
range in which the quantification’s methods are linear accordingly to BSA standard 
curve. The differences in protein concentrations obtained by different methods are 
due to GMMA properties, and not to different methods themselves. In fact, 
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quantifying by different assays purified proteins (ex. CRM197 [48]), we gained similar 
concentrations using Lowry, Bradford and NI assay (data not shown).  
 
Linearity of measurements 
 
S. sonnei –p ∆OAg GMMA were assayed at 5 to 20 µg, in terms of absolute amount 
of proteins as quantified by AA hydrolysis, for Bradford and in the range of 6.25-21.5 
µg for Lowry and NI assay to measure the linearity of each assay. Graphs obtained 
plotting directly BSA equivalents obtained from the assay in comparison to absolute 
amount as measured by AA hydrolysis (Fig. 6A), or BSA equivalents “normalized” 
using colorimetric correlation factors obtained for each assay (Fig. 6B), were 
produced to compare different colorimetric assays in terms of linearity. The criteria for 
evaluating the linearity were the analysis of the slope and the intercept of the 
trendlines obtained for each colorimetric assay: the linearity is better the closer 
intercept is to 0 and the closer the slope is  to 1. Both Lowry and NI assay fits better 
than Bradford to the previous parameters and Lowry is the closest ones to the ideal 
fits (formulas reported in Fig. 6a and Fig. 6B). Furthermore both Lowry and NI assay 
have shown an R2 more closed to 1 that Bradford assay (Fig. 6).  
 
 
Fig. 6 Linearity of assays. GMMA purified from Ss -p ∆OAg were assayed using different colorimetric 
assays starting from different absolute amounts as obtained by AA hydrolysis; values obtained from 
different colorimetric assays were plotted against quantities of GMMA as measured by AA hydrolysis 
A) as BSA equivalents B) applying a colorimetric correlation factor to BSA equivalents 
obtained by each colorimetric assay prior plotting. The colorimetric factors used were 3.5, 0.74 
and 0.76 respectively for Bradford, NI and Lowry assay basing on results shown in tab.2. Trendlines 
for each assay were afterwards obtained and formulas were shown on graphs. 
 
Evaluation of proportionality by SDS-PAGE 
 
The results obtained by different methods of protein quantification were also 
evaluated by analyzing the same amount of proteins (as quantified by the different 
assays) from different types of GMMA onto SDS-PAGE (Fig. 7). Visually, samples 
loaded according to concentration measured by AA hydrolysis (Fig. 7A) and by Lowry 
assay (Fig. 7B) gives a similar protein pattern, indicating a good correlation between 
these two methods even without application of a colorimetric correlating factor. In 
SDS-PAGE profile displayed in Fig. 7A and Fig. 7B are detectable, in fact, only small 
differences in terms of absolute amounts of GMMA in each lane, due to the general 
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overestimation by Lowry method. Anyway the proportionality between different 
samples is maintained. Due to the fact that we established an approximately 4-fold 
underestimation by Bradford method loaded on gel 2.5 µg of GMMA according to 
concentration measured by Bradford assay (Fig. 7C). Although this adjustment, we 
observed that supposedly same amounts of different types of GMMA as quantified by 
Bradford method, clearly differed to the ones loaded accordingly to AA hydrolysis 
(Fig. 7A). This behavior is most critical comparing GMMA obtained from S. sonnei 
and S. flexneri strains than between GMMA obtained from different S. sonnei 
mutants compared in previous studies (66). 
The same types of assays’ comparison for GMMA protein quantifications were 
performed for GMMA obtained from Salmonella and Neisseria, and results are 
reported in Tab. 5 and Fig. 5B. Gels after SDS-PAGE loading 10 µg of GMMA from 
those strains accordingly to AA hydrolysis and Lowry assay were also shown in Fig. 
7A and Fig. 7B; SDS-PAGE loading 2.5 µg of GMMA accordingly to Bradford assay 
were, instead, shown in Fig. 7C. Also for Salmonella and Neisseria GMMA Bradford 
assay underestimate the concentrations obtained by quantitative AA hydrolysis; 
instead the results obtained by Lowry and NI assay generally over estimates the 
concentration obtained by AA hydrolysis, following the trend observed for Shigella 
GMMA. 
 
 
Fig. 7 SDS-PAGE 12% - AA hydrolysis (A) vs Lowry (B) vs Bradford (C). 10 µg of GMMA/well 
loaded accordingly to AA hydrolysis quantification (A) or Lowry assay (B) in a 12% SDS-PAGE, 
Comassie stained. In (C) 2.5 µg of GMMA/well loaded accordingly to Bradford quantification in a 12% 
SDS-PAGE, Comassie stained. GMMA were respectively obtained from: 1. Ss –p ∆OAg; 2. Ss +p 
∆OAg, 3. Ss +p; 4. Sf +p ∆OAg; 5. Sf +p; 6. Sf -p ∆OAg; 7. Salmonella; 8. Neisseria 
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Reduction of GMMA endotoxicity 
 
General strategy of engeenerization and electron microscopy of bacteria 
 
In order to obtain GMMA-producing strains, Shigella and iNTS strains (S. Enteritidis 
and S. Typhimurium) were genetically engineered by ∆tolR deletion (66).  In case of 
N. meningitidis, hyper-blebbing strains have been obtained by the knock-out of 
gna33. Bacteria carrying tolR or gna33 kock outs were viewed by electron 
microscopy. Blebbing could be observed with all strains (Fig. 8). However, the 
difference between the electron micrographs obtained with the Neisseria gna33 
mutant compared to the Shigella and Salmonella tolR mutants is striking. Neisseria 
appears to ‘accumulate’ GMMA at the cell surface, whereas in Shigella and 
Salmonella few GMMA were detected at the cell surface but GMMA were visible in 
the surrounding milieu (see S. sonnei panel in Fig. 8). 
 
 
 
Fig. 8 Electron microscopy on GMMA-prucing bacteria bacteria (S. sonnei ∆tolR, S. flexneri 
∆tolR, S. enteritidis ∆tolR, S. typhimurium ∆tolR, N. meningitides ∆gna33). Arrows indicate 
GMMA/GMMA formation.  
 
Starting from these hyper-blebbing strains, the feasibility of reducing lipid A 
reactogenicity of GMMA was assessed using htrB and msbB knock outs for Shigella 
and iNTS or lpxL1 for Neisseria.  
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Shigella 
 
Mutants production and set up conditions for GMMA production 
 
Shigella strains with comparable genetic background were generated in order to 
better characterize and compare GMMA from different strains. Initially GMMA without 
major virulence plasmid and lacking OAg were compared, as these were used to set 
up the industrial production process (66). 
As reported in (128) mutants lacking the major virulence plasmid grow similarly to 
wild type strains, as well after tolR knock out, both at 30 than at 37°C, both in terms 
of duplication time than of optical density reached after over-night colture that was 
comparable both in Lauria Broth (LB) median than in SDM (data not shown). Strains 
carrying msbB knock out, besides maintained the ability to grow at 37°C, reached a 
higher optical density at 30°C and in chemical defined media (128). In contrast, ∆htrB 
strains only grew in chemical defined or minimal media and only at 30°C. The 
duplication time of the ∆htrB or ∆msbB strains increased from 30 min to 
approximately 2 hours, but all the strains were able to reach high ODs (OD 10) after 
overnight incubation in chemically defined medium (SDM) at 30°C. Thus 30°C in 
SDM was chosen as the standard growth condition. All strains with lipid A 
modifications yielded more than 50 mg/L GMMA protein. 
 
Characterization of GMMA from different mutants: Electromicroscopy and 
Protein pattern 
 
The shape of the GMMA from Shigella strains carrying different mutations was 
characterized by electronmicroscopy. GMMA from Shigella strains carrying different 
mutations were sishowed similar morphology by electron microscopy (fig. 9A) with 
average sizes of 30-32 nm in all 6 strains and a size distribution of 17-53 nm. A 
comparison of the GMMA sizes form the all strains gave no significant difference 
(p=0.90).  
 
 
 
Fig. 9 A) Electron microscopy of GMMA from different strains. GMMA were purified from Ss
-p-OAg  
and Sf
-p-OAg containing wild-type lipid A (Ss-p-OAg WT lip. A, Sf-p-OAg WT lipA),  Ss-p-OAg ∆msbB, Sf-p-OAg 
∆msbB, Ss
-p-OAg ∆htrB, Sf-p-OAg ∆htrB, negatively stained and viewed by electron microscopy (105,000-
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fold magnification) revealing the presence of well-organized membrane particles with diameter of 17-
53 nm in each preparation. Bar length = 100 nm. B) SDS-PAGE. 10 µg of protein of GMMA shown in 
A) and GMMA from Ss
-p-OAg ∆htrB ∆msbB, Ss-p-OAg ∆htrB (pACYChtrB) and Sf-p-OAg ∆htrB (pACYChtrB) 
produced under the same growth conditions were separated by SDS-PAGE (12% polyacrylamide) and 
Comassie stained. Four protein bands which were more abundant in GMMA from Sf
-p-OAg ∆htrB than in 
GMMA from other Sf
-p-OAg strains were identified by Peptide Mass Fingerprinting: 1, pyruvate 
dehydrogenase; 2, glutamine synthetase; 3, ketol-acid reductoisomerase; 4, D-3-phosphoglycerate 
dehydrogenase. 
 
To characterize if the genetic lipid A modifications might alter the protein composition 
of GMMA (it has been reported that the relative quantity of some of the proteins was 
affected in presence of different lipid A modifications due to sigma E-dependent 
response (132), the protein pattern of GMMA from the different mutants was 
evaluated by SDS-PAGE (fig. 9B). While the overall pattern remained similar, 4 
protein bands, identified pyruvate dehydrogenase, glutamine synthetase, ketol-acid 
recutoisomerase and D-3-phosphoglycerate dehydrogenase (fig. 9B) by Peptide 
Mass Fingerprinting were found to be upregulated in GMMA from Sf
-p-OAg ∆htrB. As 
these proteins are cytoplasmic proteins, no effect on the reactogenicity studies is 
expected.  
 
Characterization of lipid A by MALDI-TOF and MALDI-TOF/TOF 
 
In order to characterize the lipid A of LPS of the mutants produced, a lipid A 
extraction was performed followed by a MALDI-TOF analysis. The spectra obtained 
were reported in fig. 10 and correlation about the species of lipid A correspondent to 
the main peaks were also displayed basing on data obtained from similar mutants of 
Escherichia coli (160); the structure correspondent to main peaks were  also 
displayed in fig. 10L. 
The main peaks in the mass spectra obtained by MALDI-TOF from lipid A purified 
from GMMA from Shigella sonnei and S. flexneri strains with wild type (WT) LPS (fig. 
10, Ss
-p-OAg (A), Sf-p-OAg (B)) has an m/z corresponding to the theoretical mass of the 
hexa-acylated lipid A of 1798 Da.  
The main peaks obtained by mass spectrometry from the Ss
-p-OAg ∆msbB GMMA (fig. 
10C) and Sf
-p-OAg ∆msbB (fig. 10D) GMMA correspond, in both strains, to a penta-
acylated lipid A lacking a miristoyl chain (a C14 fatty acid chain, 210 m/z shift) in 
comparison to the hexa-acylated WT forms (fig. 10A and 10B respectively), 
consistent with msbB knock outs.  
The mass spectrum of lipid A from Ss
-p-OAg ∆htrB GMMA (fig. 10E) showed a main 
peak at 1615 m/z, corresponding to a penta-acylated lipid A lacking a lauroyl chain (a 
C12 fatty acid chain) in comparison to strain with unmodified lipid A (182 m/z shift, fig. 
10A), consistent with an htrB knock out. By contrast, the spectra obtained from 
GMMA ∆htrB of Sf
-p-OAg (fig. 10F), besides showing the presence of the penta-
acylated lipid A species with the deletion of a lauroyl chain, already observed in the 
Ss
-p-OAg ∆htrB mutant (peak at 1615 m/z), in addition, showed also a main peak at 
1850 m/z (fig. 10F), most likely corresponding to a hexa-acylated lipid A species with 
a m/z different to WT lipid A. The mass of this lipid A species corresponds to a lipid A 
containing a palmitoleoyl chain (a C16:1 fatty acid chain, 236 m/z shift) as a sixth acyl 
chain in penta-acylated background, most likely in the position where normally the 
lauroyl chain is attached by the htrB gene product. A further confirmation about 
palmitoleoylation has also been obtained by analyzing in MS/MS spectrometry the 
chemical species obtained fragmenting by Collision Induced Decay lipid A species 
presents in main peaks observed in first dimention MS for GMMA from Ss
-p-OAg ∆htrB 
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(m/z 1615 fig.10E) and Sf
-p-OAg ∆htrB (m/z 1850 fig.10F): the main difference 
observed when overlaying the MS/MS spectra is represented by a peak with a m/z 
correspondent to a palmitoleoyl chain(252 Da, highlighted in fig.10G) in Sf
-p-OAg ∆htrB. 
 
 
Fig. 10 MALDI-TOF spectra obtained analyzing lipid A precipitated from GMMA in refletron ion-
negative mode. GMMA from: A) Ss
-p-OAg B) Sf-p-OAg C) Ss-p-OAg ∆msbB  D) Sf-p-OAg ∆msbB E) Ss-p-OAg 
∆htrB F) Sf
-p-OAg ∆htrB H) Ss-p-OAg ∆htrB + pACYChtrB I) Sf-p-OAg ∆htrB + pACYChtrB. G) MS/MS 
spectra obtained in ion negative mode: Overlay of negative ion LIFT MALDI-TOF/TOF spectra in 
the low m/z range of the dominant species in lipid A from Ss
-p-OAg ∆htrB (E) and Sf-p-OAg ∆htrB (F) after 
Collision Induced Dissociation. L) Lipid A structures with molecular weights corresponding to the 
observed main peaks.  
 
A further indirect confirmation about the location of the sixth compensatory fatty acid 
chain, has been obtained testing by MALDI-TOF spectra of GMMA from the Ss
-p-OAg 
an Sf
-p-OAg ∆htrB strains complemented with pACYChtrB (fig. 10 H for Ss-p-OAg and fig. 
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10 I for Sf
-p-OAg) resulting in both cases in lipid A hexa-acylated WT as main peak 
(1797 m/z). The inability to detect a hepta-acetylated lipid A in either the S. flexneri 
2a GMMA or the S. flexneri 2a ∆htrB GMMA complemented with htrB expression 
from pACYChtrB suggests that the palmitoleoylation is on the same site occupied by 
lauroyl acid in the wild type lipid A. 
The MALDI-TOF profile observed in Sf
-p-OAg ∆htrB has been obtained also in Sf+p+OAg 
∆htrB, in Sf
-p+OAg ∆htrB and the palmitoleoylated hexa-acylated form has been 
confirmed to be the main form also in GMMA purified from S. flexneri 3a and 6 ∆tolR 
after htrB knock out (data not shown). 
In order to obtain a tetra-acylated lipid A a Ss
-p-OAg ∆htrB ∆msbB mutants has been 
produced and the lipid A from its GMMA has been purified and analyzed by MALDI-
TOF (fig. 11). The MALDI profile present a main population correspondent to a tetra-
acylated lipid A (peak at m/z=1404 and his respectively peak lacking phosphate 
group lost during analysis at m/z=1324), consistent with the deletion of both a lauroyl 
and a miristoyl chain. Also in that genetic background, GMMA from Ss
-p-OAg ∆htrB 
∆msbB grown at 30°C doesn’t showed the palmitoleoylation observed in various S. 
flexneri strains after htrB knock-out. 
 
Fig. 11 MALDI-TOF of lipid A from Ss
-p-OAg ∆htrB ∆msbB 
 
Similar results in terms of lipid A populations and relative abundance of different 
species obtained with GMMA have been obtained also from bacteria (data not 
shown), demonstrating that the lipid A composition of GMMA and bacteria is similar. 
 
Lipid A changes at different temperatures 
 
The palmitoleoylation observed in GMMA from Sf
-p-OAg ∆htrB is consistent with the 
activity by the late acyl transferase LpxP (108). lpxP has been reported to be 
overexpressed and more active than htrB as cold response (108). In order to test if 
the production of the palmitoleoylated hexa-acylated lipid A species (m/z 1851) could 
be induced in S. sonnei under stress conditions, Ss
-p-OAg ∆htrB was grown at 12°C to 
induce a cold stress response. In the corresponding lipid A analyzed by MALDI-TOF 
a small amount (below 5% of the total amount, fig. 12) of the palmitoleoylated lipid A 
species was identified. At 12°C a long duplication time, up to 7-8 hours, was needed 
and a long incubation, up to 1.5 days was necessary to reach O.D.=1 starting from 
O.D.=0,1. 
By this experiment we have demonstrated that “forcing the system”, as cold 
response, LpxP is “functional” also in Ss
-p-OAg ∆htrB strain, suggesting that 
differences observed were related to differential expression level of lpxP gene at 
30°C in the two Shigella strains.  
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Fig. 12 MALDI-TOF spectra obtained analyzing lipid A obtained from GMMA ∆htrB produced at 
different temperatures. GMMA from of S. flexneri ∆htrB and S. sonnei ∆htrB were produced at 12, 30 
and 37°C and tested by MALDI-TOF in reflectron ion-negative mode 
 
Lipid A from GMMA obtained from Ss
-p-OAg ∆htrB and Sf-p-OAg ∆htrB grown at 37°C. In 
that case the colture of bacteria was possile only after an adaptation in SDM at 30°C, 
by restarting the colture from O.D.=0,1 at 37°C; the OD reached was anyway lower 
than the ones obtained at 30°C after overnight, around 2. Lipid A from GMMA 
obtained at 37°C have been analyzed by MALDI-TOF (fig.12) and we have observed 
that lipid A from GMMA of Ss
-p-OAg ∆htrB is only penta-acylated, like at 30°C. Instead, 
for Sf
-p-OAg ∆htrB, besides the main peak is still represented by the palmitoleoylated 
lipid A, also another small peak, most likely correspondent to an hepta-acylated lipid 
A at m/z=2087, has been observed, correspondent to the activation of pagP and the 
attach of a palmitoleoyl chain (a C16 fatty acid chain) on the compensated hexa-
acylated lipid A (fig.12).  
 
Characterization of differences in lpxP between S. flexneri and S. sonnei 
 
The lpxP gene is present in both Shigella sonnei 53G and Shigella flexneri 2a and, 
by translating the two coding regions, only one amino acid might be different in the 
two strains (Leu116→ Pro in S. sonnei).  
As palmitoleoylation is consistent with the activity by the late acyl transferase LpxP, 
the expression of lpxP was tested in Ss
-p-OAg ∆htrB and Sf-p-OAg ∆htrB by quantitative 
real time PCR (fig. 13). When grown at 30°C, the level of transcript of lpxP was 11-
fold higher in Sf
-p-OAg ∆htrB compared to Ss-p-OAg ∆htrB, whereas level of transcript of 
msbB was 1.5-fold higher in S. flexneri compared to S. sonnei.  
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Fig. 13 qRT-PCR relative expression in comparison to lysP housekeeping of msbB and lpxP genes in 
Sf
-p-OAg ∆htrB in comparison to Ss-p-OAg ∆htrB. The mean of 3 indipendent experiment (each run in 
duplicate) have been plotted. Error bars represent the standard deviation. 
 
If we performed the analysis by comparing to the msbB gene which is part of the 
constitutive lipid A pathway. In three independent experiments, the level of transcript 
of lpxP to msbB was on average 7.3-fold higher (standard deviation 0.9) in Sf
-p-OAg 
∆htrB compared to Ss-p-OAg ∆htrB. 
 
Characterization of endotoxin activity after lipid A modifications 
 
TLR4 - NF-kB luciferase reporter assay 
 
Human Embrionic Kidney cells in fact naturally don’t express TLR. Thus, these cells 
were stably transfected in order to express only one type of human Toll-Like 
Receptor and an NF-κB-inducible luciferase reporter gene. Thus, activation of the 
TLR, results in the activation of a signaling cascade that finally activates NF-kB. The 
stronger is the activation of the specific TLR, the higher is the activation of NF-kB. 
NF-kB acts as the specific activator of the promoter of the luciferase reporter gene. 
 
 
Fig. 14 Activation of TLR4 reporter cell line by different GMMA. 25,000 of TLR4-HEK293 cells/well 
were stimulated with 1000 – 0.0001 ng/mL (5-fold steps) of GMMA obtained from A) Ss
-p-OAg, Sf-p-OAg, 
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Ss
-p-OAg ∆htrB, Sf-p-OAg ∆htrB and B) Ss-p-OAg, Sf-p-OAg, Ss-p-OAg ∆msbB, Sf-p-OAg ∆msbB and Ss-p-OAg ∆htrB 
∆msbB. After 5 h, luciferase expression was measured and expressed as fold-induction compared to 
cell incubated with PBS (averages of duplicates with standard deviation). The GMMA concentrations 
that resulted in 3-fold increased activation of NF-κB (black dashed line) over the average induction at 
the lowest concentration of GMMA are shown as x axis intercepts (colored dashed lines).  
Representative results of three independent experiments are shown.  
 
The measurement of luciferase activity by lumenometer gives us the measurements 
of the activation of the specific TLR (151). We stimulated Human Embryonic Kidney 
cells (HEK293) stably transfected to express only human TLR4 recognition complex, 
the PRR involved in the recognition of lipid A (116) and an NF-κB-inducible luciferase 
reporter gene to characterize the NF-kB specific activity associated to each lipid A. 
The results obtained with different concentrations of GMMA were displayed in fig. 14 
and analysis has been reported in Tab. 8.  
GMMA from Sf
-p-OAg ∆msbB and Ss-p-OAg ∆msbB stimulated similar levels of NF-κB 
expression in the HEK293 TLR4 transfectant cells (fig. 14A) and required 
approximately 600-fold more GMMA than the parent GMMA (fig. 14A) to give a 3 fold 
increase in activity. In contrast, GMMA from Sf
-p-OAg ∆htrB and Ss-p-OAg ∆htrB gave 
very different results. Ss
-p-OAg ∆htrB GMMA resulted in substantially lower stimulation 
than Ss
-p-OAg ∆msbB GMMA (fig. 14B), and the induction of NF-κB was only 
detectable at a high concentration of GMMA and required 60,000-fold more GMMA 
than the GMMA with wild-type lipid A to result in 3x NF-κB induction. However, Sf
-p-
OAg ∆htrB GMMA (fig. 14B) gave substantially more stimulation than Sf-p-OAg ∆msbB 
GMMA
 
 (p = 0.0286) in the HEK293 TLR4 transfectant cells (fig. 14B), and required 
only 50x more GMMA than the GMMA with wild-type lipid A to result in 3x NF-κB 
induction.  
Testing GMMA from Ss
-p-OAg ∆htrB ∆msbB by that assay the luciferase activity 
measured is similar to the ones observed for Ss
-p-OAg ∆htrB (fig.14B). 
 
 
 
Tab. 8 NF-kB specific TLR4 results analysis. Concentrations of each type of GMMA resulting in 3-
fold increased activation of NF-κB were determined using TLR4/MD2/CD14 HEK293 trasfectant cells 
as shown in Fig.14. Fold difference of the respective concentration of GMMA from lipid A mutants to 
GMMA with wild-type lipid A (obtained as mean of average concentrations resulting in 3-fold NF-kB 
induction by Ss
-p-OAg and Sf-p-OAg GMMA), to GMMA from ∆msbB (obtained as average of mean 
concentrations resulting in 3-fold NF-kB induction by Ss
-p-OAg ∆msbB and Sf-p-OAg ∆msbB GMMA) and 
to GMMA from Ss
-p-OAg ∆htrB have been displayed 
 
It has been reported that mouse and human TLR4 binds lipid A differently (161,162). 
In addition, it is know that mice are less sensitive to LPS than humans. And in mouse 
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immunization studies we observed that GMMA with and without lipid A modification 
were equally well tolerated and elicited similar antibody responses (data not shown).  
Thus, we characterized the TLR4 stimulation of mouse TLR4 by GMMA with and 
without lipid A modification using HEK293 trasfectant cells that expressed mouse 
TLR4/MD2/CD14. 
 
 
Fig. 15 NF-kB specific assay. TLR4 specific assay: 25000 of mouse HEK293 TLR4, MD2, CD14/well 
were stimulated for 5 hours with serial dilutions of GMMA obtained from different mutants.
 
 
 
By that approach we might appreciate (fig. 15 and tab. 9) that differences between 
GMMA from lipid A mutants and GMMA with wild type lipid A in terms of TLR4 
specific activaction for mice (as measured to cause a 10-fold NF-kB induction) are 
smaller than what observed by using humans receptors and GMMA carrying htrB or 
msbB knock outs gave a similar activation and without showing the difference 
observed using human cells between Sf
-p-OAg ∆htrB and Sf-p-OAg ∆htrB GMMA.  
 
 
 
Tab. 9 Fold difference in NF-kB specific assays calculated as ratio between concentration of GMMA 
needed to cause a 10-fold induction in the case of mouse TLR4 HEK293 cells  
 
Lipid A quantities in GMMA from different mutants (KDO quantitation) 
 
In order to ensure that the observed differences are the results of difference of the 
stimulatory activity of the lipid A and is not caused by different amounts of lipid A 
present in GMMA the molar amount of lipid A per mg/protein was determined by 
quantified the LPS core sugar KDO. The amounts of lipid A were similar in all GMMA. 
In comparison to GMMA from Ss
-p-OAg ∆htrB with the lowest activity, GMMA from the 
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Ss
-p-OAg contains 1.1-fold, Sf-p-OAg 2.0-fold, Sf-p-OAg ∆htrB 0.3-fold, Ss-p-OAg ∆msbB 0.8-
fold, and Sf
-p-OAg ∆msbB 1.1-fold the amount of lipid A (Tab. 10). 
 
 
 
Tab. 10 KDO quantitation using semicarbazide derivatization. Samples were normalized as 
starting volum based on protin amount and threated simulataneusly. Each sample has been run in 
duplicate. For comparison, the fold-difference in TLR4 stimulatory activity and in IL-6 stimuation is 
shown. 
 
Cytokine release from human PBMC 
 
In order measure understand the level of reactogenicity of GMMA in a more natural 
contest, GMMA purified form different mutants were used to stimulate human PBMC 
in MAT. Upon stimulation with GMMA, Pattern Recognition Receptors (PRRs) 
present in PBMC were stimulated, and cytokines would be released in a proportion 
way to the PRR’s stimulation. The GMMA concentration required to give a 10-fold 
increase over background was arbitrarily used for comparing relative activity (124) 
since that is in the middle of the linear part of the sigmoidal curves. The same 
calculations performed at other points within the linear part of curve (3-fold and 30-
fold over background, respectively) yielded similar the results (data not shown).  
So, with the objective of better characterizing the differences in cytokine stimulation 
between lipid A unmodified and modified GMMA, we have measured the release of a 
panel of cytokines simultaneously by human pro-inflammatory 7-plex MesoScale. 
GMMA purified from Shigella strains (both Ss
-p-OAg and Sf-p-OAg) without lipid A 
modifications stimulated a strong and similar cytokine response from PBMC (fig. 16) 
and whole blood (data not shown).  
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Fig. 16 Cytokine release by human PBMC after stimulation with different types of GMMA. 
200,000 human PBMC cells were stimulated for 4 hours with 1000 – 0.0001 ng/mL (10-fold steps) of 
GMMA from Ss
-p-OAg, Sf-p-OAg, Ss-p-OAg ∆msbB, Sf-p-OAg ∆msbB, Ss-p-OAg ∆htrB, Sf-p-OAg ∆htrB.Release of 
IL-6 (A), IL-8 (B), TNF-α (C), IL-1β (D), were measured by human pro-inflammatory 7-plex mesoscale 
and plotted as averages of duplicates with standard deviations. The GMMA concentrations that 
resulted in 10-fold increase of cytokine release over background are shown as x axis intercepts 
(colored dashed lines). Only small amounts of IFN-γ, IL-10 and IL-12 p70 were produced with similar 
differences in the induction by different GMMA (data not shown).  
 
GMMA without lipid A modification stimulated the release of high amounts of 
Interleukin 6 (IL-6, fig. 16A), IL-8 (fig. 16B), Tumor Necrosis Factor TNF-α  (fig. 16C), 
and IL-1β (fig. 16D). Instead, we did not observe a strong production of interferon 
gamma, IL-10 and IL-12 (data not shown). All the GMMA purified from Shigella 
strains carrying lipid A modification resulted in strong reduction of IL-6 (fig. 16A), IL-8 
(fig. 16B), TNF-α (fig. 16C) and IL-1β (fig. 16D) release upon stimulation in 
comparison to lipid A unmodified parent strains (fig. 16), with a similar trend to what 
observed in TLR4 specific assay (fig. 14).  
The MesoScale experiments demonstrated that comparative quantification of IL-6 
release between GMMA with wild type and GMMA with modified lipid A can be a 
marker of reduction of GMMA endotoxicity, representing the stimulation pattern of the 
other inflammatory cytokines, indicating that analysis of IL-6 stimulation is sufficient 
to compare the reactogenic potential of different GMMA; thus, for confirm and better 
fix the level of reduction of endotoxicity of GMMA from different lipid A mutants we 
have performed MAT using cells from 4 different donors and results obtained were 
summarized in tab. 11 (and a representative experiment analyzed by ELISA is shown 
in Fig. 17). 
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Fig. 17 IL-6 released by human PBMC after stimulation with different types of GMMA. Human 
PBMC were isolated using a Ficoll density gradient and 200,000 cells were plated in each well; PBMC 
were stimulated for 4 hours with different concentration of GMMA, supernatants were recovered and 
tested by IL6 ELISA. Dashed line represent the IL6 released 10-fold over the background (mean of 
minimum point detected). Colored dashed lines represent the GMMA concentration to reach the 10-
fold increase of cytokine over background. Data shown is representative of the ones obtained from 4 
different donors, each ones measured in duplicates. A) MAT assay obtained testing GMMA from Ss
-p-
OAg,  Sf-p-OAg and their relative ∆htrB mutant strains B) MAT assay obtained testing uGMMA from Ss-p-
OAg,  Sf-p-OAg, their relative ∆msbB mutant strains and Ss-p-OAg ∆htrB mutant (the ones that showed the 
best reduction of endotoxicity). C) MAT assay obtained testing lipid A unmodified GMMA from S. 
sonnei and S. flexneri, their relative ∆htrB mutant strains and from strains ∆htrB complemented with 
pACYChtrB D) MAT assay obtained testing GMMA from S. sonnei ∆htrB, ∆msbB or ∆htrB and ∆msbB 
mutant strains. 
 
The maximum cytokine release stimulated by all the GMMA obtained from all lipid A 
mutants (both htrB and msbB) was 2-3-fold lower for the different GMMA than the 
maximum cytokine production induced by GMMA with wild-type lipid A (Fig. 16 and 
Fig. 17). 
Furthermore is immediately appreciable in general an higher concentration of GMMA 
needed by lipid A mutants before reaching the same IL-6 release than lipid A 
unmodified strains (as measured at 10-fold increase over background, but similar 
analysis have been performed at 3-fold and 30-fold over background, and results 
obtained were similar, data not shown). 
In particular GMMA that lack the htrB gene stimulated significantly lower levels of 
cytokine release in comparison to lipid A unmodified strains for Ss
-p-OAg (fig. 17A). 
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The reduction of endotoxicity is closed to 800-fold comparing Ss
-p-OAg ∆htrB and Ss-p-
OAg (Tab. 11). GMMA lacking htrB gene in Sf-p-OAg, although showing a strong 
reduction of reactogenicity in comparison to strain with WT lipid A (around 50-fold 
lower), were about 15-fold more reactogenic than Ss
-p-OAg ∆htrB strains (fig. 17A). 
In order to test if the different behavior in reduction of reactogenicity is due to htrB 
knock out itself, mutation was complemented. Thus, complementing the knock out by 
the low copy plasmid pACYC184 that carries the htrB gene of Ss
-p-OAg (pACYChtrB) 
in ∆htrB background, the level of endotoxicity of GMMA produced from both Ss-p-OAg 
∆htrB and Sf-p-OAg ∆htrB strains comes back to the level of lipid A unmodified strain 
(Fig. 17C). 
 
 
 
Tab. 11 MAT assays results from different blood donors.  Concentrations of each type of GMMA 
resulting in 10-fold increased release of IL-6 were determined using PMBC from 4 different donors as 
shown in Fig.4.  Fold differences were calculated for each donor of the respective concentration of 
GMMA from lipid A mutants to GMMA with wild-type lipid A (obtained as mean of average 
concentrations resulting in 10-fold increased release of IL-6 by Ss
-p-OAg and Sf-p-OAg GMMA), to GMMA 
from Ss
-p-OAg ∆htrB and to GMMA from ∆msbB (obtained as average of mean concentrations resulting 
in 10-fold increased release of IL-6 by Ss
-p-OAg ∆msbB and Sf-p-OAg ∆msbB GMMA) have been 
displayed. 
 
GMMA purified from Ss
-p-OAg or Sf-p-OAg strains that carry the msbB knock-out 
produced, instead, similar level of cytokines (fig. 16 and 17 A). The level of reduction 
of endotoxicity gained is around 300-fold in comparison to the GMMA purified from 
the respective lipid A WT strains (tab. 11), and they were around 3-fold more toxic 
compared to GMMA from Ss
-p-OAg ∆htrB, the strain that showed the best reduction of 
reactogenicity (fig 17 B and tab. 11). 
No substantial differences were observed between the differently lipid A modifiyed 
Ss
-p-OAg GMMA ∆htrB mutant and lipid A ∆htrB and ∆msbB double mutant (fig. 17D), 
suggesting a strong reduction of reactogenicity already achieved with the htrB 
deletion (not additive).  
 
Characterization of residual toxicity in GMMA purified from lipid A mutants 
 
TLR blocking 
 
With the objective of identifying the TLRs that contributes to the residual activation 
observed by the lipid A modifyed GMMA, PBMC were incubated with TLR2 and/or 
TLR4 blocking antibodies, before stimulating with 1 and 10 ng/mL of GMMA, 
concentrations chosen to give a significant but not saturating increase of IL-6 (Fig.18). 
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Targeted blocking of the two TLRs (TLR4 and TLR2) highlighted which type of TLR 
receptor is important for IL-6 release.  
The three GMMA with penta-acylated lipid A (Ss
-p-OAg ∆htrB (fig.18D), Ss-p-OAg ∆msbB 
(fig.18B), Sf
-p-OAg ∆msbB (fig.18C)) gave similar results: IL-6 production gave 
substantial reduction following incubation with TLR2 blocking antibody (70-90%) but 
either no or minimal reduction with TLR4 blocking antibody (10-30%) suggesting 
residual activity was principally due to TLR2 activation.  With the Ss
-p-OAg ∆msbB and 
Sf
-p-OAg ∆msbB GMMA, a small reduction was observed with the TLR4 blocking 
antibody alone (Ss
-p-OAg ∆msbB, p = 0.0234; Sf-p-OAg ∆msbB, p = 0.0078 in 4 
experiments) suggesting that there is still residual TLR4 activation.  Further reduction 
was obtained with the combination of TLR2 and TLR4 blocking antibodies compared 
to TLR2 blocking antibody alone. With the Ss
-p-OAg ∆htrB GMMA, no effect from TLR4 
blocking was observed. 
 
Fig. 18 TLR blocking experiments. 200,000 human PBMC cells were stimulated with GMMA from 
different strains. After 4 h incubation, IL-6 release was measured by ELISA and plotted as average of 
duplicates with standard deviation. A) IL-6 release after stimulation with 1000 – 0.0001 ng/mL (10-fold 
steps) of GMMA from different strains. The rectangle highlights the concentration of GMMA used in 
blocking experiments. B-E) In blocking experiments, cells were incubated with 2.5 µg/mL anti-TLR4 
(dark red graphs), 1.5 µg/mL of anti-TLR2 (green graphs), or both (violet graphs) for 30 min before 
exposure to GMMA from Ss
-p-OAg ∆msbB (B), Sf-p-OAg ∆msbB (C),  Ss-p-OAg ∆htrB (D),  and Sf-p-OAg 
∆htrB (E). The graphs from experiments without blocking are shown in the same color as in A). A 
representative result of three independent experiments is shown.  
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The GMMA with mostly hexa-acylated GMMA (Sf
-p-OAg ∆htrB, fig. 18E) gave a 
substantial reduction with a TLR4 blocking antibody, i.e. 80% reduction at 1 ng/mL, 
40% at 10 ng/mL GMMA concentration, but not with a TLR2 blocking antibody.  
Incubation with both TLR2 and TLR4 blocking antibodies gave lower IL-6 production 
suggesting that the TLR4 activation was dominant, but both were still active. 
As controls for specificity of TLR blockings experiments with GMMA, several 
experiments have been performed. In order to prove the possibility of block specific 
TLR, we started optimizing the antibodies concentration needed for blocking, to what 
needed to avoid the stimulation due to the specific agonist (LPS from E. coli or 
PAM3CSK4 respectively) after TLR blocking (TLR4 and TLR2 respectively) (fig. 19A 
and data not shown). The optimal concentration of blocking antibodies (in order to 
block and do not increase the cytokine release aspecifically) was determined to be 
2.5 µg/mL to block TLR4, and 1.5 µg/mL to block TLR2. The decoration of GMMA 
with TLR blocking antibodies doesn’t give significant unspecific cytokine release, as 
tested stimulating PBMC with GMMA in presence of isotype control antibodies (data 
not shown).  
To further investigate if the depletion of IL-6 release observed in TLR blocking 
experiments with GMMA is not due only to the presence of Anti-TLR antibodies that 
mask the other TLRs unblocked, we have tried to stimulate with soluble LPS after 
blocking the TLR2 by Anti-TLR2 Ab. Following that approach, if the shielding effect 
was not unspecific and the molecules might reach their respective receptor, we 
should appreciate the same activation of TLR4, so the same IL-6 release. With that 
approach soluble LPS should stimulate GMMA also after blocking of TLR2, so it’s not 
present a steric hindrance effect (fig. 19 B). 
 
 
Fig. 19 IL-6 release obtained stimulating PBMC in presence or absence of Anti-TLR antibodies A) 
Stimulation with LPS (grey line) and stimulation with LPS after blocking of TLR4 with 25 µg/mL of anti-
TLR4 antibodies (orange line) B) Stimulation with LPS (grey line) and stimulation with LPS after 
blocking of TLR2 with 15 µg/mL of anti-TLR2 antibodies (blue line) C) Stimulation with 30 nm 
polistrene nanobeads conjugated with LPS (violet line) and stimulation with 30 nm nanobeads 
conjugated with LPS after blocking of TLR2 with 15 µg/mL of anti-TLR2 antibodies (dark green line) 
and stimulation with 30 nm polistrene nanobeads (light grey line). 
 
To further investigate if the depletion of IL-6 release observed in TLR blocking 
experiments with GMMA is due only to a steric hindrance effect given by the physical 
presence of Anti-TLR antibodies on the surface of PBMC that mask the other TLRs 
unblocked, we have tested polystyrene nanoparticles with 30 nm of average diameter 
(similar to the GMMA size), conjugated/not conjugated with LPS, before and after 
blocking with Anti-TLR2 Ab. Nanobeads conjugated with LPS should stimulate PBMC 
after blocking of TLR2 receptors (fig. 19C). Nanobeads unconjugated, instead, did 
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not activate at all the IL-6 release by PBMC, meaning no steric hindrance effect 
observed for TLR not blocked.  
 
Characterization differences in GMMA between S. sonnei / S. flexneri 
 
TLR2-NF-kB luciferase reporter assay 
 
To confirm that the differences in the relative contribution of TLR4 and TLR2 to 
activation observed in the blocking experiments were solely dependent on the 
differential TLR4 activation by the different GMMA, the ability of the GMMA to 
activated TLR2 was tested by stimulating HEK293-TLR2 transfectant cells (Fig. 20). 
 
 
 
Fig. 20 Activation of TLR2 reporter cell line by different GMMA. 25,000 of TLR2-HEK293 cells/well 
were stimulated with 1000 – 0.0001 ng/mL (5-fold steps) of GMMA from Ss
-p-OAg, Sf-p-OAg, Ss-p-OAg 
∆msbB, Sf
-p-OAg ∆msbB, Ss-p-OAg ∆htrB, Sf-p-OAg ∆htrB, Ss-p-OAg ∆htrB ∆msbB. After 5 h, luciferase 
expression was measured and expressed as fold-induction compared to cells incubated with PBS. 
Average induction levels and standard deviations of duplicates are plotted. The GMMA concentrations 
that resulted in 10-fold increased activation of NF-κB (black dashed line) over the average induction at 
the lowest concentration of GMMA are shown as x axis intercepts (colored dashed lines). A 
representative result of three independent experiments is shown.  
 
All 5 ∆msbB and/or ∆htrB GMMA required similar GMMA concentrations (2.6 – 4.9 
ng/mL as obtained in 4 independent experiments) to give a 10-fold NF-kB induction 
(Fig. 20), further confirming that differences observed in MAT assay reflect only 
differences in terms of TLR4 activation, so lipid A-related, and furthermore that the 
quantity of TLR2 activating molecules were similar in GMMA from all the strains 
tested; thus, TLR2 activating components were responsible of almost all the residual 
endotoxin activity of GMMA after lipid A modifications, in a comparable level. 
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Effect of lipid A modification in Shigella strains with different phenotypic 
backgrounds  
 
Endotoxin activity 
 
So far all of the data shown have been performed with GMMA without OAg. 
However, we have previously observed that the OAg can shield surface epitopes in 
in vitro grown Shigella (data not shown) and thus potential TLR activators. In order to 
test if the presence of OAg has an effect on the reactogenicity of GMMA or on the 
reduction of endotoxicity achieved with the htrB and msbB mutation, we inserted 
similar lipid A modifications in OAg-containing strains.  
First of all the effect of the presence/absence of major virulence plasmid and the 
presence/absence of OAg were evaluated in lipid A WT background. 
By MAT (fig. 21) we might appreciate that there aren’t difference bot in S. sonnei 
than in S. flexneri given by the presence of major virulence plasmid or OAg. 
 
 
Fig. 21 Cytokine release by human PBMC after stimulation with different types of GMMA. A) 
GMMA with different genetic background were compared (+/- OAg or +/- virulence plasmid). Strains 
used for purifying GMMA were listed in material and method section. Human PBMC were isolated 
using a Ficoll density gradient and 200,000 cells were plated in each well; PBMC were stimulated for 4 
hours with different concentration of GMMA, supernatants were recovered and tested by IL6 ELISA. 
Dashed line represent the IL6 released 10-fold over the background (mean of minimum point 
detected). 
 
The htrB or msbB knock out were also introduced into strains that have the intact 
OAg synthesis gene cluster. In particular S. flexneri ∆htrB mutants with OAg and with 
or without virulence plasmid were produced, and also a ∆msbB mutant without the 
virulence plasmid. For S. sonnei a ∆htrB mutant with OAg and with the major 
virulence plasmid was generated. In S. sonnei, the OAg synthesis gene cluster is 
located on the virulence plasmid (163). The plasmid also carries a second copy of 
the msbB gene. Thus, we’ve chosen OAg-containing S. flexneri as parent strain for 
msbB knock out.  
As shown in Fig. 22, the level of reactogenicity and endotoxin activity are not affected 
by the presence of OAg as resulted by comparing the IL-6 release obtained upon 
stimulating PBMC with GMMA that carries similar mutations from OAg deficient 
strains (compare Fig. 22 with Fig. 17). Nevertheless, also in OAg positive 
background, in S. flexneri we observed the compensation due to lpxP product, not 
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present in Ss+p+OAg ∆htrB that carry the same mutation. Again, by complementing the 
knock out in S. flexneri by pACYChtrB, we observed the restorying of reactogenicity 
and lipid A type to wt level (by MALDi-TOF, data not shown). 
 
Fig. 22 MAT assay obtained with GMMA from different Shigella +OAg ∆tolR strains. A) S. 
sonnei +p and relative ∆htrB mutants B) S. flexneri + and - p and relative ∆htrB mutants C) S. 
flexneri -p and relative ∆msbB mutants D) Different S. flexneri and relative htrB mutant strains. 
Human PBMC were isolated using a Ficoll density gradient and 200,000 cells were plated in each 
well; PBMC were stimulated for 4 hours with different concentration of GMMA, supernatants were 
recovered and tested by IL6 ELISA. Dashed line represent the IL-6 released 10-fold over the 
background (mean of minimum point detected).
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Salmonella  
 
GMMA generation from different mutants 
 
Salmonella enterica serovar Typhimurium and Enteritidis (animal clinical isolates) 
were chosen as parent strains and engineered to have overproduction of GMMA by 
tolR knock-out. The mutants were generated and characterized in respect to growth 
kinetics and GMMA yield by the Salmonella group at NVGH. Similar to what 
observed for Shigella GMMA, after tolR knock-out, both at 30 than at 37°C, the 
growing charateristics were similar; in fact, both duplication time and optical density 
reached after over-night colture were comparable in Lauria Broth (LB) media and in 
chemical defined media (data not shown). Strains carrying msbB and htrB knockout, 
instead were able to reach a higher optical density only at 30°C, both in chemical 
defined media and in LB. The duplication time in general increased after htrB or 
msbB deletion to up to 2 hours (data not shown) and a long lag phase (higher than 4 
hours), but all the strains were able to reach high, even if lower than parent strains 
with wild type lipid A, and comparable O.D. after incubation over night in LB at 30°C 
(O.D. reached around 10 for all of them). 30°C in LB media was chosen as growing 
condition. GMMA yield from the different lipid A mutant strains, was high, in line to 
what observed for Shigella GMMA producing strains caring similar gene knock-outs 
(data not shown).  
 
Shape (electron microscopy) 
 
The morphology of GMMA from different Salmonella mutants was also evaluated by 
electron microscopy (fig. 23). Electron micrographs showed differences, especially 
between Typhimurium and Enteritidis GMMA.  
 
 
Fig. 23 – Electron microscopy of GMMA obtained from different strains. GMMA were prepared 
for negative staining, and viewed by electron microscopy (87 000 fold magnification). Scale bar 
represent 100 nm. 
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In general, GMMA from S. Typhimurium strains, before and after lipid A 
modifications, showed a similar shape with dimensions between 20 and 80-100 nm in 
diameter, and resulted to be well organized and broken GMMA were not observed at 
all in all the different field analyzed. Furthermore, in S. Tm GMMA we observed the 
presence of some flagella (in line with the process of purification and concentration; 
in fact the GMMA purification was obtained by ultracentrifugation directly of the 
supernatants, filtere at 0,22 µm, after growth). 
In GMMA from S. Enteritidis strains we observed a general smaller organization, with 
the presence of two populations of GMMA, one really small (around 10 nm) and few 
bigger (even more than 100 nm, especially in ∆htrB mutants); this data was also 
confirmed by dynamic light scattering (data not shown). 
 
Lipid A analysis by MALDI-TOF 
 
A lipid A precipitation followed by mass spectrometry analysis by MALDI-TOF was 
performed (fig. 24) in order to evaluate the lipid A populations obtained after the htrB 
and msbB knock outs. 
By that approach we might appreciate that the starting situation for lipid A unmodifid 
GMMA is correspondent to a mixture of hexa-acylated lipid A (peak at 1797 m/z, 
same as observed in Shigella GMMA with unmodified lipid A) but also an hepta-
acylated lipid A (peak at 2035 m/z) due to the presence of a palmitoyl chain (a C16 
fatty acid chain) attached to the hydroxil group of the myristoyl chain in position 2 and 
due to the action of PagP acyltransferases. Furthermore we observed, that, in lipid A 
unmodified background, the palmitoyl chain is present in all the S. Enteritidis strains 
tested and that only GMMA from S. Typhimurium strain didn’t showed by MALDI-TOF 
the seventh chain to start with, even if PagP product is present in all the GMMA from 
lipid A mutant strains as demonstrated by the peak observed in ∆htrB and ∆msbB 
strains. Furthermore the presence of palmitoyl chan was not due to ∆tolR knock out 
itselves, because it has been observed directly on wild type bacteria, and the MALDI-
TOF profile is similar both before and after that gene knock out. 
 
 
 
Fig. 24 MALDI-TOF spectra obtained analyzing lipid A obtained from Salmonella GMMA. Spectra 
were acquired in reflectron ion-negative mode 
 
 65 
 
S. Tm ∆msbB GMMA, showed a lipid A mainly penta-acylated (peak at 1587 m/z) 
and only a small peak at 1825 m/z has been detected, most likely corresponding to a 
hexa-acylated lipid A species with a m/z different to “wild type” lipid A. The mass of 
this lipid A species corresponds to a lipid A containing a palmitoyl chain (a C16 fatty 
acid chain, 238 m/z shift) in the penta-acylated lipid A (1587 m/z), most likely due to 
activation of pagP after msbB knock out. 
The same situation in terms of peaks observed was present also in S. En ∆msbB 
GMMA (fig. 24 B) but in that case the magnitude of the peak is different with a 
predominant presence of hexa-acylated palmitoylated lipid A (m/z=1825) and most 
likely is due to the knock-out of a miristoyl chain in the hepta-acylated lipid A species 
observed in lipid A unmodified background. Furthermore, in S. En ∆msbB we 
observed a small peak at m/z 2003, most likely correspondent to an hexa-acylated 
palmitoleoylated lipid A with the attach of a phospoetanolamine to the phosphate in 
position 1’; the shift of 177 Da is due to the shift of 54 m/z due to difference between 
C16:1 fatty acid chain attached by LpxP and the C12 fatty acid chain attached by HtrB, 
plus 123 Da due to the attach of phospho-etanolamine at one of the phosphate group 
in position 1 or 4’, catalyzed by EptA in the hexa-acylated palmitoylated background 
(m/z=1825). 
In line with previous observation, we observed that S. Tm ∆htrB GMMA showed 
mainly two population of lipid A, coming from the hepta-acylated and hexa-acylated 
unmodified lipid A or to the action of PagP after knock out of htrB in the penta-
acylated lipid A, that are correspondent to an hexa-acylated palmitoylated lipid A and 
a pure penta-acylated lipid A (peaks at m/z 1851 and 1615 respectively).  
S. En ∆htrB GMMA showed the same two peaks at m/z 1615 and 1851 observed in 
S. Tm ∆htrB GMMA, but also a peak at m/z 2088 (shift of 236 Da) that is most likely 
due to the addition of the palmitoleoyl chain (a C16:1 fatty acid chain) in hexa-acylated 
palmitoylated background. This attach is most likely due to LpxP and is the same 
compensatory effect observed in S. flexneri after htrB knock out.  
 
Endotoxin activity of Salmonella GMMA 
 
TLR4-NF-kB reporter assay 
 
In order to evaluate the ability in activating TLR4 of the different “species” of lipid A 
molecules observed in GMMA purified from different lipid A mutants, experiments 
using TLR4-HEK293 cells have been performed (fig. 25). 
In terms of TLR4 specific assay, the concentration of GMMA from S. Tm ∆msbB with 
mostly penta-acylated lipid A was around 10-fold higher than concentration of S. En 
∆msbB GMMA and the GMMA from ∆htrB mutants with a mixture of hexa- (not wild 
type) and/or hepta- acylated form of lipid A to stimulate the same level of NF-kB 
induction. All the GMMA with unmodified WT lipid A, retained an at least 10-fold 
higher ability than GMMA with modified lipid A to activate TLR4 (fig. 25). The 
observations were similar to the observations in Shigella. Activation of TLR4 was 
retained in GMMA from ∆htrB mutants and S. En ∆msbB, similar to GMMA from S. 
flexneri ∆htrB with palmitoleoylated hexa-acylated lipid A. Only GMMA from S. Tm 
∆msbB showed a similar behaviout to GMMA from Shigella ∆msbB mutants in terms 
of TLR4 specific activation (compare fig. 25 and fig 14). 
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Fig. 25 TLR4-NF-kB specific assay. 25000 of HEK293 TLR4, MD2, CD14/well were stimulated for 5 
hours with serial dilutions of GMMA obtained from different mutants.
 
 
 
It’s important, to notice that the GMMA concentration to cause 3-fold NF-kB induction 
is around 10-fold lower in the Salmonella GMMA with WT lipidA in comparison to 
GMMA with WT lipid A from Shigella (compare tab. 12 and tab. 8). 
 
 
 
Tab. 12 NF-kB specific TLR4 results analysis. Table showing concentrations of each type of GMMA 
resulting in 3-fold increased activation of NF-κB and fold difference of the respective concentration of 
GMMA from lipid A mutants to GMMA with wild-type lipid A (S.Tm and S. En respectively) and of all 
GMMA to GMMA from S. Tm
 
∆msbB  
 
Comparison of endotoxicity of GMMA from different Shigella and Salmonella 
strains in MAT 
 
GMMA from different Salmonella mutants were also tested in MAT by using human 
PBMC for evaluating their endotoxin activity in a more natural context where more 
PRRs might be activated simultaneusly. In order to compare the level of IL-6 
stimulation by GMMA with lipid A modification from Shigella and Salmonella, they 
were tested together in the same PBMC experiment (fig. 26).  
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Fig. 26 Cytokine release by human PBMC after stimulation with different types of GMMA. 
200,000 human PBMC cells were stimulated for 4 hours with 0.001-1000 ng/mL (10-fold steps) of 
GMMA from Ss+p+OAg, Ss+p+OAg ∆htrB, Sf-p-OAg ∆htrB, STm, STm ∆htrB, STm ∆msbB, SEn, SEn ∆htrB, 
SEn ∆msbB. Release of IL-6 was measured by specific ELISA and plotted as averages of duplicates 
with standard deviations. The black dashed line represents a 10-fold increase of cytokine release over 
the average release at the lowest concentration of GMMA.  
 
By that approach we might appreciate that the ‘starting situation’ (with WT lipid A) is 
similar for GMMA produced from Shigella and S Tm. (tab. 13) which both contain 
hexa-acylated lipid A. In contrast, GMMA from S. Enteritidis were less stimulatory 
and required about 10-fold the amount of GMMA compared to S. Tm or Shigella 
GMMA to stimulate the same level of IL-6 release. This correlates to the fact that 
GMMA from S. Enteritidis contain a mixture of hexa-acylated and hepta-acylated 
lipid A. 
Lipid A modifications due to htrB or msbB knock-out in S. Tm and S. En resulted in 
reduction of reactogenicity in MAT, in comparison to GMMA containing WT lipid A 
with a similar trend as in the TLR4 assay. In addition, the plateau of IL-6 release is 
lower for all GMMA with lipid A modification in comparison to GMMA from lipid A 
unmodified strains. 
  
 
 
Tab. 13 MAT assays results from different blood donors. Concentrations of each type of GMMA 
resulting in 10-fold increased release of IL-6 were determined using PMBC. Fold differences were 
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calculated of the concentration of GMMA from lipid A mutants to GMMA with wild-type lipid A 
(Ss+p+OAg, S.Tm and S.En respectively) and to GMMA from Ss+p+OAg ∆htrB 
 
In particular, GMMA from S. En ∆msbB with predominantly penta-acylated lipid A 
showed a similarly low level of endotoxicity as GMMA from Ss+p+OAg ∆htrB containing 
penta-acylated lipid A that did not show detectable TLR4 activation in the PMBC 
assay ( fig.18). Instead, GMMA containing palmitoleoylated or palmitoylated hexa-
acylated lipid A or hepta-acylated lipid A retained approximately 10-fold higher IL-6 
stimulation (tab. 14), similar to the observation with GMMA from Sf ∆htrB with 
palmitoleoylated hexa-acylated lipid A. 
 
Characterization of GMMA from Salmonella strains besides lipid A 
modifications 
 
TLR2 – NF-kB reporter assay 
 
Also the TLR2 activation from different mutants has been analyzed by using HEK293 
trasfectant cells expressing human TLR2 receptors, with the objective of looking if 
something other is responsible of the endotoxicity in Salmonella GMMA besides 
TLR4 activator (lipid A) and especially if the activator of TLR2 from different mutants 
will be drastically different.  
In terms of TLR2 activation all GMMA are similar (differences observed are below 5-
fold), even if seems that all the lipid A mutants activated slightly more TLR2 than 
GMMA from strains with lipid A unmodified (most likely changes sigma E related) 
(fig.27). 
 
 
Fig. 27 TLR2 - NF-kB specific assay. 25000 of HEK293 TLR2 /well were stimulated for 5 hours with 
serial dilutions of GMMA obtained from different mutants.  
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Neisseria meningitidis 
  
Characterization of GMMA from different mutants 
 
GMMA tested were generated by strains carrying various combinations of mutations 
generated by the Neisseria group. The mutants (and GMMA generated from them) 
were engineered with the objective of obtaining a highly immunogenic and safe 
vaccine, with protection against multiple serogroups of N. meningitidis in order to use 
them in Africa. The deletion of the capsule (∆cps) allows obtaining strains that are 
safer. In fact, strains without capsule were not infectious (53) and allow to present 
better antigens known to be protective (PorA, that gave subtype-specific protection) 
and fHbp (81,124). In addition, to increase the coverage of the vaccine, fHbp, that is 
divided into three antigenic variants (v. 1, 2 or 3) (164), was deleted from parent 
strain and substituted with fHbp from a more frequent variant and over-expressed 
(150). Furthermore, the deletion of lpxL1 (81) should give strains with a reduced 
endotoxin activity, whereas the gna33 knock out (148) allowed to increase the 
release of GMMA for increasing the yield and so reducing the final cost of the 
vaccine. 
 
Shape of GMMA (Electron Microscopy) 
 
 
Fig. 28 – Electron microscopy of GMMA obtained from different strains. GMMA were prepared 
for negative staining, and viewed by electron microscopy (105,000-fold magnification). Scale bar 
represent 100 nm. 
 
The shape of GMMA from different strains were also observed in electron microscopy 
(fig. 28) in order to see if differences in lipid A acylation (due to lpxL1 knock out) or 
deletion and/or over-expression of a lipoprotein like fHbp gave significant differences 
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in terms of dimensions. We observed generally that the shape of GMMA is generally 
circular, but also different shapes have been observed and can be attributed to the 
random blebbing of Neisseria that is a high GMMA producer even in absence of 
gna33 knock out. After the gna33 knock out we observed generally an increase in 
terms of the dimension of GMMA. In any case all the GMMA seem well organized 
and only few of them were broken and bigger than Shigella or Salmonella GMMA 
(around 100 nm in diameter). 
 
MALDI-TOF analysis of lipid A 
 
Lipid A from the various mutants has been extracted from GMMA and analyzed by 
MALDI-TOF. The obtained spectra and Neisseria lipid A species corresponding to 
the observed m/z (160) are reported in fig. 29. 
The main peaks in the mass spectra obtained by MALDI-TOF in ion-negative 
reflectron mode from GMMA purified from lipid A unmodified strains of Neisseria (fig. 
29) present two main peaks; the first one has an m/z correspondent to the theoretical 
mass (1838 Da, 1837 m/z) of an hexa-acylated lipid A that present a 
phospoetanolamine attached on the phosphate 1’ due to the action of transferases 
encoded by eptA, instead the second ones is correspondent to an hexa-acylated lipid 
A without the phosphoetanolamine (1715 Da, 1714 m/z). We observed also the two 
peaks correspondent to the same two lipid A molecules described before but that 
have lost a phosphate in 4’ position, most likely during the analysis. 
 
 
Fig. 29 MALDI-TOF spectra obtained analyzing lipid A obtained from N. meningitidis GMMA. 
Spectra were acquired in reflectron ion-negative mode 
 
In the lipid A purified from GMMA from lpxL1 mutant strains we observed two 
populations, with and without phosphoetanolamine, with a shift of exactly 182 Dalton 
correspondent to the lack of a lauroyl (-C12 fatty acid chain), from the two lipid A 
species observed in GMMA purified from lipid A WT strain, consistent with an lpxL1 
knock out. The discrepancy between the theoretical m/z and the observed ones is 
only 1 Dalton and it’s due to calibration (the discrepancy is the same for all the peaks 
observed). In fact, the m/z shift is perfect at Dalton level in chemical shift due to lack 
of fatty acid chains and/or phospoetanolamine. 
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Evaluation of endotoxin activity of Neisseria GMMA after genetic manipulation 
 
Evaluation of reactogenicity by MAT and NF-kB specific assays (TLR2 and 
TLR4) 
 
We investigated the reduction of endotoxicity of GMMA after lipid A modification 
(lpxL1 knock out) by MAT (IL-6 release) and TLR4-specific assay. As shown in fig. 30 
A, we observed a reduction of around 1,000 fold of ability to release IL-6 after lpxL1 
deletion compared to GMMA with wild-typd lipid A. In the TLR4-speicifc assay, the 
large decrease of TLR4 stimulating acitivity in the ∆lpxL1 GMMA was further 
emphasized. They required 10,000-fold the amount of GMMA with unmodified lipid A 
to reach the same level of TLR4 activation. These results were in line with results 
obtained with S. sonnei ∆htrB GMMA.  
 
Fig. 30 Evaluation of endotoxin activity in Neisseria GMMA. A) IL-6 release by human PBMC: 
PBMC were stimulated for 4 hours with different concentration of GMMA (0,001-1000 bg/mL, 10-fold 
steps dilutions). B) TLR4 specific assay: 25000 of HEK293 TLR4, MD2, CD14/well were stimulated 
for 5 hours with serial dilutions of GMMA obtained from different mutants.
 
 
 
Comparison of endotoxicity of GMMA from different Shigella and Neisseria 
strains in MAT 
 
In order to directly compare the reduction of reactogenicity after lipid A modifications 
in Neisseria and Shigella, GMMA from strains with WT and modified lipid A were 
testedin the same experiment (fig. 31).  
 
Fig. 31 IL-6 release by human PBMC. PBMC were stimulated for 4 hours with different 
concentrations of GMMA and IL-6 released in the supernatants was measured by specific ELISA. 
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By that approach we might appreciate that the starting (with WT lipid A) situation is 
similar for GMMA produced from Shigella and Neisseria (tab. 14). GMMA from both, 
Ss+p+OAg ∆htrB and Nm ∆fHbp ∆lpxL1 OEfHbp, gave similarly low IL-6 release results.  
They required approximately 1000-fold less amount compared to GMMA wtihout lipid 
A to stimulate the same level of IL-6 release. In addition, the plateau of maximum 
release is lower for both in comparison to lipid A WT GMMA.  
GMMA from Ss+p+OAg ∆htrB and Nm ∆fHbp ∆lpxL1 OEfHbp both contain penta-
acylated lipid A. The result indicate that the different fatty acid composition and the 
presence of phospoetanolamine in Neisseria lipid A does not alter the activation of 
TLR4. That results further suggest that a fully pent-acylated lipid A is required for 
drastically abolish TLR4 stimulation and that reflects in a big reduction on human 
PCMC). 
 
 
 
Tab. 14 MAT assays results from different blood donors.  Concentrations of each type of GMMA 
resulting in 10-fold increased release of IL-6 were determined using PMBC. Fold differences were 
calculated of the concentration of GMMA from lipid A mutants to GMMA with wild-type lipid A 
(Ss+p+OAg, Nm) and to GMMA from Ss+p+OAg ∆htrB 
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Discussion 
 
GMMA are attractive candidates for vaccines as the present surface antigens in their 
natural environment and confirmation. For use as vaccines, depending on the dose, 
the reactogenicity might need to be reduced as GMMA contain LPS and other TLR 
stimulatory components, e.g. lipoproteins. We have developed a high yield 
production process for GMMA (128). The goal of this thesis was to demonstrate the 
feasibility of reduction of reactogenicity of GMMA by genetic modification of the lipid 
A component of LPS.  
 
We started by examining several factors to determine the most useful in-process 
assay for measuring the protein concentration of GMMA from multiple different 
bacteria, that is essential for comparing GMMA in functional assay. Those factors 
are: the ease of performing the assay, the reproducibility of the assay and the 
linearity of the assay. By comparing Bradford, Lowry and NI assays using a BSA 
standard calibrated against GMMA concentrations determined by amino acid 
analysis.  By the above criteria, the Lowry assay was superior. First, it was by far the 
simplest assay to perform, requiring neither a strong chaiotropic agent (guanidine) 
and boiling (Bradford) or multiple centrifugations (NI Assay) and took significantly 
shorter time to perform the assay (approximately 15 minutes compared to 
approximately 45 minutes (Bradford) and 35 minutes (NI)). Second, and most 
important, the Lowry also gave substantially lower inter- and intra-assay variations. 
All three assays gave good linearity over a range of protein concentrations useful for 
vaccine production and testing (around 5 to 25 µg). For all three assays, and 
especially the Bradford assay, the color yield was substantially different to the color 
yield of BSA in the same assay and highlights the necessity to calibrate a secondary 
standard such as BSA against a primary GMMA standard determined by amino acid 
concentration or some other methods. Without this calibration, the Bradford assay 
substantially under estimated the amount of protein present and the Lowry gave a 
modest over-estimate. While generally true of all GMMA tested, the details did vary 
between GMMA with the Neisseria GMMA showing lower color yields for both the 
Bradford and Lowry assays. The NI assay relies on depletion of copper ions in 
solution when they bind to peptide bonds and thus generally has minimal protein to 
protein variation. In our studies it gave color yields of the GMMA protein closest on 
average to the color yield of BSA.  However, there was substantial variation between 
different GMMA, greater intra- and inter-assay variation and it was a more 
complicated assay to perform that the Lowry assay. In the absence of a primary 
GMMA standard, for many applications these considerations are likely to outweigh 
the small underestimation in GMMA protein concentration that would result from the 
use of the Lowry assay calibrated only against a BSA standard. 
Another key aspect, especially for the work performed in this thesis, was the 
comparability of the results for GMMA from multiple different bacteria. Also by this 
criterion, the Lowry assay was superior and showed the most consistent results for 
different types of GMMA. In general Lowry assay has been reported to show better 
results than other assays for membrane containing fractions (165), further showing a 
low inter-protein variability, and thus is beneficial for analyses when the standard is a 
different protein from the measured sample (166). Finally these results highlight the 
need for caution when comparing results from different laboratories if different protein 
assays are used and if they have not been calibrated against a primary GMMA 
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standard. In the absence of such calibration, GMMA assayed by Bradford and Lowry, 
two commonly used methods would have given more than a 5-fold difference in the 
apparent protein concentrations: an error sufficiently large to impact on interpretation 
of reactogenicity and immunogenicity of GMMA based vaccines. 
 
The feasibility of reduction of GMMA reactogenicity by genetic lipid A modification 
was first assessed using Shigella. 
Various Shigella strains lacking htrB or msbB have been succesefully obtained and 
GMMA from them have been characterized. All the lipid A mutants produced were 
able to grow under same conditions, optimized to 30°C as growing temperature and 
by using chemical defined or minimal medias; all lipid A mutants, besides growing 
slower than wild type, were able to reach high O.D. after over-night under those 
conditions, maintaining the utility of the process from an industrial point of view (128). 
The preferential for minimal or not reach media by lipid A mutants and lower growing 
temperature might be explained by the fact that membrane of bacteria with modified 
lipid A growing fast, as in conditions with high nutrient, have not enough time to 
rearrange and create a shape of outer membrane compatible with life. 
The results of deleting the msbB gene from both S. sonnei ∆tolR and S. flexneri 2a 
∆tolR and by deleting the htrB gene from S. sonnei ∆tolR were as expected: 
conversion of a hexa-acylated lipid A to a penta-acylated lipid A through loss of a 
myristic acid (∆msbB) or lauric acid (∆htrB). However, we have demonstrated the 
presence of a palmitoleoyl chain in lipid A purified from Sf
-p-OAg ∆htrB GMMA by 
MALDI-TOF and MALDI TOF-TOF. 
The inability to detect a hepta-acetylated Lipid A in either the S. flexneri 2a GMMA or 
the Sf
-p-OAg ∆htrB GMMA complemented with htrB expression from pACYChtrB, 
suggests that the palmitoleoylation is on the same site occupied by lauroyl acid in the 
wild type Lipid A. This would also be consistent with palmitoleoylation catalyzed by 
the action of LpxP, a late acyltransferases that acts at the HtrB site, described as 
cold response in E. coli (108). Thus, the palmitoleoylation could be part of a stress 
response. Similarly, in the E. coli ∆lpxL mutant the abundance of the palmitoeoylated 
lipid A increased with stress: it was a medium abundant species at 30°C and the 
dominant species at 37°C (167). In S. flexneri 2a ∆htrB the palmitoleoylated lipid A 
was the dominant species at 30°C, and very small amount of penta-acylated lipid A 
has been found. In ∆tolR mutant strains, the tolR mutation could provide stress, and, 
thus, result in higher abundance of palmitoleoylated lipid A at 30°C, although why this 
was not found in the Ss
-p-OAg ∆htrB strain examined is not clear. All ∆htrB S. flexneri 
isolates examined had the palmitoleoylation of the lipid A regardless of the presence 
or type of OAg on the LPS (S. flexneri 2a, 3 and 6 have different O antigens) or the 
presence of the virulence plasmid (Sf
-p+OAg ∆htrB, Sf+p+OAg ∆htrB). For these, 
palmitoleoylation might be a strongly selected compensation after the htrB knock out. 
Consistent with this hypothesis, all the attempts to obtain an lpxP knock out in Sf
-p-OAg 
∆htrB failed, besides the possibility of knocking out the gene in Ss
-p-OAg ∆htrB. 
The reason for the differential presence of palmitoleic acid on lipid A between Ss
-p-OAg 
∆htrB and Sf
-p-OAg ∆htrB is not clear. We were able to observe a small amount of 
palmitoleoylated lipid A in this S. sonnei grown at 12°C, indicating that there was a 
functional LpxP present. However, by using quantitative real time PCR, we found a 7-
fold higher gene expression of lpxP compared to the constitutive msbB in Sf
-p-OAg 
∆htrB compared to in Ss
-p-OAg ∆htrB grown at 30°C, possibly resulting in a higher level 
of LpxP protein present at 30°C in the S. flexneri ∆htrB strain. Furthermore, LpxP 
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carries a Leu116→ Pro substitution in S. sonnei which could affects the activity of the 
enzyme. 
Interestingly, when growing bacteria at 37°C, the lipid A profile of Ss
-p-OAg ∆htrB 
remain similar to the one at 30°C (penta-acylated), instead in Sf
-p-OAg ∆htrB, besides 
the main peak is still represented by the palmitoleoylated ones, appeared also one 
peak correspondent at the addition of a palmitoyl chain, most likely due to the action 
of PagP (fig. 32). This might indicated a further stress response and again a 
difference of S. flexneri to S. sonnei besides a similar genetic background. 
 
Although the impact of lipid A modifications on TLR4 activation has been widely 
studied (117,121,168) the availability of GMMA from isogenic Shigella lines all with 
similar concentrations of lipid A enabled us to examine in more detail, the residual 
ability of modified lipid A to activate human TLR4 receptors either in HEK293-TLR4 
transfectant cells or in human PBMC in the presence or absence of TLR2 and TLR4 
blocking antibodies. We could detect no residual TLR4 activity of the 1616 Da penta-
acylated lipid A resulting from the loss of a lauroyl chain as a result of the ∆htrB 
mutation. This was accompanied by a 60,000x increase in the amount of GMMA 
required to give similar activation of TLR4 compared to the parent GMMA (500 ng/mL 
for a 3x activation measured by NF-κB luciferase induction).  GMMA from both S. 
sonnei and S. flexneri with the 1588 Da penta-acyl lipid A resulting from a loss of a 
myristoyl chain as a result of the ∆msbB mutation, gave activation at similar GMMA 
concentrations (4.7 ng/mL and 4.6 ng/mL, respectively, for a 3x NF-κB luciferase 
induction). Although this required substantially more GMMA than ones needed from 
the parent strains (0.008 ng/mL) it was still much less than the S. sonnei ∆htrB penta-
acylated lipid A, showing that this penta-acylated lipid A retains some residual ability 
to activate human TLR4.  
In S. flexneri 2a GMMA, the substitution of a lauroyl chain with the longer 
palmitoleoyl chain in hexa-acylated lipid A also led to approximately a 30x decrease 
in the ability to simulate human TLR4 as judged by the concentration of GMMA (0.42 
ng/mL) required to give a 3x NF-κB luciferase induction. Besides the fact that the 
mass spectrum is represented by a mixture of hexa-, penta- and tetra-acylated lipid A, 
the hexa-acylated peak was by far the dominant peak present, and while the 
relatively heights of the peaks in this experiment is not necessarily strictly 
proportional to the abundance in the GMMA, it seems highly unlikely that a 50x 
reduction in activation could be due to the decrease in percentage of the hexa-
acylated by the presence of these lower sized peaks. 
 
In order to evaluate the endotoxin activity of GMMA in a more natural context and in 
particular to examine if the GMMA could simulate PRRs rather than TLR4, GMMA 
purified form different mutants were used to stimulate human PBMC in MAT. In 
general, the differences in the reactogenicity measured on PBMC were smaller than 
what observed looking at the specific TLR4 response using HEK293 transfectants. 
This observation is in line with the complexity of the material tested. As GMMA are 
derived from the outer membrane of Gram-negative bacteria they also contain 
lipoproteins and thus likely stimulated TLR2 in addition to TLR4.  
The S. sonnei ∆htrB GMMA showed the biggest decrease in cytokine release in 
comparison to lipid A unmodified GMMA, approximately 800-fold on average. This 
was a 20-fold larger decrease than the decrease observed for S. flexneri ∆htrB. 
GMMA purified from S. sonnei or S. flexneri ∆msbB strains produced similar level of 
cytokines with a decrease around 300-fold to lipid A unmodified GMMA and 3-fold 
 76 
 
lower than GMMA from S. sonnei ∆htrB. GMMA from S. sonnei ∆htrB ∆msbB 
(containing only tetra-acylated lipid A) gave similar results, both in MAT and TLR4 
specific assay, as S. sonnei ∆htrB GMMA. This showed that the ∆htrB deletion 
reduces the lipid A endotoxicity to a level that cannot be further reduced by deletion 
of an additional acyl chain. 
 
 
Fig. 32 Shigella and Salmonella lipid A acylation after lipid A mpodifications. Presence of 
Phispoetanolomine due to action of EptAin phosphate in position 1 is theoretically possible in all the 
lipid A structures (not reported) 
 
As previously described, the different acylation status of lipid A, and the 
phosphorylation status of the molecule, affects the tilt angle of di-glucosammine 
blackbone and accordingly the recognition by TLR4 (109,110,113). Thus, the 
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differences observed between GMMA that carry htrB or msbB knock out are likely 
linked to the fact that HtrB and MsbB act in different position in lipid A, resulting in 
different binding to TLR4. The palmitoleoylated hexa-acylated lipid A is likely more 
similar in structure to the wild-type lipid A explaining the higher TLR4 activation by S. 
flexneri ∆htrB in comparison to S. sonnei ∆htrB GMMA.  
 
The similar strategy for reducing the endotoxin activity as used for Shigella GMMA 
has subsequently been applied to Salmonella. In these bacteria the lipid A 
composition is complicated by the constitutive presence of PagP resulting in the 
addition of a palmitoyl chain. Thus, in GMMA cointaing unmodified lipid A we 
observed a mixture of hexa-acylated lipid A and hepta-acylated lipid A by MALDI-
TOF (fig. 32 right side). In line with that observation, Salmonella ∆msbB GMMA 
showed a penta-acylated and an hexa-acylated lipid A species different to WT, 
consistent with an msbB knock-out. The ratio between penta- and hexa-acylated lipid 
A is different in S. Typhimurium and S. Enteritidis ∆msbB GMMA, with the latter 
containing mainly penta-acylated lipid A. In a similar way S. Typhimurium ∆htrB 
GMMA showed two populations of lipid A coming from the hepta-acylated and hexa-
acylated WT lipid A lacking a lauroyl chain. Furthermore, S. Enteritidis ∆htrB GMMA, 
besides showing the presence of the same two peaks observed in S. Typhimurium 
∆htrB GMMA, showed also a hepta-acylated peak given by the addition of the 
palmitoleoyl chain in hexa-acylated palmitoylated background (same compensatory 
effect observed in S. flexneri after htrB knock out). 
 
The different types of lipid A observed by MALDI in GMMA from different Salmonella 
mutants results in differences in reactogenicity, as observed by HEK-TLR4 cells and 
MAT assay. In fact, by TLR4-specific assay, the GMMA with mostly penta-acylated 
lipid A derived from S. Typhimurium ∆msbB were around 10-fold less stimulatory 
than the mixture of hexa- (not wild type) and/or hepta-acylated lipid A species 
observed in the GMMA from S. Enteritidis ∆msbB and from both ∆htrB strains. Those 
GMMA resulted in 10-fold lower TLR4-stimulatory activity than GMMA containing 
unmodified lipid A.  
S. Typhimurium ∆msbB GMMA were also the least stimulatory of all tested 
Salmonella GMMA with modified lipid A by MAT, in accordance to be the only ones 
showing mainly penta-acylated lipid A (more than 95%). The resulting difference to 
GMMA from the respective wild type was approximately 100-fold. In addition, the 
level of reactogencity was similar to GMMA from Shigella mutants cointaing penta-
acylated lipid A. The reduction of endotoxin activity observed, especially for the 
mostly penta-acylated GMMA from S. Tm ∆msbB, is in line to what was observed by 
other groups testing heat-killed bacteria (169) and rise also the problem of the needs 
of a different strategy for lipid A modifications in Salmonella in order to gain a fully 
penta-acylated lipid A.The finding that in the other analyzed S. Tm and S. En ∆htrB 
and ∆msbB mutants hexa-acylated lipid A was found (due the plamitoleoylation 
through LpxP or plamitoylation through PagP) shows that  additional genetic 
modifications to htrB and msbB will be needed to obtain predominantly penta-
acylated lipid A in Salmonella, for examples  a ∆msbB ∆pagP double mutation (170).  
 
Also the reduction of endotoxin activity in species less related to Shigella has been 
evaluated by testing GMMA from Neisseria meningitidis lipid A mutants that carries 
lpxL1 knock out (122). This gene is functionally similar to ∆htrB and the mutation has 
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been widely studied for reducing -reactogenicity on GMMA (81) and NOMV vaccines 
(126). 
Lipid A extracted from GMMA purified from non-modified lipid A Neisseria stains 
showed two main peaks correspondent to an hexa-acylated lipid A (with a different 
lipid A composition in comparison to Shigella GMMA) with and without the presence 
of a phospoetanolamine (fig. 33) as indicated by  a shift of 182 Dalton, consistent 
with an lpxL1 knock out.  
 
 
Fig. 33 Neisseria lipid A acylation pattern in lipid A mutants 
 
In TLR4 specific assay lpxL1 knock-out resulted in an almost complete reduction of 
endotoxicity of Neisseria GMMA, like what observed with S. sonnei ∆htrB, meaning 
no effect due to presence of phospoetanolamine in lipid A and due to the different 
fatty acid composition in terms of TLR4 activation. 
By MAT that translates in a reduction of 1,000 fold after lpxL1 deletion (in line to what 
has been observed with S. sonnei ∆htrB GMMA).  
 
Besides the fact that the main activator of innate immune response contained in 
GMMA is LPS, we have also evaluated other characteristics that might have been 
changed in GMMA after lipid A modification. The objective was to characterize and 
understand the relative contribution of other activators besides LPS present in 
GMMA to the activation of other pathways besides TLR4. 
By using Anti-TLRs antibodies we demonstrated that the residual reactogenicity in 
GMMA after lipid A modification is mainly mediated through TLR2, except the 
residual TLR4 activation present in S. flexneri ∆htrB with palmitoleoylated hexa-
acylated lipid A. Furthermore, by blocking with both anti-TLR4 and anti-TLR2 
antibodies, we demonstarted that the stimulation caused by GMMA is almost 
completely abolished (more than 90%), suggesting that, in the conditions used in the 
assay, the relative contribution of other pathways is marginal (lower than 10%) in the 
activation of PBMC. 
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By using HEK293-TLR2 cells we observed that TLR2 stimulation is similar for all the 
GMMA from Shigella (and Salmonella) mutants, confirming that differences observed 
in MAT assay reflects differences in terms of TLR4 activation; furthermore, we 
demonstrated that TLR2 activating components were the main responsible of the 
residual endotoxicity of GMMA after lipid A modifications, in a comparable level; thus, 
TLR2 activating components represents the target if a further reduction of 
reactogenicity of GMMA will be needed.  
Protein composition was evaluated by SDS-PAGE and the overall pattern resulted to 
be maintained in GMMA purified from different mutants from same bacteria; only 
small differences have been observed and, by identifying using Peptide Mass 
Fingerprinting the proteins correspondent to most different bands, those resulted to 
be metabolism-related and not reported as PRR activators. 
Also the shape of the GMMA from different strains was evaluated by electron-
microscopy, and GMMAresulted to be composed mainly by an homogenous 
population with no differences related to lipid A modifications. The possible presence 
of flagellin in Salmonella GMMA preparations (as impurities that remains stacked to 
GMMA during purification, or purified with them as small fragments released during 
growth of bacteria) might be evaluated in the final development of a vaccine strain, 
because the presence of flagella might mediate innate immune stimulation through 
TLR5 activation, and can be the responsible of smaller differences observed in MAT. 
 
In conclusion, the broad aim of the thesis was to examine ways of reducing the 
reactogenicity of GMMA to make them suitable for use as human vaccine. It resulted 
in surprisingly complex outcome. 
We demonstrated the feasibility to reduce GMMA reactogenicity by lipid A 
modification. We found a clear relation between the composition of the lipid A 
species and reactogenicity. Our analysis of GMMA from isogenic lines and from 
different species highlighted the importance of determining the composition of the 
lipid A after the genetic modification as the same genetic modification gave different 
outcomes even in closely related Shigella species.  
We demonstrated in Shigella, Salmonella, and Neisseria that GMMA with penta-
acylated lipid A have a marked reduction of cytokine stimulation ability. Using 
Shigella GMMA we showed that the residual reactogenicity is predominantly TLR2 
mediated. In contrast, GMMA with hexa-acylated lipid A, either through 
palmitoleoylation after htrB knock-out, and/or due to additional palmitoylation in 
Salmonella, retain TLR4 stimulatory activity and are less likely to be useful as 
vaccine. Thus, that compensatory effect must be evaluated in bacteria that 
possesses lpxP and may undergo on same compensatory effect 
Based on the results presented in this thesis, genetic modification of the lipid A 
biosynthesis pathway resulting in penta-acylated lipid A is a promising strategy for 
reducing the reactogenicity of GMMA. If further decrease of reactogenicity was 
required, modifications of TLR2 activating components would be necessary. However, 
the level of reduction required for an acceptable vaccine will depend on the dose 
necessary to give a strong immune response and that can only be determined by 
clinical trials. Clinical trials underway now using the S. sonnei ∆htrB GMMA should 
give an important indication of the tolerability of these constructs. 
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Introduction
Shigella spp. are Gram-negative bacteria that infect the intestinal
epithelium and cause dysentery. In 1999 the World Health
Organization estimated an annual burden of 164.7 million
shigellosis cases throughout the year of which 163.2 occur in
developing countries, including 1.1 million deaths, mostly in
children younger than 5 years of age [1]. Four serogroups have
been identified: S. dysenteriae (15 serotypes), S. boydii (20 serotypes),
S. flexneri (14 serotypes) and S. sonnei (1 serotype) [2]. No vaccine is
currently available. So far, vaccine candidates based on O antigen
conjugates and live attenuated strains have been shown in clinical
trials to protect against homologous strains [2–6]. Vaccines using
inactivated bacteria or subcellular components are at various
stages of development [3,6].
Gram-negative bacteria naturally shed outer membrane parti-
cles consisting of outer membrane lipids, outer membrane
proteins, and enclosed periplasmic proteins [7–9]. Unlike most
unilamellar biological vesicles, outer membrane particles are
formed by blebbing and not by invagination of the membrane.
Thus, the orientation of components in the membrane of the outer
membrane particles is the same as in the bacterial outer
membrane and the components in the outer face of the bacterial
outer membrane are also in the outer face of the outer membrane
particles [7]. Outer membrane particles are naturally shed at low
concentration. Mutations such as the deletion of gene gna33 in
Neisseria meningitidis [10] or modifications of the tol-pal pathway of
Escherichia coli, Shigella flexneri, and Salmonella enterica serovar
Typhimurium [11,12] can increase the level of shedding.
Especially, deletion of the tolR gene in E. coli has been shown to
result in substantial overproduction of outer membrane particles
without loss of membrane integrity [11,13]. Studies have
characterized the protein content of these outer membrane
particles [10,13], and unlike conventional detergent-extracted
outer membrane vesicles derived from homogenized bacteria they
are almost free of cytoplasmic and inner membrane components
and maintain lipoproteins. The outer membrane particles used for
those proteomic studies have been derived in small quantities from
cells grown to low cell density.
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It has been previously proposed that outer membrane particles
could be exploited for use as vaccines [10,12]. The immunoge-
nicity of outer membrane particles from a variety of Gram-
negative bacteria has been studied. Consistent with their high
content of stimulators of the innate immune system, e.g.
lipopolysaccharide (LPS) [7] and Toll-like receptor 2 (TLR2)
agonists [14], they are strongly immunogenic in the absence of
adjuvant. They have been shown to induce protection in mice
against multiple pathogens, including Salmonella enterica serovar
Typhimurium [15], Helicobacter pylori [16], Vibrio cholera [17,18], or
to elicit antibodies in mice with in vitro bactericidal activity, e.g. for
Neisseria meningitidis [19]. Recently, outer membrane particles from
Shigella flexneri 2a have been shown to confer protection in mice
after mucosal immunization [20]. Although these studies suggest
that outer membrane particles may form the basis of vaccines
[15,17,18], there remain several problems: their reactogenicity
and the difficulty of purifying them in the quantity and at costs
that would make them attractive as vaccines for the public sector
most impacted by diseases such as shigellosis.
The problem of reactogenicity is amenable to genetic manip-
ulation. A variety of strategies has been examined to attenuate the
pyrogenicity of LPS by modifying genes involved in lipid A
biosynthesis, e.g. msbB and htrB in Shigella and E. coli or lpxL in
Neisseria that are required for complete acylation and thereby
pyrogenicity of lipid A [21–24]. However, a major remaining
difficulty is developing a scalable method for the high volume and
low unit cost production of vaccines based on this method.
In this paper we show that high purity outer membrane
particles from Shigella sonnei mutant strains can be produced from
fermentation in chemically defined medium with high yield using a
simple purification process thus making production of inexpensive
vaccines feasible. We believe that this process will be widely
applicable for production of Gram-negative membrane antigens
and thus call it the ‘Generalized Modules for Membrane Antigens
(GMMA)’ process. In the literature, outer membrane particles that
are either naturally released or produced by genetically modified
strains are usually referred to as outer membrane vesicles (OMV).
The same term has also been used for the vesicles derived by
detergent-extraction of homogenized bacteria currently used as
vaccines, e.g. MeNZB, an outer membrane vesicle vaccine used to
control Neisseria meningitidis type B infections in New Zealand. In
order to differentiate the two substantially different types of OMV
[10] we chose the term GMMA to specify the particles released
from the surface of intact cells used in this study.
Methods
Construction of Shigella Sonnei 53G Mutants
Shigella sonnei 53G [25] was chosen as parent strain. The null
mutants tolR [13], galU [26], and msbB1 [21] were obtained by
replacing the gene coding sequence with a resistance cassette [27].
Kanamycin was used for tolR, chloramphenicol for galU and
erythromycin for msbB1. To achieve this, we used a three step
PCR protocol to fuse the gene upstream and downstream regions to
the resistance gene. Briefly, the upstream and downstream regions
of the gene were amplified from Shigella sonnei 53G genomic DNA
with the primer pairs gene.AB.500-5/gene.ABL-3 and gene.AB.L-
5/gene.AB.500-3, respectively (details of target ‘gene’, antibiotic
cassette ‘AB’ and sequence are reported in Table 1). The
kanamycin cassette was amplified from pUC4K [28] and the cat
gene from pKOBEG [29] using the primers ampli.AB-5/
ampliAB-3 (Table 1). Finally the three amplified fragments were
fused together by mixing 100 ng of each in a PCR reaction
containing the gene.AB.500-5/gene.AB.500-3 primers. The linear
fragment to delete tolR was used to transform recombination-
prone Shigella sonnei 53G carrying pAJD434 to obtain the
respective deletion mutant S. sonnei DtolR. Recombination-prone
S. sonnei DtolR was then transformed with the linear fragment for
the deletion of galU, resulting in mutant strain S. sonnei DtolR
DgalU. A clone of S. sonnei DtolR lacking the virulence plasmid,
S. sonnei –pSS DtolR, was selected by white appearance on congo
red agar. The curing of the virulence plasmid (pSS) was confirmed
by the absence of the origin of replication and the plasmid
encoded gene wzy using primers pS.so53G.oriF/pS.so53G.oriR
and pS.so53G.wzyF/pS.so53G.wzyR respectively (Table 1). Two
functional msbB genes are present in Shigella [21]. In the DtolR
background, the copy located on the virulence plasmid (msbB2)
was removed by curing the plasmid and the plasmid pDmsbBko::
ery was constructed to delete the gene msbB1 on the chromosome.
Upstream and downstream flanking regions of the msbB1 gene
were amplified by PCR with the XbaI.msbB.59.F/
EcoRV.msbB.59.R and EcoRV.msbB.39.F/XhoI.msbB.39.R prim-
ers, respectively. Both products were cloned into the pBluescript
(Stratagene) vector in Max EfficiencyH E. coli DH5aTM-T1R
(Invitrogen). The erm erythromycin resistance gene [30] was
amplified with primers EcoRV.Ery.F/EcoRV.Ery.R and was
inserted into the EcoRV site between the flanking regions
generating pDmsbBko::ery. Primers XbaI.msbB.59.F/
XhoI.msbB.39.R were used to amplify by PCR a linear fragment
from pDmsbBko::ery plasmid, containing the resistance cassette
flanked by msbB1 flanking regions that was used to transform the
recombination-prone plasmid-cured Shigella sonnei 53G DtolR strain
to generate the msbB knockout mutant. Recombination-prone
Table 1. Primers used in this study.
tolR.Kan.500-5 TCTGGAATCGAACTCTCTCG
tolR.Kan.L3 ATTTTGAGACACAACGTGGCTTTCATGGCTTACCCCTTGTTG
tolR.Kan.L5 TTCACGAGGCAGACCTCATAAACATCTGCGTTTCCCTTG
tolR.Kan.500-3 TTGCTTCTGCTTTAACTCGG
ampli.Kan-5 ATGAGCCATATTCAACGGGAAAC
ampli.Kan-3 TTAGAAAAACTCATCGAGCATCAAA
galU.Cm.500-5 AAAATCAACGGTTGCCAGAG
galU.Cm.L-3 CGAAGTGATCTTTCCGTCACATTAAATTCTCCTGGACTGTTC
galU.ext-5 GCCTGGTGCTTGATATTGC
galU.Cm.500-3 GCGCAGGCAAGAGAATGTA
galU.Cm.L-5 CAGTTATTGGTGCCCCATCCGTATCGGTGTTATCC
galU.ext-3 TCCTGGCTATTGCACAACT
ampli.Cm-5 TGTGACGGAAAGATCACTTCG
ampli.Cm-3 GGGCACCAATAACTGCCTTA
XbaI.msbB.59.F CTAGTCTAGAAGTGCTTTCAGTGGGTGACG
EcoRV.msbB.59.R AGCTTGATATCCCATGCTTTTCCAGTTTCGG
EcoRV.msbB.39.F AGCTTGATATCGGCGAAATCCAACCGTATAAG
XhoI.msbB.39.R CCGCTCGAGGGGGAAGTTGTTAAGACAGAC
EcoRV.Ery.F AGCTTGATATCAGAGTGTGTTGATAGTGCAGTATC
EcoRV.Ery.R AGCTTGATATCACCTCTTTAGCTTCTTGGAAGCT
pS.so53G.oriF CGTAACCGTAATTACAGCCG
pS.so53G.oriR GATTTCACCTTACCCATCCC
pS.so53G.wzyF CGTTGAGGTTTCACGTTTCT
pS.so53G.wzyR TTACCAATATACCCTCCGCA
doi:10.1371/journal.pone.0035616.t001
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Shigella sonnei 53G cells were produced by using the highly
proficient homologous recombination system as previously de-
scribed (red operon) [31] encoded on pAJD434 [32]. pAJD434 was
subsequently removed from the mutant strains.
Bacterial Strain Growth Conditions and Media
Shigella sonnei and E. coli strains were routinely cultured in
Luria-Bertani (LB) medium. When required, kanamycin (30 mg/
mL), chloramphenicol (20 mg/mL), trimethoprim (100 mg/mL),
or ampicillin (100 mg/mL) were added. Tryptic soy agar (30 g/L
tryptic soy broth, 15 g/L agar) supplemented with 150 mg/L
congo red was used to evaluate the presence of the virulence
plasmid in Shigella. GMMA were prepared from cultures grown
in flasks or in a 5 L fermenter (Applikon) in yeast extract
medium (HTMC) or Shigella sonnei defined medium (SSDM).
HTMC was prepared as follows: yeast extract 30 g/L, KH2PO4
5 g/L, K2HPO4 20 g/L, MgSO4*7H2O 1.2 g/L, glycerol 15 g/
L, polypropylene glycol (PPG) 0.25 g/L. SSDM was prepared as
follows: glycerol 30 g/L, KH2PO4 13.3 g/L, (NH4)2HPO4 4 g/
L, MgSO4*7H2O 1.2 g/L, citric acid 1.7 g/L, CoCl2*6H2O
2.5 mg/L, MnCl2*4H2O 15 mg/L, CuCl2*2H2O 1.5 mg/L,
H3BO3 3 mg/L, Na2MoO4*2H2O 2.5 mg/L,
Zn(CH3COO)2*2H2O 13 mg/L, ferric citrate 2 mM (unless
specified differently in text), thiamine 50 mg/L, nicotinic acid
10 mg/L, L-aspartic acid 2.5 g/L, PPG 0.25 g/L. For fermen-
tation, starter cultures were grown from glycerol stocks to OD
0.8 and subsequently transferred to the 5 L fermenter to reach a
starting OD of 0.02. Dissolved oxygen was maintained at 30%
saturation by controlling agitation and setting maximum
aeration. The pH was maintained at 7.2 in HTMC or at 6.7
in SSDM, with 4 M ammonium hydroxide by a pH controller
and temperature was kept constant either at 37uC or at 30uC.
From flask cultures, supernatants were collected by 10 min
centrifugation at 4000 g followed by 0.22 mm filtration or by
tangential flow filtration. The optical density (OD) of cultures
was measured at 600 nm wavelength.
Tangential Flow Filtration Purification
A 2-step tangential flow filtration (TFF) process was used to
purify GMMA. During the first TFF step, the culture superna-
tant which contains the GMMA was separated from the bacteria
using a 0.2 mm pore size cassette (Sartocon HYDROSART
0.2 mm, Sartorius). When approximately 80% of the starting feed
was recovered as filtrate, the remaining biomass (retentate) was
washed in five diafiltration steps with phosphate buffered saline
(PBS). The GMMA-containing culture supernatant and the
GMMA-containing filtrate of the diafiltration steps were com-
bined. In a modified process the diafiltration of the biomass was
omitted. Experiments performed without this diafiltration step
are specified in the text. In the second step, the combined filtrate
was micro-filtered using a 0.1 mm pore size membrane (Sartocon
SLICE 200 0.1 mm, Sartorius) in order to separate GMMA that
remain in the retentate from soluble proteins (filtrate). After five
diafiltration steps using PBS, the retentate containing the
GMMA was collected and sterile filtered using a 0.22 mm
ExpressTM PLUS stericup (Millipore).
Protein Quantification
Proteins were quantified by Bradford method, using bovine
serum albumin as standard. GMMA were boiled for 10 minutes in
3.0 M guanidine hydrochloride prior quantification.
Negative Staining Electron Microscopy
A drop of 5 mL of GMMA suspension was placed on copper
formvar/carbon-coated grids and adsorbed for 5 min. Grids were
then washed with few drops of distilled water and blotted with a
Whatman filter paper. For negative staining, grids were treated
with 2% uranyl acetate in ddH2O for 1 min, air-dried and viewed
with a CM100 transmission electron microscope (Philips, Eindo-
ven, the Netherlands) operating at 80 kV. Electron micrographs
were recorded at a nominal magnification of 600006.
Denaturing Mono-Dimensional Electrophoresis
GMMA were denatured for 3 min at 95uC in sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer containing 2% (wt/vol) SDS. 20 mg of proteins were loaded
onto 12% (wt/vol) or 4–12% (wt/vol) polyacrylamide gels
(BioRad, Hercules, U.S.A.). Gels were run in 3-(N-morpholino)-
propanesulfonic acid (MOPS) buffer (BioRad) and were stained
with Coomassie Blue R-250.
Two-Dimensional Electrophoresis
Two hundred micrograms of GMMA were separated by 2-
dimentional electrophoresis (2-DE) as previously described [10].
Briefly, proteins were separated in the first dimension on a non
linear pH 3–11 gradient and in the second dimension on a linear
4–12% polyacrylamide gradient unless specified in text. Gels were
stained with colloidal Coomassie G-250 [33].
Densitometry Analysis
SDS-PAGE and 2-DE gels were scanned with an Image Quant
400 (GE Healthcare). Images were analyzed with the software
Image master 2D Platinum 6.0 (Amersham Biosciences).
In-Gel Protein Digestion and MALDI-TOF Analysis
Protein spots were excised from the gels and processed as
previously described [13]. Mass spectra were acquired on a
Ultraflex MALDI TOF-TOF mass spectrometer (Bruker Dal-
Figure 1. Comparison of Shigella sonnei GMMA from different strains and different conditions. A)25 ml of culture supernatants were
collected from (1) wild type S. sonnei 53G, (2) S. sonnei DtolR (3) S. sonnei DtolR DgalU, (4) S. sonnei –pSS DtolR, and (5) S. sonnei –pSS DtolR DmsbB
grown in flasks in chemically defined medium at 30uC. Proteins were precipitated from the supernatants and quantified using Bradford assay. 10 mg
of samples 2–5, respectively, and the total quantity of sample 1 obtained from 25 mL of supernatant were separated by SDS-PAGE (12%
polyacrylamide (PA)). All strains with deletion of the tolR gene show an extensive protein profile in the supernatant compared to wild type. B) GMMA
were purified by ultracentrifugation from flask cultures of S. sonnei –pSS DtolR grown in chemically defined medium with 100 mM iron at 37uC and
30uC. 10 mg of protein were separated by SDS-PAGE (12% PA). The protein pattern of GMMA obtained at the different temperatures is similar. Visible
differences are marked by arrows. C) S. sonnei 53G –pSS DtolR was grown in flasks in chemically defined medium with defined iron concentrations.
GMMA were purified by ultracentrifugation and GMMA proteins were separated by SDS-PAGE (4–12% PA). Three bands identified as FepA, IutA, and
colicin I receptor were shown to be repressed by high iron concentration. D) Densitometry analysis of GMMA preparation from strain S. sonnei DtolR
DgalU grown in a 5 L fermenter to OD 45. The most abundant proteins were identified by protein mass fingerprint and relative amounts were
determined by densitometry analysis. Of the highlighted proteins, all proteins with exception of TolB are predicted to be associated with the outer
membrane, indicating that approximately 69% of the total protein amount in GMMA is derived from abundant proteins linked to the outer
membrane.
doi:10.1371/journal.pone.0035616.g001
Shigella Outer Membrane Particles Production
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e35616
tonics) in reflectron, positive mode, in the mass range of 900 to
3,500 Da. Spectra were externally calibrated by using a combi-
nation of standards pre-spotted on the target (Bruker Daltonics).
MS spectra were analyzed by Protein Mass Fingerprint (PMF)
with flexAnalysis (flexAnalysis version 2.4, Bruker Daltonics).
Monoisotopic peaks were annotated with flexAnalysis default
parameters and manually revised. Protein identification was
carried from the generated peak list using the Mascot program
(Mascot server version 2.2.01, Matrix Science). Mascot was run on
a database containing protein sequences deduced from seven
sequenced Shigella genomes, downloaded from NCBInr or from
the Wellcome Trust Sanger Institute database. Genomes used
were from strains Shigella sonnei 53G, Shigella flexneri 2a str. 301,
Shigella flexneri 2a str. 2457T, Shigella sonnei Ss046, Shigella boydii
Sb227, Shigella flexneri 5 str. 8401, Shigella boydii CDC 3083-94.
Search parameters, mass tolerance, known contaminant ions,
validation and handling of multiple matches were performed as
described previously [13].
Protein Precipitation and In-solution Protein Digestion
Proteins from supernatants or purified GMMA were precipi-
tated by adding TCA and deoxycholate to a final concentration of
10% and 0.04%, respectively. The precipitation was allowed to
proceed for 30 min at 4uC. The precipitate was recovered by
10 min centrifugation at 20,0006g at 4uC. The pellet was washed
once with 10% TCA (wt/vol) and twice with absolute ethanol,
dried with Speedvac (Labconco, Kansas City, U.S.A). For analysis
by SDS-PAGE, the precipitates were resuspended with 200 mM
Tris-HCl, pH 8.8, and quantified. For LC-MS/MS analysis 20 mg
of GMMA were precipitated and resuspended in 50 mL, 6 M
guanidinium chloride, 5 mM DTT, 200 mM Tris-HCl, pH 8.0.
Denaturation proceeded for 60 min at 60uC. Prior to digestion,
the solution was diluted 1:8 with a solution of 100 mM Tris-HCl,
pH 8.0, 5 mM DTT and 5 mg of trypsin (Promega) were added to
the diluted solution. Digestion was carried out over night at 37uC.
The reaction was stopped by adding formic acid to 0.1%. Peptides
were extracted using Oasis extraction cartridges (HLB 1cc (30 mg)
extraction cartridges, Waters, Milford, MA, USA) and analyzed by
LC-MS/MS.
Protein Identification by Nano-LC-MS/MS
Peptides were separated by nano-LC on a NanoAcquity UPLC
system (Waters) connected to a Q-ToF Premier ESI mass
spectrometer equipped with a nanospray source (Waters). Samples
were loaded onto a NanoAcquity 1.7 mm BEH130 C18 column
(75 mm625 mm; Waters) through a NanoAcquity 5 mm Symme-
try C18 trap column (180 mm620 mm; Waters). Peptides were
eluted with a 120 min gradient of 2–40% acetonitrile (98%), 0.1%
formic acid solution at a flow rate of 250 nL/min. The eluted
peptides were subjected to an automated data-dependent acqui-
sition using the MassLynx software, version 4.1 (Waters) where an
MS survey scan was used to automatically select multicharged
peptides over the m/z ratio range of 300–2000 for further MS/
MS fragmentation. Up to eight different peptides were individually
subjected to MS/MS fragmentation following each MS survey
scan. After data acquisition, individual MS/MS spectra were
combined, smoothed, and centroided using ProteinLynx, version
3.5 (Waters) to obtain the peak list file. The Mascot Daemon
application (Matrix Science Ltd., London, UK) was used for the
automatic submission of data files to in-house licensed Mascot,
version 2.2.1, running on a local server. The Mascot search
parameters were set to (i) 2 as the number of allowed missed
cleavages (only for trypsin digestion), (ii) methionine oxidation as
variable modifications, (iii) 0.05 Da as the peptide tolerance, and
(iv) 0.05 Da as the MS/MS tolerance. Only significant hits were
considered as defined by the Mascot scoring and probability
system.
Bioinformatics
Prediction of protein localization was carried out using
PSORTb v3.0 [34] and Lipo program [35].
Mouse Immunizations
Outbred CD1 mice (female, 4 to 6 weeks of age) received
three injections of GMMA via the subcutaneous route on days 0,
21, and 35. Each injection contained GMMA normalized to
0.2 mg or 2 mg of protein and formulated in PBS only, with
Freund’s adjuvant (FA), or adsorbed onto aluminum hydroxide
(alum), 2 mg/mL, in a final volume of 100 mL. If Freund’s
adjuvant was used, Freund’s complete adjuvant (FCA) was used
for the first immunization, Freund’s incomplete adjuvant (ICFA)
was used for the second and third immunization. Control mice
received either adjuvant or PBS alone. Blood samples were
collected before immunization and 14 days after the second and
third injection. The animal experiments complied with the
relevant guidelines of Italy and the institutional policies of
Novartis. The animal protocol was approved by the Animal
Welfare Body of Novartis Vaccines and Diagnostics, Siena, Italy,
approval number AEC 2009-05.
Western Blot
GMMA were boiled in loading buffer and loaded on 12% (wt/
vol) polyacrylamide-SDS gels (BioRad) or on 2D gels as described.
Gels were run in MOPS buffer (BioRad) and protein were
subsequently transferred onto nitrocellulose membrane using
Trans-blot transfer medium (BioRad). The membranes were
blocked in PBS containing 3% (wt/vol) powdered milk, then
incubated with mouse polyclonal antisera diluted (1:1000) in PBS
containing 3% (wt/vol) milk for 90 min at 37uC. Membranes were
washed three times with PBS containing Tween 20, 0.1% (vol/vol)
and then incubated with sheep anti-mouse horseradish peroxidase-
conjugated IgG (GE Healthcare, UK Limited), diluted (1:7500) in
PBS containing 3% (wt/vol) milk. Colorimetric staining was
performed, after washing the membranes, with SuperSignal West
Pico Chemiluminescent Substrate Kit (Pierce, Rockford, U.S.A.)
as described by the manufacturer. Positive signals were related to
the corresponding proteins by comparing the Western blot
membrane to the gel using Ponceau staining of the membrane
as a reference and aligning the images with Image master 2D
Platinum 6.0.
Enzyme-linked Immunosorbent Assay (ELISA)
To measure Shigella sonnei GMMA-specific immunoglobulin G
(IgG) in mice serum, Nunc Maxisorb 96-well plates were coated
over night at 2 to 8uC with 100 mL/well of a 0.5 mg/mL
suspension of Shigella sonnei 53G –pSS DtolR GMMA, purified from
defined medium with 2 mM ferric citrate in the same way as the
GMMA in the vaccine, diluted in phosphate-buffered saline (PBS).
Plates were then washed three times with 300 mL/well of
phosphate-buffered saline containing 0.05% (vol/vol) Tween 20
(PBST) and blocked with PBS containing 1% (wt/vol) BSA for
60 min at 37uC. Serial dilutions of reference and sample sera were
prepared in PBST, 1% (wt/vol) BSA in a separate dilution plate,
and 100 mL/well of each serial dilution was transferred to the
coated plate, incubated for 2 hours at 37uC, and then washed as
described above. Bound antibody was detected using a goat anti-
mouse IgG conjugated to alkaline phosphatase, diluted in PBST,
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Table 2. Shigella sonnei DtolR DgalU GMMA-associated proteins identified by proteomics.
A B C D E
Outer membrane
1 3 outer membrane channel protein [S. flexneri 2a str. 301] tolC gi|56480244
2 3 outer membrane porin protein C [S. sonnei Ss046] ompC gi|74312736
3 3 outer membrane protein A [S. sonnei Ss046] ompA gi|74311514
4 3 outer membrane protein induced after carbon starvation [S. flexneri 5 str. 8401] slp gi|110616891
5 3 outer membrane protein X [S. flexneri 2a str. 301] ompX gi|56479734
6 2 outer membrane protein assembly factor YaeT [S. Flexneri 2a str. 301] yaeT gi|24111612
7 2 outer membrane protein C [S. boydii CDC 3083-94] ompC gi|187733369
8 2 outer membrane receptor FepA [Shigella sonnei Ss046] fepA gi|74311118
9 2 ferrichrome outer membrane transporter [Shigella sonnei Ss046] fhuA gi|74310771
10 2 colicin I receptor [Shigella sonnei Ss046] cirA gi|74312677
11 2 maltoporin [Shigella flexneri 2a str. 301] lamB gi|56480532
12 4 putative ferric siderophore receptor [S. sonnei Ss046] iutA gi|74313972
13 2 outer membrane protein W [Shigella sonnei Ss046] yciD gi|74312394
14 2 serine protease [S. flexneri 2a str. 301] sigA gi|24114232
Outer membrane Lipoproteins
15 3 murein lipoprotein [S. flexneri 2a str. 301] lpp gi|24113066
16 2 outer membrane lipoprotein LolB [S. flexneri 2a str. 301] lolB gi|24112608
17 3 peptidoglycan-associated outer membrane lipoprotein [S. flexneri 2a str. 301] pal gi|56479690
18 1 entericidin B membrane lipoprotein [S. flexneri 2a str. 301] ecnB gi|24115506
19 1 hypothetical protein S2067 [S. flexneri 2a str. 2457T] yedD gi|30063370
20 1 hypothetical protein S4565 [S. flexneri 2a str. 2457T] yjeI gi|30065519
21 1 hypothetical protein SF0398 [S. flexneri 2a str. 301] ybaY gi|24111837
22 1 RpoE-regulated lipoprotein [S. flexneri 2a str. 301] SF2485 gi|24113773
23 1 hypothetical protein SSON_2966 [S. sonnei Ss046] SSON_2966 gi|74313380
24 1 lipoprotein [S. flexneri 2a str. 2457T] nlpB gi|30063856
25 2 entry exclusion protein 2 [S. sonnei Ss046] exc gi|145294038
26 2 LPS-assembly lipoprotein RplB [S. dysenteriae Sd197] rplB gi|82775909
27 2 putative pectinesterase [S. sonnei Ss046] ybhC gi|74311310
28 4 outer membrane protein assembly complex subunit YfiO [Shigella sonnei Ss046] SSON_2721 gi|74313154
29 3 outer membrane lipoprotein [S. flexneri 2a str. 301] yraP gi|24114441
30 3 DNA-binding transcriptional activator OsmE [S. flexneri 2a str. 301] lipo osmE gi|24112862
31 1 outer membrane protein [S. flexneri 2a str. 301] slyB gi|24113033
Periplasmic
32 3 FKBP-type peptidyl-prolyl cis-trans isomerase [S. Flexneri 2a str. 301] fkpA gi|24114611
33 3 histidine-binding periplasmic protein of high-affinity histidine transport system [S. sonnei Ss046] hisJ gi|74312826
34 3 serine endoprotease [S. flexneri 2a str. 301] htrA gi|24111599
35 3 translocation protein TolB [S. flexneri 2a str. 2457T] tolB gi|30062097
36 1 molybdate transporter periplasmic protein [S. flexneri 2a str. 301] modA gi|24111968
37 1 peptidyl-prolyl cis-trans isomerase A (rotamase A) [S. flexneri 2a str. 301] ppiA gi|24114628
38 1 peptidyl-prolyl cis-trans isomerase SurA [S. flexneri 2a str. 301] surA gi|24111499
39 1 periplasmic oligopeptide binding protein [S. flexneri 2a str. 2457T] oppA gi|30062764
40 1 periplasmic protein [S. flexneri 2a str. 2457T] osmY gi|30065614
41 2 arginine 3rd transport system periplasmic binding protein [S. sonnei Ss046] artJ gi|74311404
42 2 bifunctional UDP-sugar hydrolase/59-nucleotidase [S. sonnei Ss046] ushA gi|74311061
43 2 cystine transporter subunit [S. sonnei Ss046] fliY gi|74311733
44 2 glucan biosynthesis protein G [S. flexneri 5 str. 8401] mdoG gi|110805056
45 2 thiosulfate transporter subunit [S. sonnei Ss046] cysP gi|74312961
46 2 hypothetical protein SBO_2040 [Shigella boydii Sb227] ycdO gi|82544504
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1% (wt/vol) BSA to 1:5000 and incubated for 2 hours at 37uC.
After a wash with PBST, 100 mL/well of p-nitrophenyl phosphate
substrate dissolved in diethanolamine buffer (1 M, pH 9.8) was
added, and after 20 minutes optical densities were measured with
a plate reader (ELx800, BioTek) at 405 and 490 nm wavelength.
Absorbance at 490 nm was subtracted from the absorbance at
405 nm. Results are expressed in arbitrary ELISA units relative to
a standard serum raised against GMMA from S. sonnei 53G DtolR
DgalU. One unit equals the reciprocal of the dilution of the
standard serum giving an OD405–490 of 1 in the assay. All samples
were measured in duplicate.
Statistical Analysis
Antibody levels (ELISA units) in different groups after the third
immunization were compared by non-parametric Kruskal-Wallis
and Mann-Whitney tests. A p value of 0.05 was considered to be
significant. For multiple comparisons the p value considered to be
significant in each of the comparisons was adjusted according to
the number of analyses.
Results
Generation of a Shigella Sonnei 53G Strain Capable of
Overproducing Modified GMMA
The first aim of the study was to investigate if Shigella sonnei 53G
could be developed as a strain suitable to overproduce GMMA
through modification of the Tol-Pal system. A null mutation of the
tolR gene was introduced as this has previously been demonstrated
to result in overproduction of GMMA in E. coli [11,13]. The
mutation in the tolR gene led to the release of large amounts of
GMMA from the surface of S. sonnei 53G as assessed by SDS page
(Fig. 1A). The deletion of tolR had no detectable influence on
bacterial growth (data not shown). In addition, to test if GMMA
overproduction is also feasible in strains with additional genetic
modifications we removed the O antigen of the LPS, either by
deletion of galU [26] or by curing the virulence plasmid from strain
S. sonnei 53G DtolR as the biosynthesis genes for the O antigen in
Shigella sonnei are encoded on the plasmid [36]. GMMA obtained
from S. sonnei DtolR DgalU showed a similar protein profile to
GMMA obtained from S. sonnei DtolR with minor differences in the
37 kDa to 50 kDa range and proteins smaller than 30 kDa
appeared to be less abundant in S. sonnei DtolR DgalU (Fig. 1A).
Also GMMA obtained from the plasmid-cured S. sonnei DtolR
mutant (S. sonnei –pSS DtolR) showed a nearly identical protein
pattern to GMMA from S. sonnei DtolR (Fig. 1A).
Furthermore, the genes msbB1 and msbB2 involved in lipid A
biosynthesis were deleted since these deletions have previously
been reported to decrease LPS toxicity in Shigella [21]. As the gene
msbB2 is encoded on the virulence plasmid and thus absent in
S. sonnei –pSS DtolR we deleted the chromosomal gene msbB1 in
this strain to generate a mutant strain lacking msbB1 and msbB2.
For simplicity the DmsbB1DmsbB2 mutant is referred to as the
DmsbB mutant. The DmsbB mutant was selected at 37uC on LB
plates and grew in LB and yeast extract at 37uC with a duplication
time of about 55 min compared to a duplication time of about
28 min for the single DtolR mutant. In the defined medium
developed for fermentation, the plasmid-cured DtolR DmsbB
mutant strain (S. sonnei –pSS DtolR DmsbB) was able to grow to
high optical density (OD) at 30uC, but grew poorly at 37uC. Thus,
Table 2. Cont.
A B C D E
47 2 hypothetical protein SFV_2968 [S. flexneri 5 str. 8401] yggE gi|110806822
Cytoplasmic
48 3 chaperonin GroEL [S. flexneri 2a str. 301] groEL gi|24115498
49 3 dihydrolipoamide dehydrogenase [S. flexneri 2a str. 301] lpdA gi|56479605
50 1 purine nucleoside phosphorylase [S. flexneri 2a str. 2457T] deoD gi|30065622
51 1 succinyl-CoA synthetase subunit beta [S. flexneri 2a str. 301] sucC gi|24111996
52 2 PTS system glucose-specific transporter subunit [S. flexneri 2a str. 301] crr gi|24113762
53 2 molecular chaperone DnaK [S. flexneri 2a str. 301] dnaK gi|24111463
54 1 pyrroline-5-carboxylate reductase [S. flexneri 2a str. 301] proC gi|24111764
55 2 hypothetical protein SF1022 [S. flexneri 2a str. 301] SF1022 gi|24112431
Inner membrane
56 1 hypothetical protein SSON_1546 [S. sonnei Ss046] ydgA gi|74312061
Unknown
57 3 putative receptor [S. sonnei Ss046] SSON_1681 gi|74312191
58 2 hypothetical protein SSON_1556 [S. sonnei Ss046] ydgH gi|74312071
59 2 hypothetical protein SSON_3340 [S.sonnei Ss046] yrbC gi|74313729
60 2 putative lipoprotein [Shigella dysenteriae Sd197] ybjP gi|82777619
61 1 hypothetical protein S3269 [S. flexneri 2a str. 2457T] ygiW gi|30064374
GMMA were purified by 2-step TFF from S. sonnei DtolR DgalU grown in HTMC at 37uC to an OD of 45. GMMA-associated proteins were separated by SDS-PAGE or nano-
LC and identified by mass spectrometry. 61 GMMA-associated proteins were identified. The columns show: A) position in list, B) method used to identify each protein
(‘19: identified from total digestion LC/MS-MS, ‘29: identified from 2D SDS-PAGE PMF, ‘39 identified from LC/MS-MS and 2D SDS-PAGE PMF, ‘49 identified from 1D SDS-
PAGE PMF), C) annotation, D) gene name, E) accession number. The entries are divided by predicted location. All proteins were analyzed by PSORTb 3.0 and Lipo. If a
prediction as lipoprotein was obtained, the protein is listed as lipoprotein irrespective of its PSORTb prediction. Only lipoproteins predicted to be located in the outer
membrane have been identified. The other proteins are listed in sections corresponding to their location predicted by PSORTb. For 5 proteins no prediction was
obtained by PSORTb or Lipo. These are listed as ‘unknown’.
doi:10.1371/journal.pone.0035616.t002
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for generation of GMMA from S. sonnei –pSS DtolR DmsbB
cultivation in chemically defined medium at a growth temperature
of 30uC was chosen. GMMA from S. sonnei –pSS DtolR DmsbB
produced under these conditions showed a similar protein pattern
to GMMA generated by S. sonnei –pSS DtolR and S. sonnei DtolR
with only minor variation in relative amounts of proteins visible by
SDS-PAGE in the 45–75 kDa range (Fig. 1A). In order to test if
the lower temperature would change the GMMA composition we
compared GMMA derived from S. sonnei –pSS DtolR at 30uC or
37uC. Only few differences were detected as highlighted in Fig. 1B,
indicating that GMMA can be generated at 30uC without major
effects on the composition. In conclusion, deletion of tolR greatly
enhanced GMMA release while additional genetic modification of
the strain or a change in growth temperature only had minor
effects on the protein composition visible by SDS-PAGE.
High Density Cultivation of Shigella Sonnei
To investigate the feasibility to produce GMMA at large scale,
S. sonnei 53G DtolR DgalU, S. sonnei 53G –pSS DtolR, and S. sonnei
53G –pSS DtolR DmsbB were tested for their capacity to grow to
high densities in a 5 liter reactor. Starter cultures were grown in
flasks to OD 0.8 and were then transferred to the 5 L fermenter
to reach a starting OD of 0.02. Dissolved oxygen was maintained
at 30% saturation. The pH was maintained at 7.2 in HTMC or
at 6.7 in SSDM and the temperature was kept constant either at
37uC or at 30uC when S. sonnei 53G –pSS DtolR DmsbB was used.
Under these conditions, cultures with optical densities of 45 to 80
were obtained.
Iron-regulated proteins have previously been shown to be
important in vaccine formulations against Pasteurella and Salmonella
[37,38]. Thus, we evaluated if the GMMA process would allow the
upregulation of iron-regulated proteins. Growth of S. sonnei 53G –
pSS DtolR with 0.2 mM iron concentration in chemically defined
medium led to the induction of iron-regulated proteins but
hindered high density cultivation of bacteria. The addition of
2 mM iron to the medium was sufficient to allow optimal growth
and the induction of three iron-regulated proteins visible by SDS-
PAGE (Fig. 1C), identified by protein mass fingerprint as FepA
(gi|74311118), IutA (gi|74313972) and Colicin I receptor
(gi|74312677). The expression of these proteins was reduced
when bacteria were grown in 200 mM iron (Fig. 1C). In bacteria
grown in HTMC the iron-regulated proteins are expressed to a
similar level as in chemically defined medium with 200 mM iron
(data not shown). Their presence was confirmed by protein mass
fingerprint analysis of GMMA generated from S. sonnei DtolR
DgalU grown in HTMC (Table 2, proteins 8, 10, 12). Growth of
S. sonnei 53G –pSS DtolR DmsbB at 30uC in defined medium with
2 mM iron also enhanced expression of FepA and IutA. Colicin I
receptor (marked in Fig. 1C) was less expressed than in GMMA
from S. sonnei 53G –pSS DtolR prepared from cultures grown at
37uC (data not shown).
Purification of GMMA from High Density Culture
Supernatant
So far, GMMA have always been purified from flask cultures by
ultracentrifugation [13]. Cultures were centrifuged at low speed
(4000 g) to separate biomass from supernatant which was
subsequently filtered through a 0.22 mm filter. GMMA present
in the supernatant were collected by ultracentrifugation, washed,
and then resuspended and stored in PBS [10,13]. Since this
technique is not suitable for large volumes we developed a scalable
purification method to purify GMMA from high density cultures
using tangential flow filtration (TFF). In TFF, also known as
crossflow filtration, the feed stream is pumped tangentially across
the surface of the membrane rather than into the filter as in
conventional ‘dead-end’ filtration. A proportion of the soluble
components and particles smaller than the membrane’s pores
penetrates the filter (filtrate/permeate). The remainder (retentate)
is circulated back to the reservoir and over the filter again. In this
way, the larger particles do not build up at the surface of the filter
but are swept away by the tangential flow allowing smaller
molecules to continuously reach and pass through the membrane.
This feature makes TFF an efficient process for size separation,
concentration and diafiltration.
Figure 2. GMMA enrichment and purity after TFF. GMMA were
purified from a 5 L fermentation culture of S. sonnei DtolR DgalU grown
in HTMC at 37uC to OD 45 using 2-step TFF. In the first step, the culture
supernatant which contains the GMMA was separated from the bacteria
using a 0.2 mm filter. The biomass was subjected to 5 diafiltration steps
and all filtrates were combined with the initial supernatant to obtain
the total permeate. To determine the amount of GMMA in the
permeate, GMMA were separated from soluble proteins by ultracentri-
fugation. After ultracentrifugation, the pellet (GMMA) was resuspended
in the initial volume of the centrifuged material to normalize all samples
to fermentation volume. Equivalent volumes of the 0.2 mm filtrate
before ultracentrifugation (1), the resuspended GMMA pellet (2), and
the supernatant of the ultracentrifugation (3) were separated by SDS-
PAGE (12% PA) and showed a large amount of soluble proteins (3) in
comparison to GMMA-associated proteins (2) to be present in the post
0.2 mm TFF permeate. In the second TFF step, GMMA were separated
from soluble proteins using a 0.1 mm filter. The retentate (4) was
analyzed by ultracentrifugation as described above and was found to
contain almost exclusively GMMA (5) as determined by the strong
reduction of soluble proteins (6).
doi:10.1371/journal.pone.0035616.g002
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GMMA were purified from fermentation cultures in a 2-step
TFF process. In the first step, the culture supernatant that contains
the GMMA was separated from the bacteria using a 0.2 mm filter.
In this step, the bacteria remained in the retentate and GMMA
transferred into the filtrate. In the second filtration step using a
0.1 mm filter, GMMA were separated from soluble components
present in the culture supernatant, including proteins secreted by
the bacteria or released by lysis. In this step, GMMA were retained
by the filter and collected and concentrated in the retentate
whereas soluble proteins passed through the filter. We tested this
purification process under two slightly different conditions. Firstly,
when the fermentation culture of S. sonnei DtolR DgalU reached OD
45, the culture was transferred directly from the fermenter to the
first TFF and the culture supernatant containing the GMMA was
collected. The retained biomass was washed with 5 volumes of
PBS buffer (diafiltration) to recover remaining GMMA and the
filtrate containing these GMMA was combined with the culture
supernatant. In the slightly modified purification process tested,
this diafiltration step was omitted. Proteins were quantified by
Bradford method. In the purification performed with diafiltration
of the biomass the total protein content of the TFF 0.2 mm filtrate
was approximately 1.5 g/L of fermentation culture of which 15%
was GMMA-associated as determined by separation of the soluble
components from the high molecular weight portion (GMMA) via
an ultracentrifuge step (Fig. 2 and Table 3). In the second TFF
step, GMMA were concentrated in the retentate and washed with
five volumes of PBS to remove remaining soluble proteins. As TFF
is usually performed under non-sterile conditions, the final
retentate was sterilized by filtration through a 0.22 mm filter. An
aliquot of the sterilized retentate was subjected to ultracentrifu-
gation to determine the content of GMMA as above. As shown in
Fig. 2 most of the proteins in the retentate are GMMA-associated.
Protein quantification of the retentate, of the GMMA fraction, and
of the supernatant of the ultracentrifugation step (soluble proteins)
determined that 90% of all protein present in the retentate was
GMMA-associated (Table 3). Thus, soluble proteins were
efficiently removed in this step (Fig. 2). GMMA recovery after
the 0.1 mm TFF step was 56% of the quantity present after the
0.2 mm cassette. The final yield of GMMA was 120 milligrams of
proteins per liter of fermentation (Table 3). In two subsequent tests
of the purification method with S. sonnei DtolR DgalU without
diafiltration of the biomass, a lower amount of GMMA was
obtained in the 0.2 mm TFF filtrate (Table 3). However, recovery
of GMMA in the second TFF step (0.1 mm) was enhanced
resulting in an overall similar yield of GMMA with equivalent
purity (Table 3 and suppl. figures Fig. S1, Fig. S2). This suggests,
firstly, that washing of the biomass increases the recovery GMMA
from the fermentation culture, and secondly, that a higher starting
concentration might be beneficial for the second TFF step. The
0.1 mm TFF step can likely be optimized to take advantage of the
larger amounts of GMMA obtained by diafiltration of the biomass.
Fermentations of S. sonnei –pSS DtolR DmsbB resulted in yields of
140 mg/L from a culture at OD 65 (2.2 mg/L/OD) and 230 mg/
L from a culture at OD 80 (2.9 mg/L/OD), demonstrating that
the yield of GMMA can be further improved by growing the
culture to a higher OD.
The preparation of GMMA generated from S. sonnei –pSS DtolR
DmsbB obtained after the second TFF step was subjected to
electron microscopy analysis, revealing the presence of well-
organized membrane vesicles with a diameter of about 30–60 nm
(Fig. 3) which is consistent with the reported average size of
Table 3. Yield, purity, and recovery rate of GMMA by the high yield production process.
Fermentation A OD 45 Fermentation B1 OD 30 Fermentation B2 OD 39
Protein content [mg/L fermentation]
0.2 mm TFF permeate
Total protein* 1465 1237 797
GMMA-associated protein 214 143 138
Soluble protein 1251 1094 659
0.1 mm TFF retentate
Total protein# 108 144 118
GMMA-associated protein 120 127 114
Soluble protein 14 5 3
GMMA-associated protein per OD 2.7 mg/L/OD 4.2 mg/L/OD 2.9 mg/L/OD
Purity of GMMA after 0.1 mm TFF [%]
GMMA (GMMA-protein/total protein) 90 88 97
Soluble protein (sol. protein/total protein) 10 3 3
Recovery of GMMA by 0.1 mm TFF [%]
GMMA-protein after 0.1 mm TFF/0.2 mm 56 89 83
*Total protein amount calculated as sum of GMMA-associated protein and soluble protein.
#Total protein amount measured directly by Bradford assay.
S. sonnei DtolR DgalU was grown in HTMC in a 5 L fermenter to high densities of OD 45 (A), OD 30 (B1) and OD 39 (B2) and GMMA were purified using 2-step TFF.
Purification from fermentation A was performed including 5 diafiltration steps of the biomass, for GMMA purification from fermentations B1 and B2 the biomass was not
subjected to diafiltration. The GMMA content in the permeate of the 0.2 TFF step (culture supernatant) and the retentate of the 0.1 mm TFF (purified GMMA) were
determined by separation of GMMA from soluble protein by ultracentrifugation. Protein was quantified using Bradford assay. All samples were normalized to amount
per liter fermentation broth. To compare the yields from different ODs, yields are also expressed as amount per liter fermentation per OD.
doi:10.1371/journal.pone.0035616.t003
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40620 nm of outer membrane particles produced by E. coli tol-pal
mutants [11].
Characterization of GMMA Protein Content
GMMA purified by TFF from S. sonnei 53G DtolR DgalU grown
in high density culture were characterized to confirm their
integrity and to analyze their protein content. One- and two-
dimensional SDS-PAGE of GMMA and densitometry analysis
(Fig. 1D and Fig. 4) were used to determine the protein profile and
to study relative protein quantities of the most abundant proteins.
Most of the Coomassie blue-stained bands and spots were
identified using peptide mass fingerprint (Table 2). OmpA and
OmpC are known to be among the most abundant proteins
present in the outer membrane. In fact, densitometry analysis of
GMMA from S. sonnei DtolR DgalU grown in HTMC and analyzed
by 1D SDS-PAGE indicated that OmpA and OmpC together
contribute for 45% of the total protein; OmpX, 9%; Slp, 6%;
YfiO, 5.6%; TolB, 2.3%; TolC 1.4%; and YaeT, 1.8% (Fig. 1D).
With the exception of the predicted periplasmic protein TolB, all
of these proteins are predicted to be associated with the outer
membrane. YfiO is predicted to be an outer membrane
lipoprotein. OmpA, OmpC, OmpX, Slp, TolC, and YaeT are
predicted to be outer membrane proteins. Thus, the seven most
abundant outer membrane-associated proteins account for
approximately 69% of the protein amount in GMMA. Further
densitometry analysis after 2D SDS-PAGE determined that there
are approximately equal quantities of OmpA and OmpC
(OmpA:OmpC is 1:0.83 by densitometry of a Coomassie blue-
stained gel). In order to identify the diverse and less expressed
proteins, GMMA were studied by proteolytic digestion and reverse
Figure 3. Electron microscopy of Shigella sonnei DtolR DgalU GMMA. GMMA were isolated from the culture supernatant of S. sonnei –pSS
DtolR DmsbB by TFF, prepared for negative staining, and viewed by electron microscopy revealing the presence of well-organized membrane vesicles
with a diameter of about 30–60 nm. Bar length = 100 nm.
doi:10.1371/journal.pone.0035616.g003
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phase liquid chromatography coupled to MS/MS. 61 proteins
were identified in total (LC-MS/MS, 1D and 2D SDS-PAGE
PMF) (Table 2), with 31 of these proteins predicted to be
associated with the outer membrane (Fig. 5). Of these, 14 proteins
were predicted to be outer membrane proteins and 17 to be outer
membrane lipoproteins. In addition, 16 proteins were predicted to
be periplasmic, 8 to be cytoplasmic, 1 to be located in the inner
membrane, and for 5 proteins no prediction could be obtained. No
inner membrane lipoproteins were predicted. Thus, GMMA
generated by the high yield production process are mostly
composed of outer membrane-associated and periplasmic proteins
as previously seen for outer membrane particles release from
cultures at the early logarithmic phase [10,13].
GMMA Immunogenicity
Groups of 8 CD1 mice were immunized 3 times with GMMA
(2 mg of total protein) obtained from S. sonnei 53G –pSS DtolR and
S. sonnei 53G –pSS DtolR DmsbB, both grown in defined medium
with 2 mM iron, and S. sonnei 53G DtolR DgalU grown in HTMC.
GMMA from S. sonnei 53G –pSS DtolR DgalU, S. sonnei 53G –pSS
DtolR and S. sonnei 53G –pSS DtolR DmsbB were also administered
in combination with Freund’s adjuvant (FA). Freund’s complete
adjuvant was used in the first immunization and Freund’s
incomplete adjuvant was used in the second and third immuni-
zation. In addition, a lower dosage of 0.2 mg of GMMA from
S. sonnei 53G –pSS DtolR DmsbB was tested. Serum samples were
obtained 2 weeks after the second and third doses and analyzed
individually. Mice immunized with GMMA showed very high IgG
responses to all 3 types of GMMA that were tested. No difference
was found between groups immunized with different GMMA or
between groups receiving the same GMMA with or without FA
(Fig. 6). Adsorption of GMMA onto alum as adjuvant also did not
have an effect on the IgG response (data not shown). Control mice
immunized with PBS or FA alone had very low levels of anti-
GMMA antibodies (Fig. 6). The 10-fold lower dosage of GMMA
from S. sonnei 53G –pSS DtolR DmsbB (0.2 mg) resulted in a
statistically significant, approximately 3-fold reduction in the IgG
response compared to the group immunized with 2 mg of the same
GMMA. However, the IgG response to the lower dosage still
showed an approximately 8000-fold increase compared to
preimmune sera (Fig. 6).
To investigate which components of GMMA were responsible
for the reactivity of the sera, 2D Western blots were performed. As
GMMA from S. sonnei 53G DtolR DgalU were characterized best in
respect to their protein content, sera from mice immunized with
the GMMA from S. sonnei DtolR DgalU were used to probe blots of
2D SDS-PAGE of GMMA from the same strain. Reactive
proteins were identified by protein mass fingerprint. Several
proteins were detected by the sera (Fig. 4 B) of which OmpA gave
the strongest response. OmpC which is as abundant in GMMA as
OmpA was not detected. Not all of the visible reactive proteins
could be identified.
Discussion
Recent advances in genomics and reverse vaccinology have
identified promising protein targets for vaccines [39]. In many
cases, suitable candidate antigens for Gram-negative bacterial
vaccines are outer membrane proteins and these pose particular
challenges in their expression and purification and in serotype
variability. An ideal delivery system especially for bacterial
vaccines for developing countries will encompass multiple antigens
and enable vaccines to be rapidly tailored to local and changing
antigenic serotypes. Ideally, it will also be inexpensive to
manufacture. We propose a platform for rapid development and
delivery of vaccines against Gram-negative bacteria. The ap-
proach is based on the production of outer membrane particles we
have named GMMA by genetically modified bacteria. Using
genetic manipulation, it is possible to increase their yield, to
remove immunodominant structures, to overexpress certain
Figure 4. 2D gel electrophoresis of Shigella sonnei DtolR DgalU GMMA and immunoblot. A)200 mg of proteins from S. sonnei DtolR DgalU
GMMA were separated in the first dimension on a non linear pH 3–11 gradient, and in the second dimension on a 4–12% polyacrylamide gradient.
Visible bands were identified by protein mass fingerprint. OmpA and OmpC were quantified with Image master 2D Platinum 6.0. B) Sera from mice
immunized with GMMA from S. sonnei DtolR DgalU were used to study the subset of proteins present in GMMA that are able to raise antibodies. A 2D
gel containing 20 mg of GMMA protein from S. sonnei DtolR DgalU was blotted and the membrane was incubated with sera from immunized mice
with GMMA from S. sonnei DtolR DgalU in combination with Freund’s adjuvant. Several reactive proteins were identified. The numbers behind the
names refer to the position of the proteins in Table 2. C) To verify that the signal observed in the 2D Western blot was due exclusively to antibody
raised upon immunization with GMMA, 10 mg of GMMA were separated by 1D SDS-PAGE (12% PA) and stained with Coomassie (1) or transferred to a
membrane. Western blots were developed using (2) sera raised against GMMA from S. sonnei DtolR DgalU as used for the 2D Western blot in B, (3)
preimmune serum, (4) sera raised in mice immunized with Freund’s adjuvant or (5) PBS, or (6) secondary antibody only. A signal could only be
observed when sera raised against GMMA were used (2).
doi:10.1371/journal.pone.0035616.g004
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antigens, and to reduce the endotoxic activity
[10,13,19,21,26,40,41]. GMMA could potentially be a safe,
effective and low cost vaccine but need a practical way of
manufacture at scale.
Shigella sonnei 53G was chosen for a first approach to develop a
scalable process and a null mutation of the tolR gene was
introduced to overproduce GMMA as previously described for E.
coli [13]. To verify that the process is applicable to produce
GMMA harboring modified lipid A, which would be more suitable
for use as vaccine, and/or lacking the O antigen of the LPS we
grew high density cultures of S. sonnei DtolR DgalU, S. sonnei –pSS
DtolR (cured of the virulence plasmid pSS), and S. sonnei –pSS
DtolR DmsbB in a 5 L fermenter in complex (HTMC) or
chemically defined medium. Chemically defined medium was
used to avoid contamination from proteins present in complex
media and to have the possibility to regulate iron concentration.
Bacteria were removed from the culture supernatant by a
tangential flow filtration step using a 0.2 mm membrane. A second
tangential flow filtration step with a 0.1 mmmembrane was used to
concentrate GMMA and to remove soluble proteins. This choice
of appropriate molecular weight membranes allowed the purifi-
cation of GMMA in an easy, efficient, and scalable process. After
purification, approximately 90% of all protein was consistently
GMMA-associated with reproducible yields of more than 100 mg
of GMMA-associated protein per liter fermentation volume from
OD 30–45 cultures of S. sonnei DtolR DgalU. The integrity of
GMMA obtained by this process was confirmed using electron
microscopy. The purity and yield can likely be increased as
indicated by fermentations with S. sonnei –pSS DtolR DmsbB to
densities of 65 and 80. Furthermore, first results obtained by
quantitative amino acid analysis of different types of GMMA
indicated an at least two-fold higher protein amount in the
GMMA preparations than determined by the Bradford assay used
in this study (data not shown). Still, assuming an average yield of
100 mg/L fermentation and a dosage of 25 mg as used for the
MeNZB outer membrane vesicle meningococcal vaccine, at least
400,000 doses could be obtained from a 100 L fermenter.
A proteomic approach confirmed that Shigella sonnei 53G DtolR
DgalU-derived GMMA are composed mostly of outer membrane
and periplasmic components. They conserve lipophilic polypep-
tides. Only a small number of cytoplasmic components and one
inner membrane protein were predicted. Thus, the proteomic
analysis of GMMA obtained from an OD 45 culture revealed a
similar composition as previously seen in proteomic analyses of
outer membrane particles that were obtained from cultures at
early logarithmic phase to avoid impurities by cytoplasmic proteins
[10,13].
In accordance with previous reports [15,17] GMMA were
highly immunogenic in mice with titers around 1:100,000 after
administration of 2 mg of GMMA with and without adjuvant. A
10-fold lower dosage of GMMA (without adjuvant) resulted in
only a 3-fold reduction and still very high antibody titers
suggesting that low amounts of GMMA might be sufficient for
vaccination. GMMA from the msbB mutant S. sonnei strain did not
show a difference in immunogenicity which was expected due to a
recent report that the resulting lipid A modification does not affect
LPS recognition in mice [42]. Immunoblots confirmed that
antibodies to proteins, including outer membrane proteins OmpA,
OmpX, and YaeT, strongly contributed to the reactivity of the
sera. Interestingly, the outer membrane protein OmpC which
represents about 20% of protein in GMMA was not detected by
sera raised against GMMA. Previously, an immunoproteomic
analysis of isolated outer membrane proteins of Shigella flexneri 2a
[43] also failed to detect OmpC as immunogenic protein. This
could suggest that either OmpC is not immunogenic or that
epitopes potentially recognized by antibodies are not maintained
after SDS-PAGE. This might also apply to other membrane
proteins that were not found by the Western blot analysis even
though not all reactive proteins could be identified.
The msbB mutant strain of Shigella lacking the genes msbB1 and
msbB2 [21] was generated to investigate if the production process
was applicable to GMMA with modified lipid A. A previous
report [21] had shown that these deletions result in the synthesis
of a penta-acylated lipid A instead of a hexa-acylated lipid A in
Shigella [21]. While the S. sonnei –pSS DtolR DmsbB mutant grows
in rich media at 37uC temperature, its growth is impaired in the
chemically defined medium developed for fermentation at 37uC
but shows a normal growth in this medium at 30uC. Previously,
Figure 5. Shigella sonnei DtolR DgalU GMMA proteome. The 61
GMMA-associated proteins that were identified are grouped into
families based on their predicted cellular location, according to
bioinformatic prediction by PSORTb v3.0 [34] and Lipo program [35].
The ‘outer membrane’ column comprises outer membrane proteins
(identified by PSORTb) and lipoproteins predicted to be located in the
outer membrane (identified by Lipo). No lipoproteins associated with
the inner membrane were identified. The distribution shown is based
on the number of identified proteins predicted to be located in a
certain compartment. It does not reflect the protein amount. As
analyzed by densitometry (Fig. 1D), the outer membrane fraction
contains at least 69% of the total protein present in GMMA.
doi:10.1371/journal.pone.0035616.g005
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a Shigella flexneri 5a msbB mutant and an E. coli msbB mutant in
the K-12 background were reported not to show any growth
defects [21,23]. In contrast, an msbB mutant of the clinical isolate
E. coli H16 formed filaments when grown at 37uC but not at
30uC or when functionally complemented by the cloned msbB
gene [44]. The S. sonnei –pSS DtolR DmsbB mutant strain used in
this study does not form filaments. The reason for the slower
growth at 37uC, especially in defined medium, is not clear and
could be a result of the background of the strain, the
combination of the tolR and msbB mutation, or a suboptimal
composition of the defined medium that can likely be optimized.
Importantly, a comparison of the protein pattern of GMMA
generated from S. sonnei –pSS DtolR at 37uC and 30uC showed
only minor differences in the protein profile visible by SDS-
PAGE indicating that the change in temperature does not have
major effects on GMMA composition.
In summary, we have identified an easy process to produce large
quantities of GMMA from high density culture. GMMA purified
from fermentation are extremely pure particles composed almost
exclusively of outer membrane and periplasmic components. The
simplicity and high yield of the process support its applicability for
large scale manufacturing. We have also shown that this process
can be used with strains genetically modified to reduce reactoge-
nicity or to remove immunodominant antigens, e.g. the O antigen.
While this work focused on Shigella sonnei, we believe that this
technology is an innovative platform for efficient vaccine
manufacturing for Gram-negative bacteria.
Supporting Information
Figure S1 GMMA enrichment and purity after TFF
without diafiltration of the biomass. GMMA were purified
from a 5 L fermentation culture of S. sonnei DtolR DgalU grown in
HTMC at 37uC to OD 39 (fermentation B2 in Table 3) using 2-
step TFF. In the first step, the culture supernatant which contains
the GMMA was separated from the bacteria using a 0.2 mm filter
without further diafiltration of the biomass. To determine the
amount of GMMA in the permeate GMMA were separated from
soluble proteins by ultracentrifugation. After ultracentrifugation,
the pellet (GMMA) was resuspended in the initial volume of the
centrifuged material to normalize all samples to fermentation
volume. Equivalent volumes of the 0.2 mm filtrate before
ultracentrifugation (1), the resuspended GMMA pellet (2), and
the supernatant of the ultracentrifugation (3) were separated by
SDS-PAGE (12% PA) and showed a large amount of soluble
proteins (3) in comparison to GMMA-associated proteins (2) to be
present in the post 0.2 mm TFF permeate. In the second TFF step,
GMMA were separated from soluble proteins using a 0.1 mm
filter. The retentate (4) was analyzed by ultracentrifugation as
described above and was found to contain almost exclusively
GMMA (5) as determined by the strong reduction of soluble
proteins (6). The high recovery rate of 83% in this process (see
Table 3) is reflected in the similar strength of the visible protein
bands in lane 2 (GMMA in the 0.2 mm TFF filtrate) and lane 5
(GMMA in the 0.1 mm retentate).
(TIF)
Figure S2 Reproducibility of purity and protein com-
position of GMMA obtained by the high yield production
process. S. sonnei DtolR DgalU was grown in HTMC at 37uC in a
5 L fermenter to high densities of OD 30 (B1) and OD 39 (B2) and
GMMA were purified using 2-step TFF. To determine the amount
of GMMA in the retentate of the 0.1 mm TFF (purified GMMA)
GMMA were separated from soluble proteins by ultracentrifuga-
tion. After ultracentrifugation, the pellets (GMMA) were resus-
pended in the initial volume of the centrifuged material to
Figure 6. ELISA analysis of sera reactivity against GMMA. Groups 1–6 received 2 mg of GMMA with or without Freund’s adjuvant (FA), group
1) GMMA from S. sonnei DtolR DgalU (grown in HTMC, 37uC), 2) GMMA of group 1 plus FA, 3) GMMA S. sonnei –pSS DtolR (defined medium, 37uC), 4)
GMMA of group 3 plus FA, 5) GMMA from S. sonnei –pSS DtolR DmsbB (defined medium, 30uC), 6) GMMA of group 5 plus FA. Group 7 received 0.2 mg
of GMMA from S. sonnei –pSS DtolR DmsbB. Control groups were immunized with PBS alone (group 8) or FA alone (group 9). Sera from individual
mice obtained 14 days after the third immunization and pooled preimmune sera from each group respectively were assayed in dilutions of 1:1000,
1:10,000, and 1:100,000 on GMMA from S. sonnei 53G –pSS DtolR as coating and arbitrary units were calculated. Data are presented as scatter plots of
ELISA units determined in individual mice (groups 1–9) or of the pooled preimmune sera (pre). The horizontal lines represent the geometric mean.
ELISA units of groups 1–6 receiving 2 mg of GMMA were analyzed using the non-parametric Kruskal-Wallis test to compare the immunogenicity of the
different GMMA to each other and with and without FA. No statistically significant differences were found (n.s.). Reduction of the immunization
dosage of S. sonnei –pSS DtolR DmsbB GMMA to 0.2 mg (group 7) resulted in statistically significant reduction of ELISA units in the sera of the
immunized animals compared to sera of mice immunized with 2 mg of the same GMMA (group 5) as determined by Mann-Whitney test (p = 0.0047).
All groups receiving GMMA showed higher S. sonnei –pSS DtolR-specific antibody responses than groups immunized with PBS or FA alone (Mann-
Whitney, p#0.003). For all comparisons a p value smaller than 0.05 was considered to be significant.
doi:10.1371/journal.pone.0035616.g006
Shigella Outer Membrane Particles Production
PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e35616
normalize all samples to fermentation volume. Equivalent volumes
of the retentate before ultracentrifugation (1), the resuspended
GMMA pellet (2), and the supernatant of the ultracentrifugation
(3) were separated by SDS-PAGE (12% PA). The retentates were
found to contain almost exclusively GMMA (2) as determined by
the strong reduction of soluble proteins (3). In addition, the protein
pattern in GMMA from the 2 fermentations was very similar
suggesting good reproducibility of the process. Minor differences
in the visible amount of proteins are highlighted by arrows.
(TIF)
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